var title_f10_61_11216="Endobronchial lesion";
var content_f10_61_11216=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=ID%2F70875&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=ID%2F70875&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\" style=\"width: 470px\">",
"   <div class=\"ttl\">",
"    Polypoid endobronchial lesion (patient 18)",
"   </div>",
"   <div class=\"cntnt\" style=\"width: 395px; height: 381px; background-image: url(data:image/jpeg;base64,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);\">",
"   </div>",
"   <div class=\"lgnd\">",
"    <div class=\"footnotes\">",
"    </div>",
"    <div class=\"reference\">",
"     Reproduced with permission from: Phillips, P, Bonner, S, Gataric, N, et al. Nontuberculous Mycobacterial Immune Reconstitution Syndrome in HIV-infected patients spectrum of disease and long-term follow-up. Clin Infect Dis 2005; 41:1483. Copyright &copy; 2005 University of Chicago Press.",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f10_61_11216=[""].join("\n");
var outline_f10_61_11216=null;
var title_f10_61_11217="Patient information: Psittacosis (The Basics)";
var content_f10_61_11217=[" <noscript>",
"  <div id=\"javascriptDisabled\">",
"   It seems to us that you have your JavaScript turned off on your browser. JavaScript is required in order for our site to behave correctly.  Please enable your JavaScript to continue use our site.",
"  </div>",
" </noscript>",
" <div id=\"printHeader\">",
"  <div id=\"printHeaderLogo\">",
"   <img alt=\"UpToDate\" src=\"./../images/wk_utd-rgb.myextg\" width=\"220px\">",
"   </img>",
"  </div>",
"  <div id=\"printHeaderText\">",
"   Official reprint from  UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"   <a href=\"file://www.uptodate.com\">",
"    www.uptodate.com",
"   </a>",
"   <br>",
"    &copy;2013 UpToDate",
"    <sup>",
"     &reg;",
"    </sup>",
"   </br>",
"  </div>",
"  <div id=\"printHeaderLinks\">",
"   <a class=\"TOPIC\" href=\"#\" id=\"printHeaderPrint\" rel=\"2\" title=\"Click here to print\">",
"    Print",
"   </a>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a href=\"#\" id=\"printHeaderBack\" title=\"Back to normal view\">",
"    Back",
"   </a>",
"  </div>",
" </div>",
" <!-- TC:TOPIC_PAGE -->",
" <div id=\"topicContent\">",
"  <div>",
"   &nbsp;",
"  </div>",
"  <div id=\"basicsTopicMinWidth\">",
"   <div id=\"basicsTopicRight\">",
"    <div id=\"placeholder\">",
"     <div class=\"ieSpacer\">",
"     </div>",
"     <div id=\"basics-more\">",
"      <h4>",
"       <img src=\"file://www.uptodate.com/images/basics-more-title.png\"/>",
"      </h4>",
"      <dl>",
"       <dt class=\"basics\">",
"        The Basics",
"       </dt>",
"       <dd>",
"        <a href=\"UTD.htm?5/58/6050\">",
"         Patient information: Bird flu (avian influenza) (The Basics)",
"        </a>",
"       </dd>",
"      </dl>",
"      <div id=\"tooltipper\">",
"      </div>",
"     </div>",
"    </div>",
"   </div>",
"   <div id=\"basicsTopicLeft\">",
"    <div id=\"topicTitle\">",
"     Patient information: Psittacosis (The Basics)",
"    </div>",
"    <span class=\"view\">",
"     View in",
"     <a class=\"lang\" href=\"./es-419/psittacosis-the-basics?source=topic_page\">",
"      Spanish",
"     </a>",
"    </span>",
"    <a class=\"contributor contributor_credentials\" href=\"./authors-and-editors/patient-information\">",
"     Written by the doctors and editors at UpToDate",
"    </a>",
"    <div id=\"topicText\">",
"     <p class=\"headingAnchor\" id=\"H1684645625\">",
"      <span class=\"h1\">",
"       What is psittacosis?",
"      </span>",
"      &nbsp;&mdash;&nbsp;Psittacosis is an infection that people can catch from birds and sometimes other animals. The infection usually causes sudden fever, headache, and a dry cough. It most often affects:",
"     </p>",
"     <p>",
"      <ul class=\"bulletCompact-block\">",
"       <li>",
"        People who own a pet bird, such as a cockatiel, parakeet, parrot, or macaw",
"       </li>",
"       <li>",
"        People who own or run a pet shop",
"       </li>",
"       <li>",
"        Veterinarians (animal doctors)",
"       </li>",
"       <li>",
"        People who work in chicken, duck, or turkey processing plants",
"       </li>",
"      </ul>",
"     </p>",
"     <p>",
"      Other names for psittacosis are &ldquo;parrot fever&rdquo; and &ldquo;ornithosis.&rdquo;",
"     </p>",
"     <p class=\"headingAnchor\" id=\"H1684645640\">",
"      <span class=\"h1\">",
"       What are the symptoms of psittacosis?",
"      </span>",
"      &nbsp;&mdash;&nbsp;The symptoms usually start 5 to 21 days after being around an infected bird. They can include:",
"     </p>",
"     <p>",
"      <ul class=\"bulletCompact-block\">",
"       <li>",
"        Fever (often comes on suddenly)",
"       </li>",
"       <li>",
"        Headache (usually severe)",
"       </li>",
"       <li>",
"        Shivering",
"       </li>",
"       <li>",
"        Sweating",
"       </li>",
"       <li>",
"        Muscle aches",
"       </li>",
"       <li>",
"        Dry cough (this can develop later than other symptoms)",
"       </li>",
"      </ul>",
"     </p>",
"     <p>",
"      In severe cases, psittacosis can cause serious problems with the lungs, kidneys, liver, and other organs. In a pregnant woman, the infection can be very dangerous, even deadly, especially if the woman is infected late in pregnancy.",
"     </p>",
"     <p class=\"headingAnchor\" id=\"H1684645655\">",
"      <span class=\"h1\">",
"       Should I see a doctor or nurse?",
"      </span>",
"      &nbsp;&mdash;&nbsp;If you have symptoms of psittacosis and own a pet bird or have been around birds that might have been infected, see your doctor or nurse. Similar symptoms can occur with other infections, such as the flu. But your doctor or nurse can help figure out which infection is making you ill and give you the proper treatment.",
"     </p>",
"     <p class=\"headingAnchor\" id=\"H1684645670\">",
"      <span class=\"h1\">",
"       Will I need tests?",
"      </span>",
"      &nbsp;&mdash;&nbsp;Yes, if your doctor or nurse suspects you have psittacosis, he or she will order a blood test to check for your body&rsquo;s response to the infection.",
"     </p>",
"     <p class=\"headingAnchor\" id=\"H1684645687\">",
"      <span class=\"h1\">",
"       How is psittacosis treated?",
"      </span>",
"      &nbsp;&mdash;&nbsp;Treatment involves taking antibiotics, usually for 10 to 14 days. If you are put on antibiotics to treat psittacosis, it&rsquo;s very important that you take all your pills, even if you feel better before you finish them. If you don&rsquo;t take all your pills, your infection might come back.",
"     </p>",
"     <p class=\"headingAnchor\" id=\"H1684645702\">",
"      <span class=\"h1\">",
"       More on this topic",
"      </span>",
"     </p>",
"     <p>",
"      <a class=\"medical medical_basics\" href=\"UTD.htm?5/58/6050?source=see_link\">",
"       Patient information: Bird flu (avian influenza) (The Basics)",
"      </a>",
"     </p>",
"    </div>",
"    <div id=\"reviewProcess\">",
"     <span>",
"      All topics are updated as new evidence becomes available and our",
"      <a class=\"policy policy_editorialpolicy\" href=\"/home/editorial-policy\">",
"       peer review process",
"      </a>",
"      is complete.",
"     </span>",
"    </div>",
"    <div id=\"topicRetrievedDate\">",
"     <span class=\"emphasis\">",
"      This topic retrieved from UpToDate on:",
"     </span>",
"     Apr 14, 2013.",
"    </div>",
"    <div class=\"patTopicTool\" id=\"patTopicToolBottom\">",
"     <a class=\"toolbutton findicon findInPageLink\" href=\"#\" title=\"Find in Topic\">",
"      Find",
"     </a>",
"     <a class=\"toolbutton printicon\" href=\"UTD.htm?10/61/11217?view=print\" title=\"Print This Topic\">",
"      Print",
"     </a>",
"     <a class=\"toolbutton emailicon etacLink\" href=\"#\" title=\"Email This Topic\">",
"      Email",
"     </a>",
"    </div>",
"    <div id=\"disclaimer\">",
"     The content on the UpToDate website is not intended nor recommended as a substitute for medical advice, diagnosis, or treatment.  Always seek the advice of your own physician or other qualified health care professional regarding any medical questions or conditions.",
"The use of UpToDate content is governed by the",
"     <a class=\"legal legal_termsofuse\" href=\"/home/terms-use\" target=\"_blank\">",
"      UpToDate Terms of Use",
"     </a>",
"     . &copy;2013 UpToDate, Inc. All rights reserved.",
"    </div>",
"    <div id=\"topicVersionRevision\">",
"     Topic 83822 Version 1.0",
"    </div>",
"   </div>",
"   <!--  basicsTopicLeft -->",
"  </div>",
"  <!-- basicsTopicMinWidth -->",
" </div>",
" <!-- topicContent -->",
" <div id=\"footer\">",
"  <div id=\"supportFooter\">",
"   <span class=\"sfInfo\">",
"    &copy; 2013 UpToDate, Inc. All rights reserved.",
"   </span>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_footer\">",
"    Subscription and License Agreement",
"   </a>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Release: 21.3 - C21.34",
"   </span>",
"   <br/>",
"   <span class=\"sfInfo\">",
"    Licensed to:",
"    <span class=\"emphasis\">",
"     Morehouse School of Medicine",
"    </span>",
"   </span>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Support Tag: [0604-41.78.124.10-00EF7A87C0-S473950.14]",
"    <br/>",
"   </span>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f10_61_11217=[""].join("\n");
var outline_f10_61_11217=[" <div id=\"toggleOutline\">",
"  <a href=\"#\" title=\"Collapse Topic Outline\">",
"   <img alt=\"\" src=\"./../images/orange_arrow_left.myextg\"/>",
"  </a>",
" </div>",
" <div id=\"innerOutline\">",
"  <h1>",
"   TOPIC OUTLINE",
"  </h1>",
"  <div id=\"outline\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H1684645625\">",
"      What is psittacosis?",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H1684645640\">",
"      What are the symptoms of psittacosis?",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H1684645655\">",
"      Should I see a doctor or nurse?",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H1684645670\">",
"      Will I need tests?",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H1684645687\">",
"      How is psittacosis treated?",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H1684645702\">",
"      More on this topic",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   RELATED TOPICS",
"  </h1>",
"  <div id=\"relatedTopics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_basics\" href=\"UTD.htm?5/58/6050?source=related_link\">",
"      Patient information: Bird flu (avian influenza) (The Basics)",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
" </div>"].join("\n");
var title_f10_61_11218="Sinus rhythm tutorial";
var content_f10_61_11218=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=CARD%2F69872&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=2\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=CARD%2F69872&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=2\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\" style=\"width: 476px\">",
"   <div class=\"ttl\">",
"    Sinus rhythm",
"   </div>",
"   <div class=\"cntnt\" style=\"width: 456px; height: 103px; background-image: url(data:image/jpeg;base64,/9j/4AAQSkZJRgABAQAAAQABAAD/2wBDAAYEBQYFBAYGBQYHBwYIChAKCgkJChQODwwQFxQYGBcUFhYaHSUfGhsjHBYWICwgIyYnKSopGR8tMC0oMCUoKSj/2wBDAQcHBwoIChMKChMoGhYaKCgoKCgoKCgoKCgoKCgoKCgoKCgoKCgoKCgoKCgoKCgoKCgoKCgoKCgoKCgoKCgoKCj/wAARCABnAcgDASIAAhEBAxEB/8QAHwAAAQUBAQEBAQEAAAAAAAAAAAECAwQFBgcICQoL/8QAtRAAAgEDAwIEAwUFBAQAAAF9AQIDAAQRBRIhMUEGE1FhByJxFDKBkaEII0KxwRVS0fAkM2JyggkKFhcYGRolJicoKSo0NTY3ODk6Q0RFRkdISUpTVFVWV1hZWmNkZWZnaGlqc3R1dnd4eXqDhIWGh4iJipKTlJWWl5iZmqKjpKWmp6ipqrKztLW2t7i5usLDxMXGx8jJytLT1NXW19jZ2uHi4+Tl5ufo6erx8vP09fb3+Pn6/8QAHwEAAwEBAQEBAQEBAQAAAAAAAAECAwQFBgcICQoL/8QAtREAAgECBAQDBAcFBAQAAQJ3AAECAxEEBSExBhJBUQdhcRMiMoEIFEKRobHBCSMzUvAVYnLRChYkNOEl8RcYGRomJygpKjU2Nzg5OkNERUZHSElKU1RVVldYWVpjZGVmZ2hpanN0dXZ3eHl6goOEhYaHiImKkpOUlZaXmJmaoqOkpaanqKmqsrO0tba3uLm6wsPExcbHyMnK0tPU1dbX2Nna4uPk5ebn6Onq8vP09fb3+Pn6/9oADAMBAAIRAxEAPwD3W6ud32v/AE2zbdAF+Vfvfe4HzdeffqOKLq53fa/9Ns23QBflX733uB83Xn36jii6ud32v/TbNt0AX5V+997gfN159+o4ournd9r/ANNs23QBflX733uB83Xn36jikn/X3eZ7EY7adun+H+7/AF+WP9p3eL9e/wBNs23aVaL8q/e/eXfA+brz79RxWxdXO77X/ptm26AL8q/e+9wPm68+/UcVj/ad3i/Xv9Ns23aVaL8q/e/eXfA+brz79RxWxdXO77X/AKbZtugC/Kv3vvcD5uvPv1HFRTen9d/Upx1Wnbp/h/u/1+WP47ud3hDxR/ptm27Spl+Vfvfu5OB83Xn36jiti6ud32v/AE2zbdAF+Vfvfe4HzdeffqOKx/Hdzu8IeKP9Ns23aVMvyr9793JwPm68+/UcVsXVzu+1/wCm2bboAvyr9773A+brz79RxQn733f1uCj7q0/D/D/d/r8i6ud32v8A02zbdAF+Vfvfe4HzdeffqOKx/tO7xfr3+m2bbtKtF+VfvfvLvgfN159+o4rYurnd9r/02zbdAF+Vfvfe4HzdeffqOKx/tO7xfr3+m2bbtKtF+VfvfvLvgfN159+o4ob1j/XT1CEdNu3T/D/d/r8ti6ud32v/AE2zbdAF+Vfvfe4HzdeffqOKx/Hdzu8IeKP9Ns23aVMvyr9793JwPm68+/UcVsXVzu+1/wCm2bboAvyr9773A+brz79RxWP47ud3hDxR/ptm27Spl+Vfvfu5OB83Xn36jiib91/1+oUo+9HTt0/w/wB3+vyZ4x8Y6X4Ztri41rUVjtpYdvnQ2M0yDkjDNHuCHLgDdjOeOho0DxhpfiuyvrvRNRW4tTCFEsljNAsvLjEZkxuIIIO3OOM478r+0bcb/hH4mH2u1k3R2gwg+9i6TgfMeR1PXr2qH9nmbb8F9JX7TbpmC4XYw+Y/6TPwPm68+nccetoxi37Tlt0XT08v0Oz+07vF+vf6bZtu0q0X5V+9+8u+B83Xn36jiti6ud32v/TbNt0AX5V+997gfN159+o4rH+07vF+vf6bZtu0q0X5V+9+8u+B83Xn36jiti6ud32v/TbNt0AX5V+997gfN159+o4qKb0/rv6mzjqtO3T/AA/3f6/LH8d3O7wh4o/02zbdpUy/Kv3v3cnA+brz79RxWxdXO77X/ptm26AL8q/e+9wPm68+/UcVj+O7nd4Q8Uf6bZtu0qZflX737uTgfN159+o4rYurnd9r/wBNs23QBflX733uB83Xn36jihP3vu/rcFH3Vp+H+H+7/X5F1c7vtf8Aptm26AL8q/e+9wPm68+/UcVj/ad3i/Xv9Ns23aVaL8q/e/eXfA+brz79RxWxdXO77X/ptm26AL8q/e+9wPm68+/UcVj/AGnd4v17/TbNt2lWi/Kv3v3l3wPm68+/UcUN6x/rp6hCOm3bp/h/u/1+WxdXO77X/ptm26AL8q/e+9wPm68+/UcVj+O7nd4Q8Uf6bZtu0qZflX737uTgfN159+o4rYurnd9r/wBNs23QBflX733uB83Xn36jisfx3c7vCHij/TbNt2lTL8q/e/dycD5uvPv1HFE37r/r9QpR96Onbp/h/u/1+WxdXO77X/ptm26AL8q/e+9wPm68+/UcUXVzu+1/6bZtugC/Kv3vvcD5uvPv1HFF1c7vtf8Aptm26AL8q/e+9wPm68+/UcUXVzu+1/6bZtugC/Kv3vvcD5uvPv1HFWn/AF93mTGO2nbp/h/u/wBflj/ad3i/Xv8ATbNt2lWi/Kv3v3l3wPm68+/UcVsXVzu+1/6bZtugC/Kv3vvcD5uvPv1HFY/2nd4v17/TbNt2lWi/Kv3v3l3wPm68+/UcVsXVzu+1/wCm2bboAvyr9773A+brz79RxUU3p/Xf1KcdVp26f4f7v9flj+O7nd4Q8Uf6bZtu0qZflX737uTgfN159+o4rYurnd9r/wBNs23QBflX733uB83Xn36jisfx3c7vCHij/TbNt2lTL8q/e/dycD5uvPv1HFbF1c7vtf8Aptm26AL8q/e+9wPm68+/UcUJ+9939bgo+6tPw/w/3f6/Iurnd9r/ANNs23QBflX733uB83Xn36jisf7Tu8X69/ptm27SrRflX737y74HzdeffqOK2Lq53fa/9Ns23QBflX733uB83Xn36jisf7Tu8X69/ptm27SrRflX737y74HzdeffqOKG9Y/109QhHTbt0/w/3f6/LYurnd9r/wBNs23QBflX733uB83Xn36jisfx3c7vCHij/TbNt2lTL8q/e/dycD5uvPv1HFbF1c7vtf8Aptm26AL8q/e+9wPm68+/UcVj+O7nd4Q8Uf6bZtu0qZflX737uTgfN159+o4om/df9fqFKPvR07dP8P8Ad/r8ti6ud32v/TbNt0AX5V+997gfN159+o4ournd9r/02zbdAF+Vfvfe4HzdeffqOKLq53fa/wDTbNt0AX5V+997gfN159+o4ournd9r/wBNs23QBflX733uB83Xn36jirT/AK+7zJjHbTt0/wAP93+vyx/tO7xfr3+m2bbtKtF+VfvfvLvgfN159+o4rYurnd9r/wBNs23QBflX733uB83Xn36jisf7Tu8X69/ptm27SrRflX737y74HzdeffqOK2Lq53fa/wDTbNt0AX5V+997gfN159+o4qKb0/rv6lOOq07dP8P93+vyx/Hdzu8IeKP9Ns23aVMvyr9793JwPm68+/UcVsXVzu+1/wCm2bboAvyr9773A+brz79RxWP47ud3hDxR/ptm27Spl+Vfvfu5OB83Xn36jiti6ud32v8A02zbdAF+Vfvfe4HzdeffqOKE/e+7+twUfdWn4f4f7v8AX5F1c7vtf+m2bboAvyr9773A+brz79RxWP8Aad3i/Xv9Ns23aVaL8q/e/eXfA+brz79RxWxdXO77X/ptm26AL8q/e+9wPm68+/UcVj/ad3i/Xv8ATbNt2lWi/Kv3v3l3wPm68+/UcUN6x/rp6hCOm3bp/h/u/wBflsXVzu+1/wCm2bboAvyr9773A+brz79RxWP47ud3hDxR/ptm27Spl+Vfvfu5OB83Xn36jiti6ud32v8A02zbdAF+Vfvfe4HzdeffqOKx/Hdzu8IeKP8ATbNt2lTL8q/e/dycD5uvPv1HFE37r/r9QpR96Onbp/h/u/1+WxdXO77X/ptm26AL8q/e+9wPm68+/UcUXVzu+1/6bZtugC/Kv3vvcD5uvPv1HFF1c7vtf+m2bboAvyr9773A+brz79RxRdXO77X/AKbZtugC/Kv3vvcD5uvPv1HFWn/X3eZMY7adun+H+7/X5crr/iOy0LX9fvdSvk+zf2XaK729pLPgB7wkkR7ioAByx4GRnHGW6d8SvD2vWmpXWkalPfW8cIR3g0i7IY5xsX5eW/eKcDJwc4wCap/EG53WHxD/ANNs23eF1Hyr97i94HzdeffqOK4f9k2XZ8NteXz4Y91/INrjl/3MfC8jn8+tTT2/rv6kyb9oo26Lp6eR1mqfEvw34q8OeJ7bQdX+2ynSplYpptyiD91KQGdgFQnBxuPJ4GTxXol1c7vtf+m2bboAvyr9773A+brz79RxXyv+zlLs8C/FJfPhj3aag2uOX/dXPC8jn8+tfVF1c7vtf+m2bboAvyr9773A+brz79RxQn77+QUW504trr2/w+X9fkXVzu+1/wCm2bboAvyr9773A+brz79RxWP9p3eL9e/02zbdpVovyr9795d8D5uvPv1HFbF1c7vtf+m2bboAvyr9773A+brz79RxWP8Aad3i/Xv9Ns23aVaL8q/e/eXfA+brz79RxSb1j/XT1NIR027dP8P93+vy2Lq53fa/9Ns23QBflX733uB83Xn36jisfx3c7vCHij/TbNt2lTL8q/e/dycD5uvPv1HFbF1c7vtf+m2bboAvyr9773A+brz79RxWP47ud3hDxR/ptm27Spl+Vfvfu5OB83Xn36jiib91/wBfqFKPvR07dP8AD/d/r8ti6ud32v8A02zbdAF+Vfvfe4HzdeffqOKLq53fa/8ATbNt0AX5V+997gfN159+o4ournd9r/02zbdAF+Vfvfe4HzdeffqOKLq53fa/9Ns23QBflX733uB83Xn36jirT/r7vMmMdtO3T/D/AHf6/LH+07vF+vf6bZtu0q0X5V+9+8u+B83Xn36jiti6ud32v/TbNt0AX5V+997gfN159+o4rH+07vF+vf6bZtu0q0X5V+9+8u+B83Xn36jiti6ud32v/TbNt0AX5V+997gfN159+o4qKb0/rv6lOOq07dP8P93+vyx/Hdzu8IeKP9Ns23aVMvyr9793JwPm68+/UcVsXVzu+1/6bZtugC/Kv3vvcD5uvPv1HFY/ju53eEPFH+m2bbtKmX5V+9+7k4HzdeffqOK2Lq53fa/9Ns23QBflX733uB83Xn36jihP3vu/rcFH3Vp+H+H+7/X5F1c7vtf+m2bboAvyr9773A+brz79RxRRdXO77X/ptm26AL8q/e+9wPm68+/UcUV0UjtwKsn8vy9EZF0deb7Z/wAVB4fbdAF+XTZPm+9wP9J68+/UUXR15vtn/FQeH23QBfl02T5vvcD/AEnrz79RWvdXO77X/ptm26AL8q/e+9wPm68+/UcUXVzu+1/6bZtugC/Kv3vvcD5uvPv1HFYpf193mcUb6adun+H+6cmX1pvFOuBdd0JpTpdqGYae+1xvusKo+0cMOcnJzuHAxzq3R15vtn/FQeH23QBfl02T5vvcD/SevPv1FJ9p3eL9e/02zbdpVovyr9795d8D5uvPv1HFbF1c7vtf+m2bboAvyr9773A+brz79RxUQ2/rv6lO91p26f4f7v8AX5cn41fWv+EW8SGbXdCliOlyh1j091Zxskyqk3Bw3PXB6jj11bo6832z/ioPD7boAvy6bJ833uB/pPXn36ik8d3O7wh4o/02zbdpUy/Kv3v3cnA+brz79RxWxdXO77X/AKbZtugC/Kv3vvcD5uvPv1HFC+L7v63BX5Vp+H+H+7/X5ZF0deb7Z/xUHh9t0AX5dNk+b73A/wBJ68+/UVlF9abxTrgXXdCaU6XahmGnvtcb7rCqPtHDDnJyc7hwMc9ZdXO77X/ptm26AL8q/e+9wPm68+/UcVj/AGnd4v17/TbNt2lWi/Kv3v3l3wPm68+/UcUPdf109Qhe23bp/h/u/wBfkt0deb7Z/wAVB4fbdAF+XTZPm+9wP9J68+/UVleNX1r/AIRbxIZtd0KWI6XKHWPT3VnGyTKqTcHDc9cHqOPXrLq53fa/9Ns23QBflX733uB83Xn36jisfx3c7vCHij/TbNt2lTL8q/e/dycD5uvPv1HFE/hf9fqFK/NHTt0/w/3f6/Lz/wCPb63deBNV0sXttqk99HAI7fTNGuGZ9k6sR5iyusZA5+YfMOBzUPwM/ty2+G0Ol/a7bTJ7SCRZLXUdHuFcb5pmAV2lRXJDZ+UHG5Qeevr11c7vtf8Aptm26AL8q/e+9wPm68+/UcUXVzu+1/6bZtugC/Kv3vvcD5uvPv1HFWv6/q5lGHvqdu3T0/u/1+XJl9abxTrgXXdCaU6XahmGnvtcb7rCqPtHDDnJyc7hwMc6t0deb7Z/xUHh9t0AX5dNk+b73A/0nrz79RSfad3i/Xv9Ns23aVaL8q/e/eXfA+brz79RxWxdXO77X/ptm26AL8q/e+9wPm68+/UcVENv67+pq73Wnbp/h/u/1+XJ+NX1r/hFvEhm13QpYjpcodY9PdWcbJMqpNwcNz1weo49dW6OvN9s/wCKg8PtugC/Lpsnzfe4H+k9effqKTx3c7vCHij/AE2zbdpUy/Kv3v3cnA+brz79RxWxdXO77X/ptm26AL8q/e+9wPm68+/UcUL4vu/rcFflWn4f4f7v9flkXR15vtn/ABUHh9t0AX5dNk+b73A/0nrz79RWUX1pvFOuBdd0JpTpdqGYae+1xvusKo+0cMOcnJzuHAxz1l1c7vtf+m2bboAvyr9773A+brz79RxWP9p3eL9e/wBNs23aVaL8q/e/eXfA+brz79RxQ91/XT1CF7bdun+H+7/X5LdHXm+2f8VB4fbdAF+XTZPm+9wP9J68+/UVleNX1r/hFvEhm13QpYjpcodY9PdWcbJMqpNwcNz1weo49esurnd9r/02zbdAF+Vfvfe4HzdeffqOKx/Hdzu8IeKP9Ns23aVMvyr9793JwPm68+/UcUT+F/1+oUr80dO3T/D/AHf6/Jbo6832z/ioPD7boAvy6bJ833uB/pPXn36ii6OvN9s/4qDw+26AL8umyfN97gf6T159+orXurnd9r/02zbdAF+Vfvfe4HzdeffqOKLq53fa/wDTbNt0AX5V+997gfN159+o4q0v6+7zJjfTTt0/w/3Tky+tN4p1wLruhNKdLtQzDT32uN91hVH2jhhzk5Odw4GOdW6OvN9s/wCKg8PtugC/Lpsnzfe4H+k9effqKT7Tu8X69/ptm27SrRflX737y74HzdeffqOK2Lq53fa/9Ns23QBflX733uB83Xn36jioht/Xf1Kd7rTt0/w/3f6/Lk/Gr61/wi3iQza7oUsR0uUOsenurONkmVUm4OG564PUceurdHXm+2f8VB4fbdAF+XTZPm+9wP8ASevPv1FJ47ud3hDxR/ptm27Spl+Vfvfu5OB83Xn36jiti6ud32v/AE2zbdAF+Vfvfe4HzdeffqOKF8X3f1uCvyrT8P8AD/d/r8si6OvN9s/4qDw+26AL8umyfN97gf6T159+orKL603inXAuu6E0p0u1DMNPfa433WFUfaOGHOTk53DgY56y6ud32v8A02zbdAF+Vfvfe4HzdeffqOKx/tO7xfr3+m2bbtKtF+VfvfvLvgfN159+o4oe6/rp6hC9tu3T/D/d/r8lujrzfbP+Kg8PtugC/Lpsnzfe4H+k9effqKyvGr61/wAIt4kM2u6FLEdLlDrHp7qzjZJlVJuDhueuD1HHr1l1c7vtf+m2bboAvyr9773A+brz79RxWP47ud3hDxR/ptm27Spl+Vfvfu5OB83Xn36jiifwv+v1Clfmjp26f4f7v9fkt0deb7Z/xUHh9t0AX5dNk+b73A/0nrz79RRdHXm+2f8AFQeH23QBfl02T5vvcD/SevPv1Fa91c7vtf8Aptm26AL8q/e+9wPm68+/UcUXVzu+1/6bZtugC/Kv3vvcD5uvPv1HFWl/X3eZMb6adun+H+6cmX1pvFOuBdd0JpTpdqGYae+1xvusKo+0cMOcnJzuHAxzq3R15vtn/FQeH23QBfl02T5vvcD/AEnrz79RSfad3i/Xv9Ns23aVaL8q/e/eXfA+brz79RxWxdXO77X/AKbZtugC/Kv3vvcD5uvPv1HFRDb+u/qU73Wnbp/h/u/1+XJ+NX1r/hFvEhm13QpYjpcodY9PdWcbJMqpNwcNz1weo49dW6OvN9s/4qDw+26AL8umyfN97gf6T159+opPHdzu8IeKP9Ns23aVMvyr9793JwPm68+/UcVsXVzu+1/6bZtugC/Kv3vvcD5uvPv1HFC+L7v63BX5Vp+H+H+7/X5ZF0deb7Z/xUHh9t0AX5dNk+b73A/0nrz79RWUX1pvFOuBdd0JpTpdqGYae+1xvusKo+0cMOcnJzuHAxz1l1c7vtf+m2bboAvyr9773A+brz79RxWP9p3eL9e/02zbdpVovyr9795d8D5uvPv1HFD3X9dPUIXtt26f4f7v9fkt0deb7Z/xUHh9t0AX5dNk+b73A/0nrz79RWV41fWv+EW8SGbXdCliOlyh1j091Zxskyqk3Bw3PXB6jj16y6ud32v/AE2zbdAF+Vfvfe4HzdeffqOKx/Hdzu8IeKP9Ns23aVMvyr9793JwPm68+/UcUT+F/wBfqFK/NHTt0/w/3f6/Jbo6832z/ioPD7boAvy6bJ833uB/pPXn36ii6OvN9s/4qDw+26AL8umyfN97gf6T159+orXurnd9r/02zbdAF+Vfvfe4HzdeffqOKLq53fa/9Ns23QBflX733uB83Xn36jirS/r7vMmN9NO3T/D/AHTzD4h3erRweMYH1SwvJ73QorRY7HR55mmLi8CooSVzGc7gXbKjcuQP4uJ+AE2seGfBOu2d55+lSNO1x5F3oF3cPKpWNMoyMoJyfugEgAt0BI9t+07vF+vf6bZtu0q0X5V+9+8u+B83Xn36jiti6ud32v8A02zbdAF+Vfvfe4HzdeffqOKiG39d/UTh76lbounp/d/r8vlT4MWuteH/AAx48tL+C40r+0NPO1b3SbhhOEhnLBZQVSI4bGXzksMAng/Sl0deb7Z/xUHh9t0AX5dNk+b73A/0nrz79RSeO7nd4Q8Uf6bZtu0qZflX737uTgfN159+o4rYurnd9r/02zbdAF+Vfvfe4HzdeffqOKa1k/l/W4U4ckEkuvb/AA/3f6/LIujrzfbP+Kg8PtugC/Lpsnzfe4H+k9effqKyi+tN4p1wLruhNKdLtQzDT32uN91hVH2jhhzk5Odw4GOesurnd9r/ANNs23QBflX733uB83Xn36jisf7Tu8X69/ptm27SrRflX737y74HzdeffqOKT3X9dPUuF7bdun+H+7/X5LdHXm+2f8VB4fbdAF+XTZPm+9wP9J68+/UVleNX1r/hFvEhm13QpYjpcodY9PdWcbJMqpNwcNz1weo49esurnd9r/02zbdAF+Vfvfe4HzdeffqOKx/Hdzu8IeKP9Ns23aVMvyr9793JwPm68+/UcUT+F/1+oUr80dO3T/D/AHf6/Jbo6832z/ioPD7boAvy6bJ833uB/pPXn36ii6OvN9s/4qDw+26AL8umyfN97gf6T159+orXurnd9r/02zbdAF+Vfvfe4HzdeffqOKLq53fa/wDTbNt0AX5V+997gfN159+o4q0v6+7zJjfTTt0/w/3Tky+tN4p1wLruhNKdLtQzDT32uN91hVH2jhhzk5Odw4GOdW6OvN9s/wCKg8PtugC/Lpsnzfe4H+k9effqKT7Tu8X69/ptm27SrRflX737y74HzdeffqOK2Lq53fa/9Ns23QBflX733uB83Xn36jioht/Xf1Kd7rTt0/w/3f6/Lk/Gr61/wi3iQza7oUsR0uUOsenurONkmVUm4OG564PUceurdHXm+2f8VB4fbdAF+XTZPm+9wP8ASevPv1FJ47ud3hDxR/ptm27Spl+Vfvfu5OB83Xn36jiti6ud32v/AE2zbdAF+Vfvfe4HzdeffqOKF8X3f1uCvyrT8P8AD/d/r8si6OvN9s/4qDw+26AL8umyfN97gf6T159+oorXurnd9r/02zbdAF+Vfvfe4HzdeffqOKK3pRT/AOH/AOCduBbSenbp5eiMi68YaCftn/FU+H23QAfLcx/N9/gfvOvPv1FF14w0E/bP+Kp8PtugA+W5j+b7/A/edeffqK17q53fa/8ATbNt0AX5V+997gfN159+o4ournd9r/02zbdAF+Vfvfe4HzdeffqOKzV+/wDWnmcEVHTTt/7b/d/r8uTPivRf+Ep1yU+JdCMUml2sauLhNrkPdEqp3/eG4Z6/eHHrq3XjDQT9s/4qnw+26AD5bmP5vv8AA/edeffqKT7Tu8X69/ptm27SrRflX737y74HzdeffqOK2Lq53fa/9Ns23QBflX733uB83Xn36jiog3bf+r+pTUbrTt/7b/d/r8uT8a+K9FuPC3iSKHxLoU0sulyxokdwhaQlJAFUBz83Pv1HHrq3XjDQT9s/4qnw+26AD5bmP5vv8D95159+opPHdzu8IeKP9Ns23aVMvyr9793JwPm68+/UcVsXVzu+1/6bZtugC/Kv3vvcD5uvPv1HFCvzb9v63BKPKtP693+7/X5ZF14w0E/bP+Kp8PtugA+W5j+b7/A/edeffqKyj4r0X/hKdclPiXQjFJpdrGri4Ta5D3RKqd/3huGev3hx69ZdXO77X/ptm26AL8q/e+9wPm68+/UcVj/ad3i/Xv8ATbNt2lWi/Kv3v3l3wPm68+/UcUNu61/q3qEFG23b/wBt/u/1+S3XjDQT9s/4qnw+26AD5bmP5vv8D95159+orK8a+K9FuPC3iSKHxLoU0sulyxokdwhaQlJAFUBz83Pv1HHr1l1c7vtf+m2bboAvyr9773A+brz79RxWP47ud3hDxR/ptm27Spl+Vfvfu5OB83Xn36jiid+V6/194U1Hmjp2/wDbf7v9fkt14w0E/bP+Kp8PtugA+W5j+b7/AAP3nXn36ii68YaCftn/ABVPh9t0AHy3Mfzff4H7zrz79RWvdXO77X/ptm26AL8q/e+9wPm68+/UcUXVzu+1/wCm2bboAvyr9773A+brz79RxVq/f+tPMmKjpp2/9t/u/wBflyZ8V6L/AMJTrkp8S6EYpNLtY1cXCbXIe6JVTv8AvDcM9fvDj11brxhoJ+2f8VT4fbdAB8tzH833+B+868+/UUn2nd4v17/TbNt2lWi/Kv3v3l3wPm68+/UcVsXVzu+1/wCm2bboAvyr9773A+brz79RxUQbtv8A1f1Kajdadv8A23+7/X5cn418V6LceFvEkUPiXQppZdLljRI7hC0hKSAKoDn5uffqOPXVuvGGgn7Z/wAVT4fbdAB8tzH833+B+868+/UUnju53eEPFH+m2bbtKmX5V+9+7k4HzdeffqOK2Lq53fa/9Ns23QBflX733uB83Xn36jihX5t+39bglHlWn9e7/d/r8si68YaCftn/ABVPh9t0AHy3Mfzff4H7zrz79RWUfFei/wDCU65KfEuhGKTS7WNXFwm1yHuiVU7/ALw3DPX7w49esurnd9r/ANNs23QBflX733uB83Xn36jisf7Tu8X69/ptm27SrRflX737y74HzdeffqOKG3da/wBW9Qgo227f+2/3f6/JbrxhoJ+2f8VT4fbdAB8tzH833+B+868+/UVleNfFei3HhbxJFD4l0KaWXS5Y0SO4QtISkgCqA5+bn36jj16y6ud32v8A02zbdAF+Vfvfe4HzdeffqOKx/Hdzu8IeKP8ATbNt2lTL8q/e/dycD5uvPv1HFE78r1/r7wpqPNHTt/7b/d/r8luvGGgn7Z/xVPh9t0AHy3Mfzff4H7zrz79RRdeMNBP2z/iqfD7boAPluY/m+/wP3nXn36ite6ud32v/AE2zbdAF+Vfvfe4HzdeffqOKLq53fa/9Ns23QBflX733uB83Xn36jirV+/8AWnmTFR007f8Atv8Ad/r8uTPivRf+Ep1yU+JdCMUml2sauLhNrkPdEqp3/eG4Z6/eHHrq3XjDQT9s/wCKp8PtugA+W5j+b7/A/edeffqKT7Tu8X69/ptm27SrRflX737y74HzdeffqOK2Lq53fa/9Ns23QBflX733uB83Xn36jiog3bf+r+pTUbrTt/7b/d/r8uT8a+K9FuPC3iSKHxLoU0sulyxokdwhaQlJAFUBz83Pv1HHrq3XjDQT9s/4qnw+26AD5bmP5vv8D95159+opPHdzu8IeKP9Ns23aVMvyr9793JwPm68+/UcVsXVzu+1/wCm2bboAvyr9773A+brz79RxQr82/b+twSjyrT+vd/u/wBflkXXjDQT9s/4qnw+26AD5bmP5vv8D95159+orKPivRf+Ep1yU+JdCMUml2sauLhNrkPdEqp3/eG4Z6/eHHr1l1c7vtf+m2bboAvyr9773A+brz79RxWP9p3eL9e/02zbdpVovyr9795d8D5uvPv1HFDbutf6t6hBRtt2/wDbf7v9fkt14w0E/bP+Kp8PtugA+W5j+b7/AAP3nXn36isrxr4r0W48LeJIofEuhTSy6XLGiR3CFpCUkAVQHPzc+/UcevWXVzu+1/6bZtugC/Kv3vvcD5uvPv1HFY/ju53eEPFH+m2bbtKmX5V+9+7k4HzdeffqOKJ35Xr/AF94U1Hmjp2/9t/u/wBfkt14w0E/bP8AiqfD7boAPluY/m+/wP3nXn36ii68YaCftn/FU+H23QAfLcx/N9/gfvOvPv1Fa91c7vtf+m2bboAvyr9773A+brz79RxRdXO77X/ptm26AL8q/e+9wPm68+/UcVav3/rTzJio6adv/bf7v9flyZ8V6L/wlOuSnxLoRik0u1jVxcJtch7olVO/7w3DPX7w49dW68YaCftn/FU+H23QAfLcx/N9/gfvOvPv1FJ9p3eL9e/02zbdpVovyr9795d8D5uvPv1HFbF1c7vtf+m2bboAvyr9773A+brz79RxUQbtv/V/UpqN1p2/9t/u/wBflyfjXxXotx4W8SRQ+JdCmll0uWNEjuELSEpIAqgOfm59+o49dW68YaCftn/FU+H23QAfLcx/N9/gfvOvPv1FJ47ud3hDxR/ptm27Spl+Vfvfu5OB83Xn36jiti6ud32v/TbNt0AX5V+997gfN159+o4oV+bft/W4JR5Vp/Xu/wB3+vyyLrxhoJ+2f8VT4fbdAB8tzH833+B+868+/UVlHxXov/CU65KfEuhGKTS7WNXFwm1yHuiVU7/vDcM9fvDj16y6ud32v/TbNt0AX5V+997gfN159+o4rH+07vF+vf6bZtu0q0X5V+9+8u+B83Xn36jiht3Wv9W9Qgo227f+2/3f6/JbrxhoJ+2f8VT4fbdAB8tzH833+B+868+/UVleNfFei3HhbxJFD4l0KaWXS5Y0SO4QtISkgCqA5+bn36jj16y6ud32v/TbNt0AX5V+997gfN159+o4rH8d3O7wh4o/02zbdpUy/Kv3v3cnA+brz79RxRO/K9f6+8KajzR07f8Atv8Ad/r8luvGGgn7Z/xVPh9t0AHy3Mfzff4H7zrz79RRdeMNBP2z/iqfD7boAPluY/m+/wAD95159+orXurnd9r/ANNs23QBflX733uB83Xn36jii6ud32v/AE2zbdAF+Vfvfe4HzdeffqOKtX7/ANaeZMVHTTt/7b/d/r8uTPivRf8AhKdclPiXQjFJpdrGri4Ta5D3RKqd/wB4bhnr94ceurdeMNBP2z/iqfD7boAPluY/m+/wP3nXn36ik+07vF+vf6bZtu0q0X5V+9+8u+B83Xn36jiti6ud32v/AE2zbdAF+Vfvfe4HzdeffqOKiDdt/wCr+pTUbrTt/wC2/wB3+vy5Pxr4r0W48LeJIofEuhTSy6XLGiR3CFpCUkAVQHPzc+/UceurdeMNBP2z/iqfD7boAPluY/m+/wAD95159+opPHdzu8IeKP8ATbNt2lTL8q/e/dycD5uvPv1HFbF1c7vtf+m2bboAvyr9773A+brz79RxQr82/b+twSjyrT+vd/u/1+WRdeMNBP2z/iqfD7boAPluY/m+/wAD95159+orKPivRf8AhKdclPiXQjFJpdrGri4Ta5D3RKqd/wB4bhnr94cevWXVzu+1/wCm2bboAvyr9773A+brz79RxWP9p3eL9e/02zbdpVovyr9795d8D5uvPv1HFDbutf6t6hBRtt2/9t/u/wBfkt14w0E/bP8AiqfD7boAPluY/m+/wP3nXn36isrxr4r0W48LeJIofEuhTSy6XLGiR3CFpCUkAVQHPzc+/UcevWXVzu+1/wCm2bboAvyr9773A+brz79RxWP47ud3hDxR/ptm27Spl+Vfvfu5OB83Xn36jiid+V6/194U1Hmjp2/9t/u/1+S3XjDQT9s/4qnw+26AD5bmP5vv8D95159+oouvGGgn7Z/xVPh9t0AHy3Mfzff4H7zrz79RWvdXO77X/ptm26AL8q/e+9wPm68+/UcUXVzu+1/6bZtugC/Kv3vvcD5uvPv1HFWr9/608yYqOmnb/wBt/u/1+XJnxXov/CU65KfEuhGKTS7WNXFwm1yHuiVU7/vDcM9fvDj11brxhoJ+2f8AFU+H23QAfLcx/N9/gfvOvPv1FJ9p3eL9e/02zbdpVovyr9795d8D5uvPv1HFbF1c7vtf+m2bboAvyr9773A+brz79RxUQbtv/V/UpqN1p2/9t/u/1+XJ+NfFei3HhbxJFD4l0KaWXS5Y0SO4QtISkgCqA5+bn36jj11brxhoJ+2f8VT4fbdAB8tzH833+B+868+/UUnju53eEPFH+m2bbtKmX5V+9+7k4HzdeffqOK2Lq53fa/8ATbNt0AX5V+997gfN159+o4oV+bft/W4JR5Vp/Xu/3f6/LIuvGGgn7Z/xVPh9t0AHy3Mfzff4H7zrz79RRWvdXO77X/ptm26AL8q/e+9wPm68+/UcUVvT5ns/6+87cDypPTt+Xogurnd9r/02zbdAF+Vfvfe4HzdeffqOKLq53fa/9Ns23QBflX733uB83Xn36jisi6OvN9s/4qDw+26AL8umyfN97gf6T159+ooujrzfbP8AioPD7boAvy6bJ833uB/pPXn36is1L+vu8zgjBafLp/h/uifad3i/Xv8ATbNt2lWi/Kv3v3l3wPm68+/UcVsXVzu+1/6bZtugC/Kv3vvcD5uvPv1HFcmX1pvFOuBdd0JpTpdqGYae+1xvusKo+0cMOcnJzuHAxzL4r1PXtJ0DXtT/ALb8P3H2TTpJ/LXT5F83YkjbAftBwTjGcHqOPWIS0/rv6jlFKzfl08o/3f6/KlP4ttfGHwq1vXLCYQ215pVyqRXMQSU7RMhGBIwBypPU8EcV2l1c7vtf+m2bboAvyr9773A+brz79RxXh3wwOpj9naXytU0uKzOl3oNvLaM0pHmXGVD+cBuOTg7ONw4OOfWro6832z/ioPD7boAvy6bJ833uB/pPXn36ine038v63FCN4Rf6f4f7pr3Vzu+1/wCm2bboAvyr9773A+brz79RxWP9p3eL9e/02zbdpVovyr9795d8D5uvPv1HFLdHXm+2f8VB4fbdAF+XTZPm+9wP9J68+/UVlF9abxTrgXXdCaU6XahmGnvtcb7rCqPtHDDnJyc7hwMcpvVf109SoQVvu6f4f7v9fl1l1c7vtf8Aptm26AL8q/e+9wPm68+/UcVj+O7nd4Q8Uf6bZtu0qZflX737uTgfN159+o4pbo6832z/AIqDw+26AL8umyfN97gf6T159+orK8avrX/CLeJDNruhSxHS5Q6x6e6s42SZVSbg4bnrg9Rx6k37r/r9QpQXNH5dP8P93+vy6TWtVgsNP1W9vNRs1tYLNpZXVCfkUOTgBicgZ6Z6jj1S31a31TTjfWWo2k1reWaSxOIyhkRgzLgFsg4I4IzyOK4f4u6pqulfDzxTc3utaPc28mn/AGVkttOcO5lLRAKTckDBkBJwcDnBxgz+ATrR+HehCHW9ESI6HaKkb6e7OB5PCEi4GWGeTgdegq0/6/pmUV7/AC+S6en906L7Tu8X69/ptm27SrRflX737y74HzdeffqOK2Lq53fa/wDTbNt0AX5V+997gfN159+o4rky+tN4p1wLruhNKdLtQzDT32uN91hVH2jhhzk5Odw4GOdW6OvN9s/4qDw+26AL8umyfN97gf6T159+oqIPT+u/qauCuvl0/wAP93+vyTx3c7vCHij/AE2zbdpUy/Kv3v3cnA+brz79RxWxdXO77X/ptm26AL8q/e+9wPm68+/UcVyfjV9a/wCEW8SGbXdCliOlyh1j091Zxskyqk3Bw3PXB6jj11bo6832z/ioPD7boAvy6bJ833uB/pPXn36ihP3vu/rcFBcq/wAv8P8Ad/r8te6ud32v/TbNt0AX5V+997gfN159+o4rH+07vF+vf6bZtu0q0X5V+9+8u+B83Xn36jilujrzfbP+Kg8PtugC/Lpsnzfe4H+k9effqKyi+tN4p1wLruhNKdLtQzDT32uN91hVH2jhhzk5Odw4GORvVf109QhBW+7p/h/u/wBfl0i6ta339pfY9W0268pTby+QwbbIu7MZw5w4yMg88jj1z/Hdzu8IeKP9Ns23aVMvyr9793JwPm68+/UcV5l8Eb6/1PTvHd/pOtaStrea7dzK82nyE3G4A7kBmUoCCMKQxGeSa7nxq+tf8It4kM2u6FLEdLlDrHp7qzjZJlVJuDhueuD1HHq5v3X/AF+pNCKbi/Tp/h/u/wBfl1l1c7vtf+m2bboAvyr9773A+brz79RxRdXO77X/AKbZtugC/Kv3vvcD5uvPv1HFZF0deb7Z/wAVB4fbdAF+XTZPm+9wP9J68+/UUXR15vtn/FQeH23QBfl02T5vvcD/AEnrz79RVKX9fd5hGC0+XT/D/dE+07vF+vf6bZtu0q0X5V+9+8u+B83Xn36jiti6ud32v/TbNt0AX5V+997gfN159+o4rky+tN4p1wLruhNKdLtQzDT32uN91hVH2jhhzk5Odw4GOdW6OvN9s/4qDw+26AL8umyfN97gf6T159+oqIPT+u/qU4K6+XT/AA/3f6/JPHdzu8IeKP8ATbNt2lTL8q/e/dycD5uvPv1HFbF1c7vtf+m2bboAvyr9773A+brz79RxXJ+NX1r/AIRbxIZtd0KWI6XKHWPT3VnGyTKqTcHDc9cHqOPXVujrzfbP+Kg8PtugC/Lpsnzfe4H+k9effqKE/e+7+twUFyr/AC/w/wB3+vy17q53fa/9Ns23QBflX733uB83Xn36jisf7Tu8X69/ptm27SrRflX737y74HzdeffqOKW6OvN9s/4qDw+26AL8umyfN97gf6T159+orKL603inXAuu6E0p0u1DMNPfa433WFUfaOGHOTk53DgY5G9V/XT1CEFb7un+H+7/AF+XWXVzu+1/6bZtugC/Kv3vvcD5uvPv1HFY/ju53eEPFH+m2bbtKmX5V+9+7k4HzdeffqOKW6OvN9s/4qDw+26AL8umyfN97gf6T159+orK8avrX/CLeJDNruhSxHS5Q6x6e6s42SZVSbg4bnrg9Rx6k37r/r9QpQXNH5dP8P8Ad/r8usurnd9r/wBNs23QBflX733uB83Xn36jii6ud32v/TbNt0AX5V+997gfN159+o4rIujrzfbP+Kg8PtugC/Lpsnzfe4H+k9effqKLo6832z/ioPD7boAvy6bJ833uB/pPXn36irUv6+7zJjBafLp/h/uifad3i/Xv9Ns23aVaL8q/e/eXfA+brz79RxWxdXO77X/ptm26AL8q/e+9wPm68+/UcVyZfWm8U64F13QmlOl2oZhp77XG+6wqj7Rww5ycnO4cDHOrdHXm+2f8VB4fbdAF+XTZPm+9wP8ASevPv1FRB6f139SnBXXy6f4f7v8AX5J47ud3hDxR/ptm27Spl+Vfvfu5OB83Xn36jiti6ud32v8A02zbdAF+Vfvfe4HzdeffqOK5Pxq+tf8ACLeJDNruhSxHS5Q6x6e6s42SZVSbg4bnrg9Rx66t0deb7Z/xUHh9t0AX5dNk+b73A/0nrz79RQn733f1uCguVf5f4f7v9flr3Vzu+1/6bZtugC/Kv3vvcD5uvPv1HFY/2nd4v17/AE2zbdpVovyr9795d8D5uvPv1HFLdHXm+2f8VB4fbdAF+XTZPm+9wP8ASevPv1FZRfWm8U64F13QmlOl2oZhp77XG+6wqj7Rww5ycnO4cDHI3qv66eoQgrfd0/w/3f6/LrLq53fa/wDTbNt0AX5V+997gfN159+o4rH8d3O7wh4o/wBNs23aVMvyr9793JwPm68+/UcUt0deb7Z/xUHh9t0AX5dNk+b73A/0nrz79RWV41fWv+EW8SGbXdCliOlyh1j091Zxskyqk3Bw3PXB6jj1Jv3X/X6hSguaPy6f4f7v9fl1l1c7vtf+m2bboAvyr9773A+brz79RxRdXO77X/ptm26AL8q/e+9wPm68+/UcVkXR15vtn/FQeH23QBfl02T5vvcD/SevPv1FF0deb7Z/xUHh9t0AX5dNk+b73A/0nrz79RVqX9fd5kxgtPl0/wAP90T7Tu8X69/ptm27SrRflX737y74HzdeffqOK2Lq53fa/wDTbNt0AX5V+997gfN159+o4rky+tN4p1wLruhNKdLtQzDT32uN91hVH2jhhzk5Odw4GOdW6OvN9s/4qDw+26AL8umyfN97gf6T159+oqIPT+u/qU4K6+XT/D/d/r8k8d3O7wh4o/02zbdpUy/Kv3v3cnA+brz79RxWxdXO77X/AKbZtugC/Kv3vvcD5uvPv1HFcn41fWv+EW8SGbXdCliOlyh1j091Zxskyqk3Bw3PXB6jj11bo6832z/ioPD7boAvy6bJ833uB/pPXn36ihP3vu/rcFBcq/y/w/3f6/LXurnd9r/02zbdAF+Vfvfe4HzdeffqOKx/tO7xfr3+m2bbtKtF+VfvfvLvgfN159+o4pbo6832z/ioPD7boAvy6bJ833uB/pPXn36isovrTeKdcC67oTSnS7UMw099rjfdYVR9o4Yc5OTncOBjkb1X9dPUIQVvu6f4f7v9fl1l1c7vtf8Aptm26AL8q/e+9wPm68+/UcVj+O7nd4Q8Uf6bZtu0qZflX737uTgfN159+o4pbo6832z/AIqDw+26AL8umyfN97gf6T159+orK8avrX/CLeJDNruhSxHS5Q6x6e6s42SZVSbg4bnrg9Rx6k37r/r9QpQXNH5dP8P93+vy6y6ud32v/TbNt0AX5V+997gfN159+o4ournd9r/02zbdAF+Vfvfe4HzdeffqOKyLo6832z/ioPD7boAvy6bJ833uB/pPXn36ii6OvN9s/wCKg8PtugC/Lpsnzfe4H+k9effqKtS/r7vMmMFp8un+H+6J9p3eL9e/02zbdpVovyr9795d8D5uvPv1HFbF1c7vtf8Aptm26AL8q/e+9wPm68+/UcVyZfWm8U64F13QmlOl2oZhp77XG+6wqj7Rww5ycnO4cDHOrdHXm+2f8VB4fbdAF+XTZPm+9wP9J68+/UVEHp/Xf1KcFdfLp/h/u/1+SeO7nd4Q8Uf6bZtu0qZflX737uTgfN159+o4rYurnd9r/wBNs23QBflX733uB83Xn36jiuT8avrX/CLeJDNruhSxHS5Q6x6e6s42SZVSbg4bnrg9Rx66t0deb7Z/xUHh9t0AX5dNk+b73A/0nrz79RQn733f1uCguVf5f4f7v9flr3Vzu+1/6bZtugC/Kv3vvcD5uvPv1HFFZF0deb7Z/wAVB4fbdAF+XTZPm+9wP9J68+/UUVvSk+39feduBgknr2/L0Rr3Vzu+1/6bZtugC/Kv3vvcD5uvPv1HFF1c7vtf+m2bboAvyr9773A+brz79RxWHf8Ajjw3G12svi7w2Ga3AwbyIbh8/A/edfz6imXXjzwuftn/ABWPhlt0AHy3sXzff4H7zrz79RULX+vTzPM5oxaT8v8A23+7/X5T/ad3i/Xv9Ns23aVaL8q/e/eXfA+brz79RxVf4l3O7wD4x/02zbdotwPlX737qXgfN159+o4rhvGHxi8O+HPF2oFbwa3He6Xbp5ujpHcJHskuMh280BT+8B79eQOMt+NXjzRtV+E/iA6D4q0u4ubq1tgsVrOEneNpl3Ls37x8jMGUjOCQQOaiF7f1/mTVnBx07fov7v8AX5cv8Bb2Z/gH4zimvV8uJbuKKOZi2FNuG2pkjaNzscAdWJ78/Qd1c7vtf+m2bboAvyr9773A+brz79RxXz34G1rQvDWifFDwhHqFjaNI97c6cplEkV1bvFtjWKXeQz4C/KSW57lWx7Hq3j/wvaRajJceLvDxCW2WWO5RnYAOdqqHJLewBJyMD1ad56eRcbRppy6P/wCR8v6/Lobq53fa/wDTbNt0AX5V+997gfN159+o4rH+07vF+vf6bZtu0q0X5V+9+8u+B83Xn36jivMta+Ld/wCKNT1Ox+H+p+HLbT4rLbNq2tM1sJJGB2rbxsdxZck5ZSMjkAbd7/AHxK8zXvEVh451rQrTVrawgtRdxzqbbUUjaY+bHJkIGImXK9c5+UYZVHq1/X6ihJWu1pprbT7PkexXVzu+1/6bZtugC/Kv3vvcD5uvPv1HFY/ju53eEPFH+m2bbtKmX5V+9+7k4HzdeffqOKLjxjoEi3TL4q8Pur24wVuo/nHzcD95159+orkviR8T/CdrpWuaVJ4n02a+vNMeKJbaJ5lZmWRVUuhZUOT/ABHoQTgclSd4tL+vxLglBxclZaf+2/3f6/I/aNuN/wAI/Ew+12sm6O0GEH3sXScD5jyOp69e1SfAvVbnUPhBo0t7e27SrZNbAMgDFIpZY0QYI5CKozjJ4zk8nC+PniPTNY0DTdHtvEmmTWeqarZWl/8AY5omYW+6Riclm27WVDu+meMgx/s/+LNEtfhRbadda7plneWkc0M9tdSCKQEzTOAAzDOQ4OQCOcdQatNWvcyjTaq7dF09PL9D0r7Tu8X69/ptm27SrRflX737y74HzdeffqOK2Lq53fa/9Ns23QBflX733uB83Xn36jiuRl8XaFH4m124l8T6AIH0u1jEhuYwrkSXWVU+ZjcNy+v3l49eL8WfGe9udS1mw8CWuj6oltGkEmpXt9FawM+W3CJHkUygDI3K3XBwRtLRB6X/AK/M1n7skra2Wltdo/3T0rx3c7vCHij/AE2zbdpUy/Kv3v3cnA+brz79RxWxdXO77X/ptm26AL8q/e+9wPm68+/UcV4XbfGSfW9J8RaX4tg03SLrU9Jml0xoJRNHIhjfbBIwc7J+ejYJJA2qdob1268YaCftn/FU+H23QAfLcx/N9/gfvOvPv1FCa5t+39bjhHmirLZ9v8P9017q53fa/wDTbNt0AX5V+997gfN159+o4rH+07vF+vf6bZtu0q0X5V+9+8u+B83Xn36jim3/AI08OxrdtL4s8OhWgC5N3GA33/lH7zr+fUcVzfiLxvpllN4v1PT/ABDoFzKmgxNbATKyTyIbthGuJOTyuQDn5h6jI38L/rb1CK5U7rZLp/h/u/1+XnP7IuqSnw54t0xpbaKCKSKdd6ne7SI6sAdwHSJccdzXtnju53eEPFH+m2bbtKmX5V+9+7k4HzdeffqOK8L/AGbLvSfDD+LrW58QaXGLmx064QzyJGZC8DyPGuX5KNJsPXkcgdK9g8a+K9FuPC3iSKHxLoU0sulyxokdwhaQlJAFUBz83Pv1HHqVJe69TPBxlJRduvbzXl/X5dZdXO77X/ptm26AL8q/e+9wPm68+/UcUXVzu+1/6bZtugC/Kv3vvcD5uvPv1HFcJ47+Lnhrw0ArapDq895H5awaSi3DhQHyx/eYUDI6nJzwDg4qeAfjBpHi/StQl1K6sdB1OKPy5rK8kClh85UxszLuBB54yCcEYwWpP+v6Y4pXSt26en93+vy677Tu8X69/ptm27SrRflX737y74HzdeffqOK2Lq53fa/9Ns23QBflX733uB83Xn36jiuTPivRf+Ep1yU+JdCMUml2sauLhNrkPdEqp3/eG4Z6/eHHrq3XjDQT9s/4qnw+26AD5bmP5vv8D95159+oqISVt/6v6mrpyuvd7dP8P93+vyTx3c7vCHij/TbNt2lTL8q/e/dycD5uvPv1HFbF1c7vtf8Aptm26AL8q/e+9wPm68+/UcVyfjXxXotx4W8SRQ+JdCmll0uWNEjuELSEpIAqgOfm59+o49dW68YaCftn/FU+H23QAfLcx/N9/gfvOvPv1FCkubft/W4KnLlXu/h/h/u/1+WvdXO77X/ptm26AL8q/e+9wPm68+/UcVj/AGnd4v17/TbNt2lWi/Kv3v3l3wPm68+/UcUt14w0E/bP+Kp8PtugA+W5j+b7/A/edeffqKyj4r0X/hKdclPiXQjFJpdrGri4Ta5D3RKqd/3huGev3hx6jkrrX+reoQpyt8Pbp/h/u/1+XWXVzu+1/wCm2bboAvyr9773A+brz79RxWP47ud3hDxR/ptm27Spl+Vfvfu5OB83Xn36jiluvGGgn7Z/xVPh9t0AHy3Mfzff4H7zrz79RWV418V6LceFvEkUPiXQppZdLljRI7hC0hKSAKoDn5uffqOPUnJcr1/r7wp05c0fd7dP8P8Ad/r8usurnd9r/wBNs23QBflX733uB83Xn36jii6ud32v/TbNt0AX5V+997gfN159+o4rIuvGGgn7Z/xVPh9t0AHy3Mfzff4H7zrz79RRdeMNBP2z/iqfD7boAPluY/m+/wAD95159+oq1Jd/608yY0pae726f4f7v9fkn2nd4v17/TbNt2lWi/Kv3v3l3wPm68+/UcVsXVzu+1/6bZtugC/Kv3vvcD5uvPv1HFcmfFei/wDCU65KfEuhGKTS7WNXFwm1yHuiVU7/ALw3DPX7w49dW68YaCftn/FU+H23QAfLcx/N9/gfvOvPv1FRCStv/V/Up05XXu9un+H+7/X5J47ud3hDxR/ptm27Spl+Vfvfu5OB83Xn36jiqPxT8Tt4b8DeI9VivYWnjshFC0MSsfNdjGhAZ8fKzqTnPHY9D5X8QPjm8tv4kstP0q0vNHkaTRzqK3yBmJRgZVhUsxT5mIfO0jbyCcVt/H/xZpmr+B30fSdc0K/k1q7tLIyw3a7IF8xpPMbazfKDGAT23g9sFr4n8v63MG06do7/AP7P93v/AF27vwB4kbxJ4C03VZNTtri4utNjFw5i8svMoZZVAyMEOGHAweMDGM3PtO7xfr3+m2bbtKtF+VfvfvLvgfN159+o4rzb4AeKtGtfhNa2F1rmmWd3apPDNb3TiJwxmlcKNzDPyupyARzjqDXanxXov/CU65KfEuhGKTS7WNXFwm1yHuiVU7/vDcM9fvDj1JSV1r/X3mtGm3G9ui6f4f7p1l1c7vtf+m2bboAvyr9773A+brz79RxWP47ud3hDxR/ptm27Spl+Vfvfu5OB83Xn36jivMfGPxV1LxBq2qaJ8P8AUtDtoYQsVxr9/cxww5UOxSFHLGTOAu8Bh83QAq9SWvxYTxD4d8WaN4mbTNH8QJpUirFHcpNBeAwt/qZFcru3NjZljzxkhsE37rX9fmTRacou2l1rb0/unsV1c7vtf+m2bboAvyr9773A+brz79RxRdXO77X/AKbZtugC/Kv3vvcD5uvPv1HFZF14w0E/bP8AiqfD7boAPluY/m+/wP3nXn36isbxz8S9C8P+HtW1KPWtJ1OWO3RI7W0uIzJOzMyhV+c4xuyxwcLk4OMGlJd/608w5eRc0lZLy/w/3f6/LY+07vF+vf6bZtu0q0X5V+9+8u+B83Xn36jiuL+IHxCm0f4ueFvD6amkdjf20n23Zbq6TGQOlugOWZW8wHkED5lJyM4oeDPipb6t4t8SxeKJNI8PXv2C2hiia+S4iuFUzMdkykRlv3yjaCT14+VsebfGTX7TVfjRZa79v06TS/D9zptq81vL5hmRmedpVVc5VPmRsE4O3u2AoabmdSW1vK+nZLyXY+jPHdzu8IeKP9Ns23aVMvyr9793JwPm68+/UcVsXVzu+1/6bZtugC/Kv3vvcD5uvPv1HFcn418V6LceFvEkUPiXQppZdLljRI7hC0hKSAKoDn5uffqOPWXxR8RfDWjaVqd/c+JNIuES3AEVpIsssxJYBEUOSWyevQZycAE0oyXNv2/rc3ceWCclZen+H+7/AF+XT3Vzu+1/6bZtugC/Kv3vvcD5uvPv1HFY/wBp3eL9e/02zbdpVovyr9795d8D5uvPv1HFeMXfxV8dzmbxHFH4Xj0l7dI30FtSha6MW0uZgdwbzPvJs+8CQDETzXb+Efid4e8T6nrmpR6va6erafb27W+oqtvKHWS6yoBkIJwynKlh8wHBBFDautf6+8mmn8LjZ6dPOP8Ad/r8vSLq53fa/wDTbNt0AX5V+997gfN159+o4rH8d3O7wh4o/wBNs23aVMvyr9793JwPm68+/UcUt14w0E/bP+Kp8PtugA+W5j+b7/A/edeffqK5f4p/EPQNO8Ha2Brmn3897aGxhgsCs0kjyLIoAAf5QMkljxj1JAJJ3i0n/X3lQg4tSktFbp/h/u/1+Xf3Vzu+1/6bZtugC/Kv3vvcD5uvPv1HFcRL4/E3xd1Dwil/pbW6aN5zuY2SRrndkQoS+G/dPv4B7+hFJ4U+K/h3xZpup3aanbaW0Y+ztb6mY4JnwCcqvmnj5sZ9QeOOfFU8QWN9+1BN4ga+tIdLaa5sxdSyxojNFZGIkfOcKzY2MThtwxzkC09TnkmuRpaXXT08j6K+07vF+vf6bZtu0q0X5V+9+8u+B83Xn36jiti6ud32v/TbNt0AX5V+997gfN159+o4rkz4r0X/AISnXJT4l0IxSaXaxq4uE2uQ90Sqnf8AeG4Z6/eHHrL4o+IvhrRtK1O/ufEmkXCJbgCK0kWWWYksAiKHJLZPXoM5OACainJW3/r7zonHltJrTTp/h/ul/wAd3O7wh4o/02zbdpUy/Kv3v3cnA+brz79RxWxdXO77X/ptm26AL8q/e+9wPm68+/UcV89638dbq9sdfj1fSFt9E1aymtdOlgKyXCEbo83EfmZj3FyemQBwJB81e2XHjHQJFumXxV4fdXtxgrdR/OPm4H7zrz79RQn7179v63FGN0o219P8P93+vy2Lq53fa/8ATbNt0AX5V+997gfN159+o4orHuPGOgSLdMvirw+6vbjBW6j+cfNwP3nXn36iitqcordndgIS5XZdunl6IXxDoWg63dT3OsWWgalcpbCNJbmzjlfALnapYkjkk/j09aFx4J8Hf6Vt0Dwmf3I27dMhGT83C+h6fpXTXVzu+1/6bZtugC/Kv3vvcD5uvPv1HFF1c7vtf+m2bboAvyr9773A+brz79RxUL+vw8zzowWmn4en905fRdO0rRfE/iGDRYtGsIJdMtGeOytkhWRt90OinG7GOee1Z3iH4X+BNXZjc6LoaGCImP7FGbUMTnIxE67jwOucZ4Ayc9D9p3eL9e/02zbdpVovyr9795d8D5uvPv1HFbF1c7vtf+m2bboAvyr9773A+brz79RxUQen9d/UpwWit26f4f7pxHxd8MeH/Enh7WL3WYNMu72y095be4ClJQyJKVUOrgkAsTtJKkkEjinad8NPA2j2t5b2WiaBLGyeYDcwfaXLEEYVpXZh0HAOOenXO747ud3hDxR/ptm27Spl+Vfvfu5OB83Xn36jiti6ud32v/TbNt0AX5V+997gfN159+o4oT977v63BU1yp2/D/D/dC6ud32v/AE2zbdAF+Vfvfe4HzdeffqOK5TWdJ0bXfGOrtrVtoeptDpVqITc2iSlcyXWQm4naTgZx7eldXdXO77X/AKbZtugC/Kv3vvcD5uvPv1HFY/2nd4v17/TbNt2lWi/Kv3v3l3wPm68+/UcUN6x/rp6jhHTbt0/w/wB3+vy4yb4K/DpftGzS7M7Ygy7by55PzcD9914Hr1HHra1XwT4W8NfD3xhp+i2mmRWl3p8ksqHdKZXRHKYZ5GOVIBHPBOQAeT6DdXO77X/ptm26AL8q/e+9wPm68+/UcVj+O7nd4Q8Uf6bZtu0qZflX737uTgfN159+o4ok/df9fqKnTjzL3e3T0/unDP8ABfwjZ6vBe6Rf3OnxWckF4LK2ui0FxNEzlGYSM5LDJHB4DcAZJOp4u+HGka54lvPEFtr+oaPq81uEuLjSLwwtdrgKEbLNwBGnC4zwSCcV3t1c7vtf+m2bboAvyr9773A+brz79RxRdXO77X/ptm26AL8q/e+9wPm68+/UcVS/r8PMmNNaK34en93+vy8h034ReDbfxPqS35XWbmC1gvftV/cPJJPPJLcFi4DhXJ2ICCpBAGQSWLeqW0FlpljPZaW2l2lmkGEgtYVjj5LkhVVsA5Yk+7dPWj9p3eL9e/02zbdpVovyr9795d8D5uvPv1HFbF1c7vtf+m2bboAvyr9773A+brz79RxUwen9d/UrkSasu3T/AA/3Tlvivp2na94I8QQ6s2n3kcNi1zDlSCssayMpQh8hgfTqGwRgkHmD8ING06S+Xw74t1/Q7KRRL9h0vUjHCzbdpADFmJO0ZJJ69hgV3Hju53eEPFH+m2bbtKmX5V+9+7k4HzdeffqOK2Lq53fa/wDTbNt0AX5V+997gfN159+o4oT977v63BU00nb8P8P9084t/hVokeq/b9c8Qaj4pe1t3W3i125F3EhfIJVTxuwo65HIOMgEczc/CdLbVNb0rwv431HS7H+z0P2Rn+0W7Qztdq9uIyw4GSVJLEF2P3jur226ud32v/TbNt0AX5V+997gfN159+o4rH+07vF+vf6bZtu0q0X5V+9+8u+B83Xn36jihvVf109RRpRlFpr+vd/u/wBflxviH4ZwX1j4dew8T/2frvhvTorS01G1hT98qrtKuhYlgQrDbux+8bIIJBy/GHgfXLjRtfv/ABD8T9Wv3g01zFDYKlhDKFWRikkaMVfOQOgODjnjHr11c7vtf+m2bboAvyr9773A+brz79RxWP47ud3hDxR/ptm27Spl+Vfvfu5OB83Xn36jinJ+6/6/UVOjFyjddv08v6/LH8GeAfDHgaO9/wCEeWzW6ls1hlupGaSWYDOQCXIUkgEhQATt+XgUvxA8FaV4u1CDUZ9Vk0/VrCLEGoaXL5E5Qhw0W7JyDuPqeeMAtu6+6ud32v8A02zbdAF+Vfvfe4HzdeffqOKLq53fa/8ATbNt0AX5V+997gfN159+o4ql/X4eYRgtFb8PT+6eR2vhLxbY67rFlpvxTmMcdjCyy3enw3U0sbS3JWJndssV+b5u+8DACgV65dXO77X/AKbZtugC/Kv3vvcD5uvPv1HFY/2nd4v17/TbNt2lWi/Kv3v3l3wPm68+/UcVsXVzu+1/6bZtugC/Kv3vvcD5uvPv1HFTB3X9d/UapKLVl27/AN3y/r8sfx3c7vCHij/TbNt2lTL8q/e/dycD5uvPv1HFbF1c7vtf+m2bboAvyr9773A+brz79RxWL4+nL+EfEpGoWv8AyC5gQij95+6l+UfMeec8e347V1c7vtf+m2bboAvyr9773A+brz79RxST977v63KUfdWn4f4f7v8AX5F1c7vtf+m2bboAvyr9773A+brz79RxWP8Aad3i/Xv9Ns23aVaL8q/e/eXfA+brz79RxWxdXO77X/ptm26AL8q/e+9wPm68+/UcVj/ad3i/Xv8ATbNt2lWi/Kv3v3l3wPm68+/UcUN6x/rp6hCOm3bp/h/u/wBflsXVzu+1/wCm2bboAvyr9773A+brz79RxWP47ud3hDxR/ptm27Spl+Vfvfu5OB83Xn36jiti6ud32v8A02zbdAF+Vfvfe4HzdeffqOKx/Hdzu8IeKP8ATbNt2lTL8q/e/dycD5uvPv1HFE37r/r9QpR96Onbp/h/u/1+WxdXO77X/ptm26AL8q/e+9wPm68+/UcUXVzu+1/6bZtugC/Kv3vvcD5uvPv1HFF1c7vtf+m2bboAvyr9773A+brz79RxRdXO77X/AKbZtugC/Kv3vvcD5uvPv1HFWn/X3eZMY7adun+H+7/X5eT33w30+bx34on0zxZrWjreQw6hPFpV95KTzSPOHBBJJ5TOMnBc4wMAWP8AhS/g+SS+uNcvLrxFfyKJPtupX0jTNhdoQFHUHAUdQTyO2BXcfad3i/Xv9Ns23aVaL8q/e/eXfA+brz79RxWxdXO77X/ptm26AL8q/e+9wPm68+/UcVEHdf1/mDpK607dP8P93+vy5LxTo+kad8M9d0Wyj0pdKt9JkWG2EQZMqruuMscuGw245O4huvJpW3wv8DadrsusWOl6Wl/Fm4iKtIY1kO77kZkKKRwQAuFO0gDArovHdzu8IeKP9Ns23aVMvyr9793JwPm68+/UcVsXVzu+1/6bZtugC/Kv3vvcD5uvPv1HFCfvfd/W41BWTt+H+H+6fNOkaRe+Ivin4z8Ea1qAs9BGo3XiC5t7dh/xMNzxmKNnDcIQ6Pgcg5z8wBXuR8Hvh+fEeq2o02zaCCwt5olW7uP9Yz3AbB87OcRp1yOnHXPoVlolnpviPxTrVvqUcl1rcVubhWxszFG0arGAcg465LckdKf9p3eL9e/02zbdpVovyr9795d8D5uvPv1HFDeq/r9SKNHR8yv8vOP93sWdLsdP0LSDpejvp9tp9vaiKKGFeMfOcDLkliSSScklsnnrzfxf8P6L4m8LatNra6feTafYy3FpINyOkgRzhWVweuCVOQcLkHArs7q53fa/9Ns23QBflX733uB83Xn36jisfx3c7vCHij/TbNt2lTL8q/e/dycD5uvPv1HFOT91/wBfqaU4JtJrt0/w/wB3+vy4i/8Agp4FFveJpi/2bcGAqtzZXswkwwYOi75GU7lyjAg5VyMDrWhpnwo8B6Jqf9oabpunrd2qeZA7TTSgPhhlVeVhuHBBIODgjBGa7+6ud32v/TbNt0AX5V+997gfN159+o4ournd9r/02zbdAF+Vfvfe4HzdeffqOKpf1+HmRGmrp27dPT+6cV4p8N6B4t8T63D4hg0rUAulWYjdo8SL+9uWxHIH3KcgZweRgEY68t8S/AujeHfg94x0/wAHWtjCJ4oLqZUlLNIIpQ7fPJIT8qKx25PU4GTz6N9p3eL9e/02zbdpVovyr9795d8D5uvPv1HFXPEUEWsaRrOnXN/b+Re2L20jRABirq6kLliA2G9D1HHrEHp/X+YVKSasl0XTyj/dPCNM8N2PxD8Aa34/8bXSahrd3Z3E1pCzvFHYrEZlSKJVkGRld3zbs7hkE7mf0TTPhR4D0TU/7Q03TdPW7tU8yB2mmlAfDDKq8rDcOCCQcHBGCM1sa5aQaL8M9W0m01CCW2stBa0iZwC8ixwuoGQ2N2Bzgd+grp7q53fa/wDTbNt0AX5V+997gfN159+o4pp+9939bhCkoxjp+H+H+6F1c7vtf+m2bboAvyr9773A+brz79RxXm3i3wTYeI/iJqmpxeILzR76LSrdXm0acWz3YZ5gVkPJY4ijH0CjsK9Jurnd9r/02zbdAF+Vfvfe4HzdeffqOKx/tO7xfr3+m2bbtKtF+VfvfvLvgfN159+o4pN6r+unqVGCa1Xbp/h/unE3nw0vY47hLH4o+KtsiIJzPfCYyxBtxjjOQY3yo+cZ4YgghiDS8Q/DHSbLTdY1bVPEuq+JLqw0u5NmNZu/tKRO0bfNGOMONox1AJBxkKR63dXO77X/AKbZtugC/Kv3vvcD5uvPv1HFY/ju53eEPFH+m2bbtKmX5V+9+7k4HzdeffqOKJv3X/X6hSppTi7dv0/u/wBflzXjL4a+H/EOv3OvLqVxpuvFVkOoaZdNFLJiNo/LGWZQCoUHAyePU54L4taDafD3wNpU+kzXGsC18R2+r3s80pkluJMS5eR+QMnYucdWXOSSW96urnd9r/02zbdAF+Vfvfe4HzdeffqOK5z4l6EvjLwjrOhtrFpbC7ihPnJFv5jl8wALvGT8uOv8Q/G0/wCvu8zNwfL7q19PT+7/AF+XmPhnw3rXjK6vdd8R+O9Wsr3UdNtNQW20W7NvDHFKZ9lvg5ztVQfrI2dxyzddp3wx0my12PVtU8S6p4jurGFjZjWbv7SkTt/Eg4w42jHUAkHGQpHTWhhtfEusW1pcafFbx6PZQxRQxhUCq90AiANgYHGB7cVu3Vzu+1/6bZtugC/Kv3vvcD5uvPv1HFTB3X9d/UtUlG2nb/23+7/X5Y3j6cSeDvFKteWbq+kzqQF+/wDu5PlHzdeffqOK4hfhJp+nx3Nvo/jnxRp1gqs8VlZapshQMzt5aDk4BJ6kn5uck5PceO7nd4Q8Uf6bZtu0qZflX737uTgfN159+o4rYurnd9r/ANNs23QBflX733uB83Xn36jikn733f1uPkTitPw/w/3f6/KLMNrazW1pcafFbx2qwxRQxhUCqGARAGwMDjA9uKKlurnd9r/02zbdAF+Vfvfe4HzdeffqOKK6KR3YFWT+X5eiM+8tfE/+nbtX0U/6MN2NKlGR8/A/0njvReWvif8A07dq+in/AEYbsaVKMj5+B/pPHeiio5EeVGtLTbp0X93yMp7bxH/wlOvD+1dI80aVal2/syTay77rAA+0cEfNk5OcjgY51by18T/6du1fRT/ow3Y0qUZHz8D/AEnjvRRUQirf13K9rK626dF/d8jK8cW3iNfC3ic3Gq6RJENKlMix6ZIjMuyTIBNwcHryQfp66t5a+J/9O3avop/0YbsaVKMj5+B/pPHeiihRXN9wRqy5Y7fcv7vkF5a+J/8ATt2r6Kf9GG7GlSjI+fgf6Tx3rKe28R/8JTrw/tXSPNGlWpdv7Mk2su+6wAPtHBHzZOTnI4GOSihxV1/XQKdWVunTov7vkat5a+J/9O3avop/0YbsaVKMj5+B/pPHesrxxbeI18LeJzcarpEkQ0qUyLHpkiMy7JMgE3BwevJB+nqUUTiuVhSqy5o7dOi/u+Rq3lr4n/07dq+in/RhuxpUoyPn4H+k8d6Ly18T/wCnbtX0U/6MN2NKlGR8/A/0njvRRV8iJjWlpt06L+75GU9t4j/4SnXh/aukeaNKtS7f2ZJtZd91gAfaOCPmycnORwMc6t5a+J/9O3avop/0YbsaVKMj5+B/pPHeiiohFW/ruV7WV1t06L+75GV44tvEa+FvE5uNV0iSIaVKZFj0yRGZdkmQCbg4PXkg/T11by18T/6du1fRT/ow3Y0qUZHz8D/SeO9FFCiub7gjVlyx2+5f3fILy18T/wCnbtX0U/6MN2NKlGR8/A/0njvWU9t4j/4SnXh/aukeaNKtS7f2ZJtZd91gAfaOCPmycnORwMclFDirr+ugU6srdOnRf3fI1by18T/6du1fRT/ow3Y0qUZHz8D/AEnjvWV44tvEa+FvE5uNV0iSIaVKZFj0yRGZdkmQCbg4PXkg/T1KKJxXKwpVZc0dunRf3fI1by18T/6du1fRT/ow3Y0qUZHz8D/SeO9F5a+J/wDTt2r6Kf8ARhuxpUoyPn4H+k8d6KKvkRMa0tNunRf3fIyntvEf/CU68P7V0jzRpVqXb+zJNrLvusAD7RwR82Tk5yOBjnVvLXxP/p27V9FP+jDdjSpRkfPwP9J470UVEIq39dyvayutunRf3fIyvHFt4jXwt4nNxqukSRDSpTIsemSIzLskyATcHB68kH6eureWvif/AE7dq+in/RhuxpUoyPn4H+k8d6KKFFc33BGrLljt9y/u+QXlr4n/ANO3avop/wBGG7GlSjI+fgf6Tx3rKe28R/8ACU68P7V0jzRpVqXb+zJNrLvusAD7RwR82Tk5yOBjkoocVdf10CnVlbp06L+75GreWvif/Tt2r6Kf9GG7GlSjI+fgf6Tx3rK8cW3iNfC3ic3Gq6RJENKlMix6ZIjMuyTIBNwcHryQfp6lFE4rlYUqsuaO3Tov7vkat5a+J/8ATt2r6Kf9GG7GlSjI+fgf6Tx3ovLXxP8A6du1fRT/AKMN2NKlGR8/A/0njvRRV8iJjWlpt06L+75GU9t4j/4SnXh/aukeaNKtS7f2ZJtZd91gAfaOCPmycnORwMc6t5a+J/8ATt2r6Kf9GG7GlSjI+fgf6Tx3ooqIRVv67le1ldbdOi/u+RleOLbxGvhbxObjVdIkiGlSmRY9MkRmXZJkAm4OD15IP09dW8tfE/8Ap27V9FP+jDdjSpRkfPwP9J470UUKK5vuCNWXLHb7l/d8gvLXxP8A6du1fRT/AKMN2NKlGR8/A/0njvWU9t4j/wCEp14f2rpHmjSrUu39mSbWXfdYAH2jgj5snJzkcDHJRQ4q6/roFOrK3Tp0X93yNW8tfE/+nbtX0U/6MN2NKlGR8/A/0njvWV44tvEa+FvE5uNV0iSIaVKZFj0yRGZdkmQCbg4PXkg/T1KKJxXKwpVZc0dunRf3fI1by18T/wCnbtX0U/6MN2NKlGR8/A/0njvReWvif/Tt2r6Kf9GG7GlSjI+fgf6Tx3ooq+RExrS026dF/d8jKe28R/8ACU68P7V0jzRpVqXb+zJNrLvusAD7RwR82Tk5yOBjnVvLXxP/AKdu1fRT/ow3Y0qUZHz8D/SeO9FFRCKt/Xcr2srrbp0X93yMrxxbeI18LeJzcarpEkQ0qUyLHpkiMy7JMgE3BwevJB+nrq3lr4n/ANO3avop/wBGG7GlSjI+fgf6Tx3oooUVzfcEasuWO33L+75BeWvif/Tt2r6Kf9GG7GlSjI+fgf6Tx3rKe28R/wDCU68P7V0jzRpVqXb+zJNrLvusAD7RwR82Tk5yOBjkoocVdf10CnVlbp06L+75GreWvif/AE7dq+in/RhuxpUoyPn4H+k8d6yvHFt4jXwt4nNxqukSRDSpTIsemSIzLskyATcHB68kH6epRROK5WFKrLmjt06L+75GreWvif8A07dq+in/AEYbsaVKMj5+B/pPHei8tfE/+nbtX0U/6MN2NKlGR8/A/wBJ470UVfIiY1pabdOi/u+RlPbeI/8AhKdeH9q6R5o0q1Lt/Zkm1l33WAB9o4I+bJyc5HAxzq3lr4n/ANO3avop/wBGG7GlSjI+fgf6Tx3ooqIRVv67le1ldbdOi/u+RleOLbxGvhbxObjVdIkiGlSmRY9MkRmXZJkAm4OD15IP09dW8tfE/wDp27V9FP8Aow3Y0qUZHz8D/SeO9FFCiub7gjVlyx2+5f3fILy18T/6du1fRT/ow3Y0qUZHz8D/AEnjvRRRW0IL+mz0MtqNxlt06Lsf/9k=);\">",
"   </div>",
"   <div class=\"lgnd\">",
"    The normal P wave in sinus rhythm is slightly notched since activation of the right atrium precedes that of the left atrium. The P wave is upright in a positive direction in leads I and II. A P wave with a uniform morphology precedes each QRS complex. The rate is between 60 and 100 beats per minute and the cycle length is uniform between sequential P waves and QRS complexes. In addition, the P wave morphology and PR intervals are identical from beat to beat.",
"    <div class=\"footnotes\">",
"    </div>",
"    <div class=\"reference\">",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f10_61_11218=[""].join("\n");
var outline_f10_61_11218=null;
var title_f10_61_11219="MCL normal MRI";
var content_f10_61_11219=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=EM%2F69553&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=EM%2F69553&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\" style=\"width: 470px\">",
"   <div class=\"ttl\">",
"    MRI of normal medial collateral ligament",
"   </div>",
"   <div class=\"cntnt\" style=\"width: 380px; height: 368px; background-image: url(data:image/jpeg;base64,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);\">",
"   </div>",
"   <div class=\"lgnd\">",
"    The normal MCL appears as a linear low signal \"strap\" on all sequences, extending from the medial epicondyle of the femur to a point on the tibia approximately 7 cm below the tibial plateau.",
"    <div class=\"footnotes\">",
"    </div>",
"    <div class=\"reference\">",
"     Courtesy of Mary Hochman, MD.",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f10_61_11219=[""].join("\n");
var outline_f10_61_11219=null;
var title_f10_61_11220="AIDS-related Kaposis sarcoma - ulcerating";
var content_f10_61_11220=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=DERM%2F60162&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=DERM%2F60162&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\" style=\"width: 470px\">",
"   <div class=\"ttl\">",
"    AIDS-related Kaposi's sarcoma",
"   </div>",
"   <div class=\"cntnt\" style=\"width: 432px; height: 324px; background-image: url(data:image/jpeg;base64,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);\">",
"   </div>",
"   <div class=\"lgnd\">",
"    An ulcerating plaque is present on the sole of the foot.",
"    <div class=\"footnotes\">",
"    </div>",
"    <div class=\"reference\">",
"     Reproduced with permission from: www.visualdx.com. Copyright Logical Images, Inc.",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f10_61_11220=[""].join("\n");
var outline_f10_61_11220=null;
var title_f10_61_11221="Linear scleroderma face 2";
var content_f10_61_11221=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=DERM%2F83579&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=2\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=DERM%2F83579&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=2\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\" style=\"width: 524px\">",
"   <div class=\"ttl\">",
"    Linear scleroderma (morphea) of the face: Advanced lesion",
"   </div>",
"   <div class=\"cntnt\" style=\"width: 504px; height: 378px; background-image: url(data:image/jpeg;base64,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);\">",
"   </div>",
"   <div class=\"lgnd\">",
"    <div class=\"footnotes\">",
"    </div>",
"    <div class=\"reference\">",
"     Reproduced with permission from: www.visualdx.com. Copyright Logical Images, Inc.",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f10_61_11221=[""].join("\n");
var outline_f10_61_11221=null;
var title_f10_61_11222="Intracranial epidural hematoma in children: Epidemiology, anatomy and pathophysiology";
var content_f10_61_11222=[" <noscript>",
"  <div id=\"javascriptDisabled\">",
"   It seems to us that you have your JavaScript turned off on your browser. JavaScript is required in order for our site to behave correctly.  Please enable your JavaScript to continue use our site.",
"  </div>",
" </noscript>",
" <div id=\"printHeader\">",
"  <div id=\"printHeaderLogo\">",
"   <img alt=\"UpToDate\" src=\"./../images/UTD2_masthead.myextg\">",
"    <img align=\"right\" alt=\"Wolters Kluwer Health\" height=\"40\" src=\"./../images/logoWKH.myextg\" width=\"175\">",
"     <br>",
"      <div id=\"printHeaderText\">",
"       Official reprint from  UpToDate",
"       <sup>",
"        &reg;",
"       </sup>",
"       <br>",
"        <a href=\"file://www.uptodate.com\">",
"         www.uptodate.com",
"        </a>",
"        &copy;2013 UpToDate",
"        <sup>",
"         &reg;",
"        </sup>",
"       </br>",
"      </div>",
"     </br>",
"    </img>",
"   </img>",
"  </div>",
"  <div id=\"printHeaderLinks\">",
"   <a class=\"TOPIC\" href=\"#\" id=\"printHeaderPrint\" rel=\"3\" title=\"Click here to print\">",
"    Print",
"   </a>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a href=\"#\" id=\"printHeaderBack\" title=\"Back to normal view\">",
"    Back",
"   </a>",
"  </div>",
" </div>",
" <!-- TC:TOPIC_PAGE -->",
" <div id=\"topicContent\">",
"  <div id=\"topicTitle\">",
"   Intracranial epidural hematoma in children: Epidemiology, anatomy and pathophysiology",
"  </div>",
"  <div id=\"topicContributors\">",
"   <div>",
"    <a id=\"authors\">",
"    </a>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"UTD.htm?10/61/11222/contributors\">",
"     Authors",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"UTD.htm?10/61/11222/contributors\">",
"     Edward S Ahn, MD",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"UTD.htm?10/61/11222/contributors\">",
"     Mark R Proctor, MD",
"    </a>",
"    <br/>",
"   </div>",
"   <div>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"UTD.htm?10/61/11222/contributors\">",
"     Section Editor",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"UTD.htm?10/61/11222/contributors\">",
"     Richard G Bachur, MD",
"    </a>",
"    <br/>",
"   </div>",
"   <div>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"UTD.htm?10/61/11222/contributors\">",
"     Deputy Editor",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"UTD.htm?10/61/11222/contributors\">",
"     James F Wiley, II, MD, MPH",
"    </a>",
"    <br/>",
"   </div>",
"  </div>",
"  <div id=\"disclosures\">",
"   <a href=\"UTD.htm?10/61/11222/contributor-disclosure\" target=\"_blank\">",
"    Disclosures",
"   </a>",
"  </div>",
"  <div id=\"reviewProcess\">",
"   <span>",
"    All topics are updated as new evidence becomes available and our",
"   </span>",
"   <a href=\"/home/editorial-policy\" target=\"_blank\">",
"    peer review process",
"   </a>",
"   <span>",
"    is complete.",
"   </span>",
"  </div>",
"  <div id=\"literatureReviewDate\">",
"   <span class=\"emphasis\">",
"    Literature review current through:",
"   </span>",
"   Oct 2013.",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <span class=\"emphasis\">",
"    This topic last updated:",
"   </span>",
"   Feb 23, 2012.",
"  </div>",
"  <div id=\"topicText\">",
"   <p class=\"headingAnchor\" id=\"H1\">",
"    <span class=\"h1\">",
"     INTRODUCTION",
"    </span>",
"    &nbsp;&mdash;&nbsp;Epidural hematoma (EDH), also known as extradural hematoma, is a hemorrhage into the space between the dura and the overlying calvarium. It is almost exclusively the result of trauma. The morbidity and mortality result from mass effect on the brain as the hematoma grows and strips the dura away from the skull. EDH in children is managed similarly to adults, but it requires special knowledge of location and clinical presentation. Prompt diagnosis is critical to the successful management of EDH.",
"   </p>",
"   <p>",
"    This topic discusses epidemiology, anatomy, and pathophysiology of EDH in children. Clinical features, evaluation, and management of EDH are presented separately. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?10/35/10808?source=see_link\">",
"     \"Intracranial epidural hematoma in children: Clinical features, evaluation, and management\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?18/42/19112?source=see_link\">",
"     \"Intracranial epidural hematoma in adults\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H2\">",
"    <span class=\"h1\">",
"     EPIDEMIOLOGY",
"    </span>",
"    &nbsp;&mdash;&nbsp;EDH occurs infrequently among the large population of infants and children seen in emergency departments and physician offices for head trauma but is present in about 1 to 3 percent of pediatric closed head injury admissions [",
"    <a class=\"abstract\" href=\"UTD.htm?10/61/11222/abstract/1-4\">",
"     1-4",
"    </a>",
"    ]. There is a strong gender difference, with a 2 to 2.5:1 male predominance [",
"    <a class=\"abstract\" href=\"UTD.htm?10/61/11222/abstract/4-6\">",
"     4-6",
"    </a>",
"    ]. The etiology varies by age:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      EDH occurs rarely in neonates and is associated with delivery by forceps or vacuum extraction [",
"      <a class=\"abstract\" href=\"UTD.htm?10/61/11222/abstract/7\">",
"       7",
"      </a>",
"      ].",
"     </li>",
"     <li>",
"      In infancy and the intermediate childhood years, low velocity impact (such as falls) comprise the most common mechanism of injury [",
"      <a class=\"abstract\" href=\"UTD.htm?10/61/11222/abstract/8-10\">",
"       8-10",
"      </a>",
"      ]. Even falls less than five feet (1.5 meters) may rarely result in EDH in this age group [",
"      <a class=\"abstract\" href=\"UTD.htm?10/61/11222/abstract/10\">",
"       10",
"      </a>",
"      ]. Although intentional head injury in young children and infants typically causes subdural hematomas, child abuse accounts for 6 to 18 percent of EDH in case series [",
"      <a class=\"abstract\" href=\"UTD.htm?10/61/11222/abstract/9,11\">",
"       9,11",
"      </a>",
"      ]. (See",
"      <a class=\"medical medical_review\" href=\"UTD.htm?32/13/32985?source=see_link&amp;anchor=H9#H9\">",
"       \"Child abuse: Epidemiology, mechanisms, and types of abusive head trauma in infants and children\", section on 'Epidural hemorrhage'",
"      </a>",
"      and",
"      <a class=\"medical medical_review\" href=\"UTD.htm?21/4/21575?source=see_link\">",
"       \"Intracranial subdural hematoma in children: Epidemiology, anatomy, and pathophysiology\"",
"      </a>",
"      .)",
"     </li>",
"     <li>",
"      In the adolescent years, motor vehicle collisions (MVCs) are the primary cause of EDH [",
"      <a class=\"abstract\" href=\"UTD.htm?10/61/11222/abstract/4,5\">",
"       4,5",
"      </a>",
"      ].",
"     </li>",
"    </ul>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H3\">",
"    <span class=\"h1\">",
"     ANATOMY",
"    </span>",
"    &nbsp;&mdash;&nbsp;During direct impact, the skull is deflected inward and the dura is stripped from the undersurface of the bone where blood can accumulate. EDH generally does not cross suture lines of the skull (",
"    <a class=\"graphic graphic_diagnosticimage graphicRef79566 \" href=\"UTD.htm?25/52/26432\">",
"     image 1",
"    </a>",
"    ). This is because the dura is less adherent to the skull in the center of the bone plate where bone resorption and remodeling takes place and it is more adherent at the suture lines where osteoblastic activity is the highest.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H4\">",
"    <span class=\"h2\">",
"     Location of hematoma",
"    </span>",
"    &nbsp;&mdash;&nbsp;The most common locations of EDH in children are frontal, parietooccipital, and posterior fossa. Compared with their adult counterparts, children differ in the distribution of the location of EDH in the following ways:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      There is a decreased incidence of purely temporal EDH because the middle meningeal artery is not indented into the temporal bone as frequently as it is in adults [",
"      <a class=\"abstract\" href=\"UTD.htm?10/61/11222/abstract/4,12,13\">",
"       4,12,13",
"      </a>",
"      ].",
"     </li>",
"     <li>",
"      There is an increased incidence of posterior fossa EDH in children associated with occipital skull fractures in proximity to dural sinuses [",
"      <a class=\"abstract\" href=\"UTD.htm?10/61/11222/abstract/4\">",
"       4",
"      </a>",
"      ].",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    The source of hemorrhage in posterior fossa EDH is usually venous and slower to accumulate compared with arterial hemorrhages. Despite a relatively benign presentation, these children can deteriorate rapidly with lethal outcomes caused by compression of the brainstem or by hydrocephalus secondary to fourth ventricular obstruction (",
"    <a class=\"graphic graphic_diagnosticimage graphicRef82581 \" href=\"UTD.htm?29/32/30223\">",
"     image 2",
"    </a>",
"    and",
"    <a class=\"graphic graphic_diagnosticimage graphicRef75448 \" href=\"UTD.htm?23/44/24270\">",
"     image 3",
"    </a>",
"    ). (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?10/35/10808?source=see_link&amp;anchor=H8#H8\">",
"     \"Intracranial epidural hematoma in children: Clinical features, evaluation, and management\", section on 'Posterior fossa EDH findings'",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?10/35/10808?source=see_link&amp;anchor=H23#H23\">",
"     \"Intracranial epidural hematoma in children: Clinical features, evaluation, and management\", section on 'Posterior fossa epidural hematoma'",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H5\">",
"    <span class=\"h2\">",
"     Blood vessel injury",
"    </span>",
"    &nbsp;&mdash;&nbsp;In older children and adolescents, hemorrhage most commonly arises from lacerated branches of meningeal arteries that are injured by fractured bone edges. In infants and young children, hemorrhage more often follows disruption of emissary venous channels in the bone, large venous sinuses in the dura, or from multiple bleeding sources on the dural surface [",
"    <a class=\"abstract\" href=\"UTD.htm?10/61/11222/abstract/14\">",
"     14",
"    </a>",
"    ]. Infants and young children have a higher frequency of venous EDH due to the abundance of dural and diploic vasculature in areas of rapid bone growth [",
"    <a class=\"abstract\" href=\"UTD.htm?10/61/11222/abstract/4,15\">",
"     4,15",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H6\">",
"    <span class=\"h2\">",
"     Associated abnormalities",
"    </span>",
"    &nbsp;&mdash;&nbsp;Although fracture is a marker of EDH in infants under one to two years of age, skull fractures are associated with EDH less often in children than in adults, occurring in 40 to 80 percent in case series of pediatric patients [",
"    <a class=\"abstract\" href=\"UTD.htm?10/61/11222/abstract/4-6,8,12,15-17\">",
"     4-6,8,12,15-17",
"    </a>",
"    ]. When there is no associated fracture, detection may be challenging.",
"   </p>",
"   <p>",
"    The associated fractures are almost always linear and usually cross either middle meningeal arterial branches or a dural venous sinus. Often, blood collects on either side of the bone adjacent to the fracture. Thus, subgaleal hematoma is frequently present in association with EDH and fracture as a result of bone bleeding and direct soft tissue injury from impact.",
"   </p>",
"   <p>",
"    Based on observational studies, children with EDH also have fewer concomitant intracranial injuries (ICI) than adults [",
"    <a class=\"abstract\" href=\"UTD.htm?10/61/11222/abstract/14,17\">",
"     14,17",
"    </a>",
"    ]. This may, in part, explain improved outcomes following EDH in children [",
"    <a class=\"abstract\" href=\"UTD.htm?10/61/11222/abstract/17\">",
"     17",
"    </a>",
"    ]. When EDH coexists with another ICI in children, it typically takes the form of diffuse cerebral edema rather than hemorrhagic cerebral contusion often seen in adults [",
"    <a class=\"abstract\" href=\"UTD.htm?10/61/11222/abstract/14\">",
"     14",
"    </a>",
"    ]. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?10/35/10808?source=see_link&amp;anchor=H25#H25\">",
"     \"Intracranial epidural hematoma in children: Clinical features, evaluation, and management\", section on 'Outcome'",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H7\">",
"    <span class=\"h1\">",
"     PATHOPHYSIOLOGY",
"    </span>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H8\">",
"    <span class=\"h2\">",
"     Increased intracranial pressure (ICP)",
"    </span>",
"    &nbsp;&mdash;&nbsp;In children with closed sutures, the intracranial compartment is protected by the skull, a rigid structure with a fixed internal volume. The intracranial contents include (by volume) [",
"    <a class=\"abstract\" href=\"UTD.htm?10/61/11222/abstract/18\">",
"     18",
"    </a>",
"    ]:",
"   </p>",
"   <p>",
"    <ul class=\"bulletCompact-block\">",
"     <li>",
"      Brain parenchyma &ndash; 80 percent",
"     </li>",
"     <li>",
"      Cerebrospinal fluid (CSF) &ndash; 10 percent",
"     </li>",
"     <li>",
"      Blood &ndash; 10 percent",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    ICP is a function of the volume and compliance of each component of the intracranial compartment, an interrelationship recognized over 150 years ago and known as the Monro-Kellie doctrine [",
"    <a class=\"abstract\" href=\"UTD.htm?10/61/11222/abstract/19,20\">",
"     19,20",
"    </a>",
"    ]. Because the overall volume of the cranial vault cannot change in children with closed sutures, an increase in the volume of one component, or the presence of pathologic components, necessitates the displacement of other structures, an increase in ICP, or both [",
"    <a class=\"abstract\" href=\"UTD.htm?10/61/11222/abstract/18,20-23\">",
"     18,20-23",
"    </a>",
"    ]. With an expanding epidural hematoma, CSF, intracranial venous blood, and then brain parenchyma are displaced. If the epidural hematoma continues to increase in size, then death due to brain herniation through the foramen magnum ensues. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?43/37/44633?source=see_link\">",
"     \"Elevated intracranial pressure in children\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    This pathophysiology does not necessarily apply in young children because the sutures of the skull remain open until approximately 18 months of age. In addition, young children have larger subarachnoid and extracellular spaces than adults. As a result, they tend to tolerate an expanding EDH better than older children or adults. An associated fracture or subgaleal hematoma may also allow an EDH to decompress to extracranial spaces. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?3/25/3477?source=see_link&amp;anchor=H5#H5\">",
"     \"Trauma management: Unique pediatric considerations\", section on 'Brain'",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    Because of the capacity for large volume intracranial bleeding, young infants occasionally become anemic from hemorrhage before showing objective signs of increased intracranial pressure (eg, altered mental status, seizures, pupillary changes, vomiting) [",
"    <a class=\"abstract\" href=\"UTD.htm?10/61/11222/abstract/9\">",
"     9",
"    </a>",
"    ]. Pallor was the presenting feature in 30 of 31 patients in one series [",
"    <a class=\"abstract\" href=\"UTD.htm?10/61/11222/abstract/9\">",
"     9",
"    </a>",
"    ]. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?10/35/10808?source=see_link&amp;anchor=H4#H4\">",
"     \"Intracranial epidural hematoma in children: Clinical features, evaluation, and management\", section on 'Physical examination'",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H9\">",
"    <span class=\"h2\">",
"     Delayed epidural hematoma",
"    </span>",
"    &nbsp;&mdash;&nbsp;EDH may also arise in delayed fashion without being detected on initial imaging studies in about 9 to 10 percent of multiple trauma patients resuscitated from hypovolemic shock or undergoing craniectomy [",
"    <a class=\"abstract\" href=\"UTD.htm?10/61/11222/abstract/24-27\">",
"     24-27",
"    </a>",
"    ]. The blood may begin to accumulate well after the initial injury. Delayed hematomas are prone to form if there are measures that decrease intracranial pressure (ICP), such as loss of cerebrospinal fluid through traumatic fistulae, surgical evacuation of hematomas at other sites [",
"    <a class=\"abstract\" href=\"UTD.htm?10/61/11222/abstract/26,28,29\">",
"     26,28,29",
"    </a>",
"    ], or pharmacological reduction of ICP. The majority of delayed EDH will arise within 8 to 24 hours, and therefore, repeat imaging within the first day following an injury is likely to detect them and allow for timely surgical intervention. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?10/35/10808?source=see_link&amp;anchor=H18#H18\">",
"     \"Intracranial epidural hematoma in children: Clinical features, evaluation, and management\", section on 'Operative treatment'",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H10\">",
"    <span class=\"h2\">",
"     Spontaneous epidural hematoma",
"    </span>",
"    &nbsp;&mdash;&nbsp;Spontaneous acute EDH is rare. Potential etiologies in children include [",
"    <a class=\"abstract\" href=\"UTD.htm?10/61/11222/abstract/30-33\">",
"     30-33",
"    </a>",
"    ]:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Middle ear and sinus infection [",
"      <a class=\"abstract\" href=\"UTD.htm?10/61/11222/abstract/30\">",
"       30",
"      </a>",
"      ]",
"     </li>",
"     <li>",
"      Complication of neurosurgical procedures, such as ventricular shunt placement [",
"      <a class=\"abstract\" href=\"UTD.htm?10/61/11222/abstract/31\">",
"       31",
"      </a>",
"      ]",
"     </li>",
"     <li>",
"      Minor head trauma in children with coagulopathy (eg, hemophilia, thrombocytopenia) [",
"      <a class=\"abstract\" href=\"UTD.htm?10/61/11222/abstract/30\">",
"       30",
"      </a>",
"      ]",
"     </li>",
"     <li>",
"      Invasive skull tumors, such as Langerhans cell histiocytosis or solid tumor metastasis to the skull [",
"      <a class=\"abstract\" href=\"UTD.htm?10/61/11222/abstract/32\">",
"       32",
"      </a>",
"      ]",
"     </li>",
"     <li>",
"      Sickle cell anemia with skull infarction [",
"      <a class=\"abstract\" href=\"UTD.htm?10/61/11222/abstract/33\">",
"       33",
"      </a>",
"      ]",
"     </li>",
"    </ul>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H11\">",
"    <span class=\"h1\">",
"     SUMMARY",
"    </span>",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Epidural hematoma (EDH) is a potentially life-threatening hemorrhage in the space between the dura and the overlying calvarium that usually results from trauma. (See",
"      <a class=\"local\" href=\"#H3\">",
"       'Anatomy'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      In infancy and the intermediate childhood years, low velocity impact (such as falls) comprise the most common mechanism of injury for intracranial EDH. Even falls less than five feet (1.5 meters) may rarely result in EDH. Child abuse accounts for a significant portion of EDH in case series. In adolescents, motor vehicle accidents account for most EDH. (See",
"      <a class=\"local\" href=\"#H2\">",
"       'Epidemiology'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      During direct impact, the skull is deflected inward and the dura is stripped from the undersurface of the bone where blood can accumulate. EDH generally does not cross suture lines of the skull (",
"      <a class=\"graphic graphic_diagnosticimage graphicRef79566 \" href=\"UTD.htm?25/52/26432\">",
"       image 1",
"      </a>",
"      ). (See",
"      <a class=\"local\" href=\"#H3\">",
"       'Anatomy'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      Infants and young children have a higher frequency of venous than arterial EDH. In older children and adolescents, bleeding typically arises from the middle meningeal artery in association with a temporal skull fracture. (See",
"      <a class=\"local\" href=\"#H5\">",
"       'Blood vessel injury'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      EDH in children frequently occurs without an associated skull fracture, making detection more challenging than in adults. Children with EDH also have fewer concomitant intracranial injuries than adults. (See",
"      <a class=\"local\" href=\"#H6\">",
"       'Associated abnormalities'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      An expanding EDH causes increased intracranial pressure in children with closed sutures and may result in death due to brain herniation without prompt intervention. (See",
"      <a class=\"local\" href=\"#H8\">",
"       'Increased intracranial pressure (ICP)'",
"      </a>",
"      above and",
"      <a class=\"medical medical_review\" href=\"UTD.htm?43/37/44633?source=see_link\">",
"       \"Elevated intracranial pressure in children\"",
"      </a>",
"      .)",
"     </li>",
"     <li>",
"      The impact of increased ICP may be blunted in children with open sutures and larger subarachnoid and extracellular spaces. (See",
"      <a class=\"local\" href=\"#H8\">",
"       'Increased intracranial pressure (ICP)'",
"      </a>",
"      above.)",
"     </li>",
"    </ul>",
"   </p>",
"  </div>",
"  <div id=\"topicAgreement\">",
"   Use of UpToDate is subject to the",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_in_page\" target=\"_blank\">",
"    Subscription and License Agreement",
"   </a>",
"   .",
"  </div>",
"  <div class=\"headingAnchor\" id=\"references\">",
"   <h1>",
"    REFERENCES",
"   </h1>",
"   <ol id=\"reference\">",
"    <li>",
"     Choux M, Lena G, Genitori L. Intracranial hematomas. In: Head Injuries in the Newborn and Infant, Raimondi A, Choux M, DiRocco C.  (Eds), Springer-Verlag Inc, New York 1986. p.204.",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?10/61/11222/abstract/2\">",
"      Kim KA, Wang MY, Griffith PM, et al. Analysis of pediatric head injury from falls. Neurosurg Focus 2000; 8:e3.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?10/61/11222/abstract/3\">",
"      Obana WG, Pitts LH. Management of head injury. Extracerebral lesions. Neurosurg Clin N Am 1991; 2:351.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?10/61/11222/abstract/4\">",
"      Rocchi G, Caroli E, Raco A, et al. Traumatic epidural hematoma in children. J Child Neurol 2005; 20:569.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?10/61/11222/abstract/5\">",
"      Erahin Y, Mutluer S, G&uuml;zelbag E. Extradural hematoma: analysis of 146 cases. Childs Nerv Syst 1993; 9:96.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?10/61/11222/abstract/6\">",
"      Paaolu A, Orhon C, Ko&ccedil; K, et al. Traumatic extradural haematomas in pediatric age group. Acta Neurochir (Wien) 1990; 106:136.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?10/61/11222/abstract/7\">",
"      Noetzel MJ. Perinatal trauma and cerebral palsy. Clin Perinatol 2006; 33:355.",
"     </a>",
"    </li>",
"    <li>",
"     Aronyk KE. Post-traumatic hematomas. In: Pediatric Neurosurgery: Surgery of the Developing Nervous System, Cheek WR, Marlin AE, McLone DG, et al.  (Eds), WB Mason, Philadelphia 1994. p.279.",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?10/61/11222/abstract/9\">",
"      Ciurea AV, Kapsalaki EZ, Coman TC, et al. Supratentorial epidural hematoma of traumatic etiology in infants. Childs Nerv Syst 2007; 23:335.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?10/61/11222/abstract/10\">",
"      Schutzman SA, Barnes PD, Mantello M, Scott RM. Epidural hematomas in children. Ann Emerg Med 1993; 22:535.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?10/61/11222/abstract/11\">",
"      Wells RG, Vetter C, Laud P. Intracranial hemorrhage in children younger than 3 years: prediction of intent. Arch Pediatr Adolesc Med 2002; 156:252.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?10/61/11222/abstract/12\">",
"      Pillay R, Peter JC. Extradural haematomas in children. S Afr Med J 1995; 85:672.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?10/61/11222/abstract/13\">",
"      Gallagher JP, Browder EJ. Extradural hematoma. Experience with 167 patients. J Neurosurg 1968; 29:1.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?10/61/11222/abstract/14\">",
"      Jamjoom A, Cummins B, Jamjoom ZA. Clinical characteristics of traumatic extradural hematoma: a comparison between children and adults. Neurosurg Rev 1994; 17:277.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?10/61/11222/abstract/15\">",
"      Choux M, Grisoli F, Peragut JC. Extradural hematomas in children. 104 cases. Childs Brain 1975; 1:337.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?10/61/11222/abstract/16\">",
"      Ammirati M, Tomita T. Posterior fossa epidural hematoma during childhood. Neurosurgery 1984; 14:541.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?10/61/11222/abstract/17\">",
"      Mohanty A, Kolluri VR, Subbakrishna DK, et al. Prognosis of extradural haematomas in children. Pediatr Neurosurg 1995; 23:57.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?10/61/11222/abstract/18\">",
"      Allen CH, Ward JD. An evidence-based approach to management of increased intracranial pressure. Crit Care Clin 1998; 14:485.",
"     </a>",
"    </li>",
"    <li>",
"     Monro A. Observations on the Structure and Functions of the Nervous System, Creech and Johnson, Edinburgh 1783.",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?10/61/11222/abstract/20\">",
"      Kellie, G. An account of the appearances observed in the dissection of two of the individuals presumed to have perished in the storm of the third, and whose bodies were discovered in the vicinity of Leith on the morning of the 4th November 1821; with some reflections on the pathology of the brain. Trans Med Chir Soc (Edinburgh) 1821-1832;1:84.",
"     </a>",
"    </li>",
"    <li>",
"     Steele DW. Neurosurgical emergencies, nontraumatic. In: Textbook of Pediatric Emergency Medicine, 5th, Fleisher GR, Ludwig S, Henretig FM.  (Eds), Lippincott Williams &amp; Wilkins, Philadelphia 2006. p.1717.",
"    </li>",
"    <li>",
"     Poss WB, Brockmeyere DL, Clay B, Dean JM. Pathophysiology and management of the intracranial vault. In: Textbook of Pediatric Intensive Care, Rogers MC.  (Ed), Williams &amp; Wilkins, Baltimore 1996. p.645.",
"    </li>",
"    <li>",
"     Greenes DS. Neurotrauma. In: Textbook of Pediatric Emergency Medicine, 5th, Fleisher GR, Ludwig S, Henretig FM (Eds), Lippincott Williams &amp; Wilkins, Philadelphia 2006. p.1361.",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?10/61/11222/abstract/24\">",
"      Borovich B, Braun J, Guilburd JN, et al. Delayed onset of traumatic extradural hematoma. J Neurosurg 1985; 63:30.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?10/61/11222/abstract/25\">",
"      Jaimovich, R, Monges, JA. Delayed posttraumatic intracranial lesions in children. Pediatr Neurosurg 1991-1992; 17:25.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?10/61/11222/abstract/26\">",
"      Piepmeier JM, Wagner FC Jr. Delayed post-traumatic extracerebral hematomas. J Trauma 1982; 22:455.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?10/61/11222/abstract/27\">",
"      Summers LE, Mascott CR. Delayed epidural hematoma: presentation in a pediatric patient. J La State Med Soc 2001; 153:81.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?10/61/11222/abstract/28\">",
"      Bullock R, Hanemann CO, Murray L, Teasdale GM. Recurrent hematomas following craniotomy for traumatic intracranial mass. J Neurosurg 1990; 72:9.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?10/61/11222/abstract/29\">",
"      Feuerman T, Wackym PA, Gade GF, et al. Intraoperative development of contralateral epidural hematoma during evacuation of traumatic extraaxial hematoma. Neurosurgery 1988; 23:480.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?10/61/11222/abstract/30\">",
"      Griffiths SJ, Jatavallabhula NS, Mitchell RD. Spontaneous extradural haematoma associated with craniofacial infections: case report and review of the literature. Br J Neurosurg 2002; 16:188.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?10/61/11222/abstract/31\">",
"      Fujimoto Y, Aguiar PH, Carneiro JD, et al. Spontaneous epidural hematoma following a shunt in an infant with congenital factor X deficiency. Case report and literature review. Neurosurg Rev 1999; 22:226.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?10/61/11222/abstract/32\">",
"      Chen HC, Shen WC, Chou DY, Chiang IP. Langerhans cell histiocytosis of the skull complicated with an epidural hematoma. AJNR Am J Neuroradiol 2002; 23:493.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?10/61/11222/abstract/33\">",
"      Naran AD, Fontana L. Sickle cell disease with orbital infarction and epidural hematoma. Pediatr Radiol 2001; 31:257.",
"     </a>",
"    </li>",
"   </ol>",
"  </div>",
"  <div id=\"topicVersionRevision\">",
"   Topic 6529 Version 3.0",
"  </div>",
" </div>",
" <div id=\"footer\">",
"  <div id=\"supportFooter\">",
"   <span class=\"sfInfo\">",
"    &copy; 2013 UpToDate, Inc. All rights reserved.",
"   </span>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_footer\">",
"    Subscription and License Agreement",
"   </a>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Release: 21.6- C21.56",
"   </span>",
"   <br/>",
"   <span class=\"sfInfo\">",
"    Licensed to:",
"    <span class=\"emphasis\">",
"     AsanBook Dig. Med. Lib.",
"    </span>",
"   </span>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Support Tag: [0603-61.234.146.186-996A9847C3-S244013.14]",
"    <br/>",
"   </span>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f10_61_11222=[""].join("\n");
var outline_f10_61_11222=[" <div id=\"toggleOutline\">",
"  <a href=\"#\" title=\"Collapse Topic Outline\">",
"   <img alt=\"\" src=\"./../images/orange_arrow_left.myextg\"/>",
"  </a>",
" </div>",
" <div id=\"innerOutline\">",
"  <h1>",
"   TOPIC OUTLINE",
"  </h1>",
"  <div id=\"outline\">",
"   <ul>",
"    <li>",
"     <a class=\"sr_button\" href=\"#H11\" id=\"summRecButton\">",
"      <span>",
"       SUMMARY",
"      </span>",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H1\">",
"      INTRODUCTION",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H2\">",
"      EPIDEMIOLOGY",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H3\">",
"      ANATOMY",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H4\">",
"      Location of hematoma",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H5\">",
"      Blood vessel injury",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H6\">",
"      Associated abnormalities",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H7\">",
"      PATHOPHYSIOLOGY",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H8\">",
"      Increased intracranial pressure (ICP)",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H9\">",
"      Delayed epidural hematoma",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H10\">",
"      Spontaneous epidural hematoma",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H11\">",
"      SUMMARY",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a href=\"#references\">",
"      REFERENCES",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   <div class=\"openRelatedGraphics\" id=\"EM/6529\" rel=\"outline_link\">",
"    GRAPHICS",
"    <a class=\"graphics_icon\" href=\"#\" title=\"View All Related Graphics\">",
"     View All",
"    </a>",
"   </div>",
"  </h1>",
"  <div id=\"relatedGraphics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <div class=\"openRelatedGraphics\" id=\"EM/6529|DiagnosticImage\">",
"      <a href=\"#\" title=\"DIAGNOSTIC IMAGES\">",
"       DIAGNOSTIC IMAGES",
"      </a>",
"     </div>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_diagnosticimage\" href=\"UTD.htm?25/52/26432\" title=\"diagnostic image 1\">",
"      Epidural hematoma",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_diagnosticimage\" href=\"UTD.htm?29/32/30223\" title=\"diagnostic image 2\">",
"      Posterior fossa epidural hematoma",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_diagnosticimage\" href=\"UTD.htm?23/44/24270\" title=\"diagnostic image 3\">",
"      Occipital fracture",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   RELATED TOPICS",
"  </h1>",
"  <div id=\"relatedTopics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?32/13/32985?source=related_link\">",
"      Child abuse: Epidemiology, mechanisms, and types of abusive head trauma in infants and children",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?43/37/44633?source=related_link\">",
"      Elevated intracranial pressure in children",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?18/42/19112?source=related_link\">",
"      Intracranial epidural hematoma in adults",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?10/35/10808?source=related_link\">",
"      Intracranial epidural hematoma in children: Clinical features, evaluation, and management",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?21/4/21575?source=related_link\">",
"      Intracranial subdural hematoma in children: Epidemiology, anatomy, and pathophysiology",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?3/25/3477?source=related_link\">",
"      Trauma management: Unique pediatric considerations",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
" </div>"].join("\n");
var title_f10_61_11223="Major side effects of low-dose methotrexate";
var content_f10_61_11223=[" <noscript>",
"  <div id=\"javascriptDisabled\">",
"   It seems to us that you have your JavaScript turned off on your browser. JavaScript is required in order for our site to behave correctly.  Please enable your JavaScript to continue use our site.",
"  </div>",
" </noscript>",
" <div id=\"printHeader\">",
"  <div id=\"printHeaderLogo\">",
"   <img alt=\"UpToDate\" src=\"./../images/UTD2_masthead.myextg\">",
"    <img align=\"right\" alt=\"Wolters Kluwer Health\" height=\"40\" src=\"./../images/logoWKH.myextg\" width=\"175\">",
"     <br>",
"      <div id=\"printHeaderText\">",
"       Official reprint from  UpToDate",
"       <sup>",
"        &reg;",
"       </sup>",
"       <br>",
"        <a href=\"file://www.uptodate.com\">",
"         www.uptodate.com",
"        </a>",
"        &copy;2013 UpToDate",
"        <sup>",
"         &reg;",
"        </sup>",
"       </br>",
"      </div>",
"     </br>",
"    </img>",
"   </img>",
"  </div>",
"  <div id=\"printHeaderLinks\">",
"   <a class=\"TOPIC\" href=\"#\" id=\"printHeaderPrint\" rel=\"2\" title=\"Click here to print\">",
"    Print",
"   </a>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a href=\"#\" id=\"printHeaderBack\" title=\"Back to normal view\">",
"    Back",
"   </a>",
"  </div>",
" </div>",
" <!-- TC:TOPIC_PAGE -->",
" <div id=\"topicContent\">",
"  <div id=\"topicTitle\">",
"   Major side effects of low-dose methotrexate",
"  </div>",
"  <div id=\"topicContributors\">",
"   <div>",
"    <a id=\"authors\">",
"    </a>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"UTD.htm?10/61/11223/contributors\">",
"     Author",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"UTD.htm?10/61/11223/contributors\">",
"     Joel M Kremer, MD",
"    </a>",
"    <br/>",
"   </div>",
"   <div>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"UTD.htm?10/61/11223/contributors\">",
"     Section Editor",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"UTD.htm?10/61/11223/contributors\">",
"     RN Maini, BA, MB BChir, FRCP, FMedSci, FRS",
"    </a>",
"    <br/>",
"   </div>",
"   <div>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"UTD.htm?10/61/11223/contributors\">",
"     Deputy Editor",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"UTD.htm?10/61/11223/contributors\">",
"     Paul L Romain, MD",
"    </a>",
"    <br/>",
"   </div>",
"  </div>",
"  <div id=\"disclosures\">",
"   <a href=\"UTD.htm?10/61/11223/contributor-disclosure\" target=\"_blank\">",
"    Disclosures",
"   </a>",
"  </div>",
"  <div id=\"reviewProcess\">",
"   <span>",
"    All topics are updated as new evidence becomes available and our",
"   </span>",
"   <a href=\"/home/editorial-policy\" target=\"_blank\">",
"    peer review process",
"   </a>",
"   <span>",
"    is complete.",
"   </span>",
"  </div>",
"  <div id=\"literatureReviewDate\">",
"   <span class=\"emphasis\">",
"    Literature review current through:",
"   </span>",
"   Oct 2013.",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <span class=\"emphasis\">",
"    This topic last updated:",
"   </span>",
"   Dec 18, 2012.",
"  </div>",
"  <div id=\"topicText\">",
"   <p class=\"headingAnchor\" id=\"H1\">",
"    <span class=\"h1\">",
"     INTRODUCTION",
"    </span>",
"    &nbsp;&mdash;&nbsp;Potentially life-threatening hepatotoxicity, pulmonary damage, and myelosuppression are sometimes seen with use of",
"    <a class=\"drug drug_general\" href=\"UTD.htm?23/38/24170?source=see_link\">",
"     methotrexate",
"    </a>",
"    (MTX) and can occur with either high-dose therapy as used for malignant diseases (eg, cyclic use of 1 gram or more) or with low-dose therapy (eg, weekly doses of 7.5 to 25 mg) as used in other disorders such as rheumatoid arthritis and psoriasis.",
"   </p>",
"   <p>",
"    The most commonly observed side effects of MTX (at doses typically used for the treatment of rheumatoid arthritis as opposed to the high doses used in malignancy) are never life-threatening. Nevertheless, they may become clinically significant if they result in premature discontinuation of a drug that is the best therapeutic alternative for a given individual. It is, therefore, important to learn the effective management of common toxicities in order to achieve optimal utilization MTX.",
"   </p>",
"   <p>",
"    The major side effects of low-dose",
"    <a class=\"drug drug_general\" href=\"UTD.htm?23/38/24170?source=see_link\">",
"     methotrexate",
"    </a>",
"    are discussed here. The clinical use of high-dose methotrexate and related adverse effects are discussed separately. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?32/55/33658?source=see_link\">",
"     \"Therapeutic use and toxicity of high-dose methotrexate\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H2\">",
"    <span class=\"h1\">",
"     HEPATOTOXICITY",
"    </span>",
"    &nbsp;&mdash;&nbsp;Hepatotoxicity due to MTX may result from direct damage to hepatocytes, or, in patients with concomitant viral hepatitis, MTX may enhance viral damage. Screening for hepatitis B and hepatitis C virus infection before initiating long-term MTX therapy allows for detection and a decision whether to avoid the use of MTX, to try to eradicate the viral infection before initiating therapy, or to suppress viral replication during immunosuppressive therapy. Periodic monitoring of aminotransaminase and albumin (eg, every four to eight weeks) is suggested to detect hepatotoxicity during chronic treatment with MTX [",
"    <a class=\"abstract\" href=\"UTD.htm?10/61/11223/abstract/1,2\">",
"     1,2",
"    </a>",
"    ]. Early studies in Scandinavian psoriatic patients on MTX indicated that alcohol ingestion was a clear risk factor for hepatotoxicity [",
"    <a class=\"abstract\" href=\"UTD.htm?10/61/11223/abstract/3\">",
"     3",
"    </a>",
"    ]. As no one has studied the amount of alcohol which might be safe with MTX, a general recommendation would be to avoid, or minimize, alcohol intake while on the drug. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?31/24/32134?source=see_link\">",
"     \"Hepatotoxicity associated with chronic oral methotrexate for nonmalignant disease\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?25/25/26009?source=see_link\">",
"     \"Hepatitis B virus reactivation associated with immunosuppression\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H3\">",
"    <span class=\"h1\">",
"     PULMONARY TOXICITY",
"    </span>",
"    &nbsp;&mdash;&nbsp;Pulmonary toxicity of MTX is seen with both high- and low-dose treatment and may present with acute or chronic symptoms. Either symptomatic or asymptomatic radiographic lung damage may be due to inflammation, infection, or MTX-related neoplasia. We recommend that a chest radiograph be obtained prior to initiating MTX treatment [",
"    <a class=\"abstract\" href=\"UTD.htm?10/61/11223/abstract/4\">",
"     4",
"    </a>",
"    ]. Pulmonary toxicity is discussed in detail separately. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?9/5/9306?source=see_link\">",
"     \"Methotrexate-induced lung injury\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H4\">",
"    <span class=\"h1\">",
"     MYELOSUPPRESSION",
"    </span>",
"    &nbsp;&mdash;&nbsp;Myelosuppression is the major dose-limiting side effect of high-dose MTX. With low-dose weekly therapy, as used in rheumatoid arthritis, hematologic toxicity in association with macrocytic red blood cells may be seen [",
"    <a class=\"abstract\" href=\"UTD.htm?10/61/11223/abstract/5\">",
"     5",
"    </a>",
"    ], but a more serious abnormality is the development of pancytopenia [",
"    <a class=\"abstract\" href=\"UTD.htm?10/61/11223/abstract/6\">",
"     6",
"    </a>",
"    ]. Occasionally, anemia, leukopenia, or thrombocytopenia may occur without significant reductions in other cell lines. To prevent these complications, the American College of Rheumatology suggests that a routine peripheral blood count should be performed periodically (eg, every four to eight weeks) [",
"    <a class=\"abstract\" href=\"UTD.htm?10/61/11223/abstract/2\">",
"     2",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Myelosuppression with low-dose MTX is more likely if renal function is impaired or if MTX is taken daily instead of weekly. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?31/26/32169?source=see_link&amp;anchor=H2#H2\">",
"     \"Use of methotrexate in the treatment of rheumatoid arthritis\", section on 'Pharmacology'",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H5\">",
"    <span class=\"h1\">",
"     NEPHROTOXICITY",
"    </span>",
"    &nbsp;&mdash;&nbsp;Significant nephrotoxicity due to MTX may occur with use of high doses. MTX is primarily cleared via the kidneys, with 80 to 90 percent being excreted unchanged in the urine. Thus, impaired renal excretion of the administered MTX and consequent prolonged exposure to the drug increase the risk of myelosuppression and other toxicities.",
"    <a class=\"drug drug_general\" href=\"UTD.htm?7/27/7605?source=see_link\">",
"     Glucarpidase",
"    </a>",
"    (carboxypeptidase G2), a recombinant bacterial enzyme that cleaves MTX into inactive metabolites, speeds clearance, and may be used when impaired renal function causes delayed elimination of MTX in patients receiving high-dose MTX. Its role in patients who develop renal toxicity while receiving chronic low-dose therapy is unclear. MTX-induced renal failure and the use of glucarpidase in the management of this complication are discussed in more detail elsewhere. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?34/2/34857?source=see_link&amp;anchor=H4164341#H4164341\">",
"     \"Crystal-induced acute kidney injury (acute renal failure)\", section on 'Methotrexate'",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?32/55/33658?source=see_link&amp;anchor=H39#H39\">",
"     \"Therapeutic use and toxicity of high-dose methotrexate\", section on 'Glucarpidase (carboxypeptidase G2)'",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    Kidney damage due to precipitation of MTX crystals and tubular injury may occur with high-dose MTX; it is very rare with chronic low-dose therapy. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?32/55/33658?source=see_link&amp;anchor=H13#H13\">",
"     \"Therapeutic use and toxicity of high-dose methotrexate\", section on 'Renal toxicity'",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H6\">",
"    <span class=\"h1\">",
"     COMMON TOXICITIES",
"    </span>",
"    &nbsp;&mdash;&nbsp;Common toxicities associated with MTX include the following:",
"   </p>",
"   <p>",
"    <ul class=\"bulletCompact-block\">",
"     <li>",
"      Gastrointestinal problems such as nausea, stomach upset, and loose stools",
"     </li>",
"     <li>",
"      Stomatitis or soreness of the mouth",
"     </li>",
"     <li>",
"      Macular punctate rash that usually occurs on the extremities and spares the trunk",
"     </li>",
"     <li>",
"      Central nervous system problems including headache, fatigue, or impaired ability to concentrate",
"     </li>",
"     <li>",
"      Alopecia",
"     </li>",
"     <li>",
"      Fever, but infection should be excluded",
"     </li>",
"     <li>",
"      Hematologic abnormalities, particularly macrocytosis",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    One or more of these side effects are seen in some form, at some time, in most patients. They usually occur within 24 to 48 hours after the weekly MTX dose. This is particularly true with regard to central nervous system and gastrointestinal complaints. Rash may appear within days of each weekly MTX dose and fade by the time of the next week's dose. On the other hand, stomatitis may persist for days or weeks; it can be mild, or on occasion, painful enough to make eating difficult and result in a desire to discontinue therapy.",
"   </p>",
"   <p>",
"    Patients who continue to have nausea associated with MTX administration may get some relief with a histamine H2 blocker or a proton pump inhibitor. These drugs are usually cycled in a weekly manner with MTX, being used the evening before, the day of, and the morning after the weekly MTX dose.",
"   </p>",
"   <p>",
"    Stomatitis (oral mucositis) can occur at any dose of MTX but is more likely to be seen at higher doses. Data regarding the usefulness of supplements of folic or folinic acid are mixed. A systematic review in 1998 of folic or folinic acid supplementation concluded that these agents reduced the risk of stomatitis and other disorders of the digestive tract [",
"    <a class=\"abstract\" href=\"UTD.htm?10/61/11223/abstract/7\">",
"     7",
"    </a>",
"    ]. However, no difference in the proportion of patients developing mucositis (15 to 18 percent) or diarrhea (8 to 14 percent) were noted in a subsequent randomized trial in 434 patients that compared",
"    <a class=\"drug drug_general\" href=\"UTD.htm?8/61/9174?source=see_link\">",
"     folic acid",
"    </a>",
"    , folinic acid, and placebo [",
"    <a class=\"abstract\" href=\"UTD.htm?10/61/11223/abstract/8\">",
"     8",
"    </a>",
"    ]. Nevertheless, if a patient is not receiving folate supplementation, addition of folic or folinic acid may speed healing.",
"    <a class=\"drug drug_general\" href=\"UTD.htm?24/40/25223?source=see_link\">",
"     Allopurinol",
"    </a>",
"    mouthwashes have also been suggested as a treatment for stomatitis [",
"    <a class=\"abstract\" href=\"UTD.htm?10/61/11223/abstract/9\">",
"     9",
"    </a>",
"    ]. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?37/22/38250?source=see_link\">",
"     \"Oral toxicity associated with chemotherapy\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    It has been suggested that the neurotoxicity of MTX may be related to the accumulation of adenosine due to the inhibition of purine synthesis [",
"    <a class=\"abstract\" href=\"UTD.htm?10/61/11223/abstract/10,11\">",
"     10,11",
"    </a>",
"    ]. As an example, children with acute leukemia and MTX-related neurotoxicity had markedly elevated cerebrospinal fluid adenosine levels, and central nervous system symptoms were relieved by a one hour infusion of",
"    <a class=\"drug drug_general\" href=\"UTD.htm?14/19/14648?source=see_link\">",
"     aminophylline",
"    </a>",
"    (which displaces adenosine from its receptor) [",
"    <a class=\"abstract\" href=\"UTD.htm?10/61/11223/abstract/12\">",
"     12",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Fever can be induced by MTX, but infection should be excluded. Infections with Pneumocystis carinii and fungi can occur; herpes zoster is rare (in contrast to its more frequent occurrence with",
"    <a class=\"drug drug_general\" href=\"UTD.htm?38/3/38967?source=see_link\">",
"     azathioprine",
"    </a>",
"    or",
"    <a class=\"drug drug_general\" href=\"UTD.htm?9/20/9546?source=see_link\">",
"     cyclophosphamide",
"    </a>",
"    ). Infections are a common cause of drug withdrawal among those administered MTX for prolonged periods [",
"    <a class=\"abstract\" href=\"UTD.htm?10/61/11223/abstract/13\">",
"     13",
"    </a>",
"    ]. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?29/0/29706?source=see_link&amp;anchor=H12#H12\">",
"     \"Secondary immune deficiency induced by drugs and biologics\", section on 'Methotrexate'",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H7\">",
"    <span class=\"h2\">",
"     Role of folate",
"    </span>",
"    &nbsp;&mdash;&nbsp;",
"    <a class=\"drug drug_general\" href=\"UTD.htm?8/61/9174?source=see_link\">",
"     Folic acid",
"    </a>",
"    at a dose of 1",
"    <span class=\"nowrap\">",
"     mg/day",
"    </span>",
"    should be given routinely to",
"    <strong>",
"     all",
"    </strong>",
"    patients taking MTX on a chronic basis. There does not appear to be a downside to this recommendation because of the lack of toxicity of folic acid. The dose may be increased to 5",
"    <span class=\"nowrap\">",
"     mg/day",
"    </span>",
"    as needed, based upon reporting of residual symptoms.",
"   </p>",
"   <p>",
"    MTX interferes with the cellular utilization of",
"    <a class=\"drug drug_general\" href=\"UTD.htm?8/61/9174?source=see_link\">",
"     folic acid",
"    </a>",
"    , and folate depletion is considered to be the cause of most of these complaints. Most, but not all, studies that lend support to this theory have noted that many of these reactions can be alleviated or prevented by the addition of supplemental folic acid, without changing the efficacy of MTX [",
"    <a class=\"abstract\" href=\"UTD.htm?10/61/11223/abstract/7,10,14,15\">",
"     7,10,14,15",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    However, some data suggest that daily folate may reduce the efficacy of MTX for RA. This was illustrated in a post-hoc analysis of the outcomes of two control groups in two separate randomized controlled trials that compared",
"    <a class=\"drug drug_general\" href=\"UTD.htm?18/36/19015?source=see_link\">",
"     leflunomide",
"    </a>",
"    with",
"    <a class=\"drug drug_general\" href=\"UTD.htm?23/38/24170?source=see_link\">",
"     methotrexate",
"    </a>",
"    [",
"    <a class=\"abstract\" href=\"UTD.htm?10/61/11223/abstract/16\">",
"     16",
"    </a>",
"    ]. A clinically modest, but statistically significant, decrease in efficacy was noted in those who received MTX and folate concomitantly (ACR20, ACR50, and ACR70 response rates in patients not receiving folate were a mean of 17, 14, and 12 percent higher, respectively, compared with patients who did take folate) [",
"    <a class=\"abstract\" href=\"UTD.htm?10/61/11223/abstract/16\">",
"     16",
"    </a>",
"    ]. Liver enzyme abnormalities were less frequently noted in those receiving folate. Adverse effects of MTX were not reduced by folate administration in this study, although they clearly are overall.",
"   </p>",
"   <p>",
"    These toxicities can be predicted by the baseline folate status at the time of initiation of MTX therapy. If possible, patients should avoid other medications that have the potential for depleting",
"    <a class=\"drug drug_general\" href=\"UTD.htm?8/61/9174?source=see_link\">",
"     folic acid",
"    </a>",
"    such as",
"    <a class=\"drug drug_general\" href=\"UTD.htm?25/36/26182?source=see_link\">",
"     trimethoprim",
"    </a>",
"    (which is most often given as",
"    <a class=\"drug drug_general\" href=\"UTD.htm?4/58/5034?source=see_link\">",
"     trimethoprim-sulfamethoxazole",
"    </a>",
"    ).",
"   </p>",
"   <p>",
"    Folinic acid (racemic",
"    <a class=\"drug drug_general\" href=\"UTD.htm?23/54/24423?source=see_link\">",
"     leucovorin",
"    </a>",
"    ) also reduces MTX toxicity [",
"    <a class=\"abstract\" href=\"UTD.htm?10/61/11223/abstract/17-20\">",
"     17-20",
"    </a>",
"    ], although at doses above 7",
"    <span class=\"nowrap\">",
"     mg/week",
"    </span>",
"    it may diminish the efficacy of MTX [",
"    <a class=\"abstract\" href=\"UTD.htm?10/61/11223/abstract/19,20\">",
"     19,20",
"    </a>",
"    ]. Folinic acid is reduced folate (FH4), while",
"    <a class=\"drug drug_general\" href=\"UTD.htm?8/61/9174?source=see_link\">",
"     folic acid",
"    </a>",
"    is the form of the vitamin found prior to the metabolic reduction to FH4 by the enzyme dihydrofolate reductase (DHFR). Since DHFR is one of the target enzymes of MTX, folinic acid is more potent in overcoming the metabolic block in this pathway.",
"   </p>",
"   <p>",
"    Folinic acid should only be used in patients who have not had a satisfactory response to",
"    <a class=\"drug drug_general\" href=\"UTD.htm?8/61/9174?source=see_link\">",
"     folic acid",
"    </a>",
"    . Folinic acid is considerably more expensive than folic acid, and dosing is critical both in preventing toxicity and in maintaining the efficacy of MTX. A typical dose is 2.5 to 5 mg given once weekly, 8 to 12 hours after MTX administration. The dose of the L-isomer (L-",
"    <a class=\"drug drug_general\" href=\"UTD.htm?23/54/24423?source=see_link\">",
"     leucovorin",
"    </a>",
"    ) is one half the dose of the racemic preparation (leucovorin calcium).",
"   </p>",
"   <p>",
"    In contrast to the efficacy of",
"    <a class=\"drug drug_general\" href=\"UTD.htm?8/61/9174?source=see_link\">",
"     folic acid",
"    </a>",
"    in relieving the above symptoms, there is no compelling evidence that the hepatic or pulmonary toxicity are related to folate depletion. Hepatic folate stores are depleted by MTX at the doses used in RA, and these stores can be repleted by short-term oral folinic acid [",
"    <a class=\"abstract\" href=\"UTD.htm?10/61/11223/abstract/21\">",
"     21",
"    </a>",
"    ]. However, a relationship between folate depletion and hepatic toxicity has not been established. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?31/24/32134?source=see_link\">",
"     \"Hepatotoxicity associated with chronic oral methotrexate for nonmalignant disease\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H14365930\">",
"    <span class=\"h1\">",
"     LYMPHOPROLIFERATIVE DISORDERS",
"    </span>",
"    &nbsp;&mdash;&nbsp;Lymphoproliferative disorders occur with increased frequency in RA, independent of specific therapies, but MTX and other immune-modulating therapies may increase such risk. Lymphoproliferative &ldquo;malignancies&rdquo; may develop after long-term therapy. They are usually of B-cell origin and may be due to Epstein Barr virus infection [",
"    <a class=\"abstract\" href=\"UTD.htm?10/61/11223/abstract/22\">",
"     22",
"    </a>",
"    ]. One prospective study collected 25 cases of lymphoma in patients with RA who were being treated with MTX throughout France. Among these were seven cases of Hodgkin disease (27.8 and 2.8 cases per 100,000 per year for men and women respectively) an incidence that was more than expected for an age and gender matched population (adjusted standardized incidence ratio [SIR] of 7.4) [",
"    <a class=\"abstract\" href=\"UTD.htm?10/61/11223/abstract/23\">",
"     23",
"    </a>",
"    ]. The incidence of non-Hodgkin lymphoma was not increased by MTX therapy. Chemotherapy should be withheld until MTX has been stopped, since some of these tumors regress within four weeks after MTX has been discontinued [",
"    <a class=\"abstract\" href=\"UTD.htm?10/61/11223/abstract/24-26\">",
"     24-26",
"    </a>",
"    ]. Continued vigilance is necessary in those who regress, since relapse has occurred [",
"    <a class=\"abstract\" href=\"UTD.htm?10/61/11223/abstract/23\">",
"     23",
"    </a>",
"    ]. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?0/11/184?source=see_link&amp;anchor=H10#H10\">",
"     \"Disease outcome and functional capacity in rheumatoid arthritis\", section on 'Lymphoproliferative disorders'",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H8\">",
"    <span class=\"h1\">",
"     NODULOSIS",
"    </span>",
"    &nbsp;&mdash;&nbsp;MTX is postulated to exacerbate rheumatoid nodule formation (accelerated nodulosis) in some patients with rheumatoid arthritis, despite the effective suppression of synovial inflammation. This activity may be mediated via the agonist stimulation of adenosine A1 receptors by MTX, thereby leading to enhanced giant cell formation [",
"    <a class=\"abstract\" href=\"UTD.htm?10/61/11223/abstract/27\">",
"     27",
"    </a>",
"    ]. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?29/7/29815?source=see_link\">",
"     \"Rheumatoid nodules\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H9\">",
"    <span class=\"h1\">",
"     PREGNANCY",
"    </span>",
"    &nbsp;&mdash;&nbsp;MTX is an abortifacient that can also induce congenital anomalies if taken during pregnancy. It is, therefore, contraindicated in pregnant women. We advise contraceptive use in women taking MTX as well as discontinuation of therapy in both women and men at least three months prior to conception. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?37/59/38842?source=see_link\">",
"     \"Use of antiinflammatory and immunosuppressive drugs in rheumatic diseases during pregnancy and lactation\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H10\">",
"    <span class=\"h1\">",
"     BONE",
"    </span>",
"    &nbsp;&mdash;&nbsp;High-dose MTX regimens (such as those used for osteosarcoma or acute lymphoblastic leukemia) are associated with an increase in bone resorption and inhibition of bone formation, possibly resulting in both osteoporosis and fractures [",
"    <a class=\"abstract\" href=\"UTD.htm?10/61/11223/abstract/28,29\">",
"     28,29",
"    </a>",
"    ]. This has not been observed with MTX in the dose range used for rheumatic disease [",
"    <a class=\"abstract\" href=\"UTD.htm?10/61/11223/abstract/30,31\">",
"     30,31",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H11\">",
"    <span class=\"h1\">",
"     OTHERS",
"    </span>",
"    &nbsp;&mdash;&nbsp;MTX given concomitantly with radiotherapy may increase the risk of soft tissue necrosis and osteonecrosis [",
"    <a class=\"abstract\" href=\"UTD.htm?10/61/11223/abstract/32\">",
"     32",
"    </a>",
"    ]. Use of MTX may interfere with the response to pneumococcal vaccine when used alone or in combination with the anti-tumor necrosis factor alpha agent,",
"    <a class=\"drug drug_general\" href=\"UTD.htm?27/31/28151?source=see_link\">",
"     etanercept",
"    </a>",
"    [",
"    <a class=\"abstract\" href=\"UTD.htm?10/61/11223/abstract/33,34\">",
"     33,34",
"    </a>",
"    ]. MTX only rarely affects the eye; reported adverse effects include periorbital edema, pain, blurred vision, photophobia, blepharitis, conjunctivitis, and optic neuropathy related to folate deficiency [",
"    <a class=\"abstract\" href=\"UTD.htm?10/61/11223/abstract/35\">",
"     35",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H12\">",
"    <span class=\"h1\">",
"     SUMMARY AND RECOMMENDATIONS",
"    </span>",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Hepatotoxicity due to MTX may result from direct damage to hepatocytes, or, in patients with concomitant viral hepatitis, MTX may enhance viral damage. Patients should be screened for hepatitis before beginning therapy and should be monitored for toxicity regularly while receiving the drug. (See",
"      <a class=\"local\" href=\"#H2\">",
"       'Hepatotoxicity'",
"      </a>",
"      above and",
"      <a class=\"medical medical_review\" href=\"UTD.htm?31/24/32134?source=see_link\">",
"       \"Hepatotoxicity associated with chronic oral methotrexate for nonmalignant disease\"",
"      </a>",
"      .)",
"     </li>",
"     <li>",
"      Pulmonary toxicity of MTX may present with acute or chronic symptoms. Either symptomatic or asymptomatic radiographic lung damage may be due to inflammation, infection, or MTX-related pneumonitis. We recommend a baseline chest radiograph before initiating MTX treatment. (See",
"      <a class=\"local\" href=\"#H3\">",
"       'Pulmonary toxicity'",
"      </a>",
"      above and",
"      <a class=\"medical medical_review\" href=\"UTD.htm?9/5/9306?source=see_link\">",
"       \"Methotrexate-induced lung injury\"",
"      </a>",
"      .)",
"     </li>",
"     <li>",
"      Hematologic toxicity of low-dose weekly therapy included red blood cell macrocytosis and, less often, anemia, thrombocytopenia, or leukopenia. Pancytopenia is very uncommon. Patients receiving MTX should be monitored periodically with a complete blood count and platelet count. Myelosuppression with low-dose MTX is more likely if renal function is impaired. MTX may also increase the risk of lymphoproliferative malignancy in RA. (See",
"      <a class=\"local\" href=\"#H4\">",
"       'Myelosuppression'",
"      </a>",
"      above and",
"      <a class=\"local\" href=\"#H14365930\">",
"       'Lymphoproliferative disorders'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      Impairment of glomerular filtration rate will result in sustained serum levels of the drug that may induce bone marrow or other toxicities, because it is primarily cleared unchanged through the kidneys. Kidney damage due to precipitation of MTX crystals and tubular injury may occur with high-dose MTX, but it is very rare with chronic low-dose therapy. (See",
"      <a class=\"local\" href=\"#H5\">",
"       'Nephrotoxicity'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      One or more of the common toxicities associated with MTX are seen at some time in most patients. These include gastrointestinal problems such as nausea, stomach upset, and loose stools; stomatitis or soreness of the mouth; a macular punctate rash that usually occurs on the extremities and that spares the trunk; central nervous system problems including headache, fatigue, or impaired ability to concentrate; alopecia; fever; and hematologic abnormalities, particularly macrocytosis. (See",
"      <a class=\"local\" href=\"#H6\">",
"       'Common toxicities'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      <a class=\"drug drug_general\" href=\"UTD.htm?8/61/9174?source=see_link\">",
"       Folic acid",
"      </a>",
"      at a dose of 1",
"      <span class=\"nowrap\">",
"       mg/day",
"      </span>",
"      should be given routinely to",
"      <strong>",
"       all",
"      </strong>",
"      patients taking MTX on a chronic basis. The dose may be increased up to 5",
"      <span class=\"nowrap\">",
"       mg/day",
"      </span>",
"      as needed, based upon reporting of residual symptoms. Folinic acid should only be used in patients who have not had a satisfactory response to folic acid (ie, toxicities remain). (See",
"      <a class=\"local\" href=\"#H7\">",
"       'Role of folate'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      Additional adverse effects include exacerbation of rheumatoid nodulosis; marked adverse effects upon the fetus during pregnancy, which should be avoided while on MTX; diminished vaccine responses; and rare ocular abnormalities. (See",
"      <a class=\"local\" href=\"#H8\">",
"       'Nodulosis'",
"      </a>",
"      above and",
"      <a class=\"local\" href=\"#H9\">",
"       'Pregnancy'",
"      </a>",
"      above and",
"      <a class=\"local\" href=\"#H10\">",
"       'Bone'",
"      </a>",
"      above and",
"      <a class=\"local\" href=\"#H11\">",
"       'Others'",
"      </a>",
"      above.)",
"     </li>",
"    </ul>",
"   </p>",
"  </div>",
"  <div id=\"topicAgreement\">",
"   Use of UpToDate is subject to the",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_in_page\" target=\"_blank\">",
"    Subscription and License Agreement",
"   </a>",
"   .",
"  </div>",
"  <div class=\"headingAnchor\" id=\"references\">",
"   <h1>",
"    REFERENCES",
"   </h1>",
"   <ol id=\"reference\">",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?10/61/11223/abstract/1\">",
"      Kremer JM, Alarc&oacute;n GS, Lightfoot RW Jr, et al. Methotrexate for rheumatoid arthritis. Suggested guidelines for monitoring liver toxicity. American College of Rheumatology. Arthritis Rheum 1994; 37:316.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?10/61/11223/abstract/2\">",
"      Guidelines for monitoring drug therapy in rheumatoid arthritis. American College of Rheumatology Ad Hoc Committee on Clinical Guidelines. Arthritis Rheum 1996; 39:723.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?10/61/11223/abstract/3\">",
"      Nyfors A. Liver biopsies from psoriatics related to methotrexate therapy. 3. Findings in post-methotrexate liver biopsies from 160 psoriatics. Acta Pathol Microbiol Scand A 1977; 85:511.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?10/61/11223/abstract/4\">",
"      Kremer JM, Alarc&oacute;n GS, Weinblatt ME, et al. Clinical, laboratory, radiographic, and histopathologic features of methotrexate-associated lung injury in patients with rheumatoid arthritis: a multicenter study with literature review. Arthritis Rheum 1997; 40:1829.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?10/61/11223/abstract/5\">",
"      Weinblatt ME, Fraser P. Elevated mean corpuscular volume as a predictor of hematologic toxicity due to methotrexate therapy. Arthritis Rheum 1989; 32:1592.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?10/61/11223/abstract/6\">",
"      Gutierrez-Ure&ntilde;a S, Molina JF, Garc&iacute;a CO, et al. Pancytopenia secondary to methotrexate therapy in rheumatoid arthritis. Arthritis Rheum 1996; 39:272.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?10/61/11223/abstract/7\">",
"      Ortiz Z, Shea B, Suarez-Almazor ME, et al. The efficacy of folic acid and folinic acid in reducing methotrexate gastrointestinal toxicity in rheumatoid arthritis. A metaanalysis of randomized controlled trials. J Rheumatol 1998; 25:36.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?10/61/11223/abstract/8\">",
"      van Ede AE, Laan RF, Rood MJ, et al. Effect of folic or folinic acid supplementation on the toxicity and efficacy of methotrexate in rheumatoid arthritis: a forty-eight week, multicenter, randomized, double-blind, placebo-controlled study. Arthritis Rheum 2001; 44:1515.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?10/61/11223/abstract/9\">",
"      Montecucco C, Caporali R, Rossi S, Porta C. Allopurinol mouthwashes in methotrexate-induced stomatitis. Arthritis Rheum 1994; 37:777.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?10/61/11223/abstract/10\">",
"      Morgan SL, Baggott JE, Vaughn WH, et al. The effect of folic acid supplementation on the toxicity of low-dose methotrexate in patients with rheumatoid arthritis. Arthritis Rheum 1990; 33:9.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?10/61/11223/abstract/11\">",
"      Quinn CT, Kamen BA. A biochemical perspective of methotrexate neurotoxicity with insight on nonfolate rescue modalities. J Investig Med 1996; 44:522.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?10/61/11223/abstract/12\">",
"      Bernini JC, Fort DW, Griener JC, et al. Aminophylline for methotrexate-induced neurotoxicity. Lancet 1995; 345:544.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?10/61/11223/abstract/13\">",
"      Alarc&oacute;n GS, Tracy IC, Strand GM, et al. Survival and drug discontinuation analyses in a large cohort of methotrexate treated rheumatoid arthritis patients. Ann Rheum Dis 1995; 54:708.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?10/61/11223/abstract/14\">",
"      Morgan SL, Baggott JE, Vaughn WH, et al. Supplementation with folic acid during methotrexate therapy for rheumatoid arthritis. A double-blind, placebo-controlled trial. Ann Intern Med 1994; 121:833.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?10/61/11223/abstract/15\">",
"      Hornung N, Ellingsen T, Stengaard-Pedersen K, Poulsen JH. Folate, homocysteine, and cobalamin status in patients with rheumatoid arthritis treated with methotrexate, and the effect of low dose folic acid supplement. J Rheumatol 2004; 31:2374.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?10/61/11223/abstract/16\">",
"      Khanna D, Park GS, Paulus HE, et al. Reduction of the efficacy of methotrexate by the use of folic acid: post hoc analysis from two randomized controlled studies. Arthritis Rheum 2005; 52:3030.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?10/61/11223/abstract/17\">",
"      Shiroky JB, Neville C, Esdaile JM, et al. Low-dose methotrexate with leucovorin (folinic acid) in the management of rheumatoid arthritis. Results of a multicenter randomized, double-blind, placebo-controlled trial. Arthritis Rheum 1993; 36:795.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?10/61/11223/abstract/18\">",
"      Weinblatt ME, Maier AL, Coblyn JS. Low dose leucovorin does not interfere with the efficacy of methotrexate in rheumatoid arthritis: an 8 week randomized placebo controlled trial. J Rheumatol 1993; 20:950.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?10/61/11223/abstract/19\">",
"      Joyce DA, Will RK, Hoffman DM, et al. Exacerbation of rheumatoid arthritis in patients treated with methotrexate after administration of folinic acid. Ann Rheum Dis 1991; 50:913.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?10/61/11223/abstract/20\">",
"      Tishler M, Caspi D, Fishel B, Yaron M. The effects of leucovorin (folinic acid) on methotrexate therapy in rheumatoid arthritis patients. Arthritis Rheum 1988; 31:906.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?10/61/11223/abstract/21\">",
"      Rodenhuis S, Kremer JM, Bertino JR. Increase of dihydrofolate reductase in peripheral blood lymphocytes of rheumatoid arthritis patients treated with low-dose oral methotrexate. Arthritis Rheum 1987; 30:369.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?10/61/11223/abstract/22\">",
"      Menke DM, Griesser H, Moder KG, et al. Lymphomas in patients with connective tissue disease. Comparison of p53 protein expression and latent EBV infection in patients immunosuppressed and not immunosuppressed with methotrexate. Am J Clin Pathol 2000; 113:212.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?10/61/11223/abstract/23\">",
"      Mariette X, Cazals-Hatem D, Warszawki J, et al. Lymphomas in rheumatoid arthritis patients treated with methotrexate: a 3-year prospective study in France. Blood 2002; 99:3909.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?10/61/11223/abstract/24\">",
"      Kamel OW, van de Rijn M, Weiss LM, et al. Brief report: reversible lymphomas associated with Epstein-Barr virus occurring during methotrexate therapy for rheumatoid arthritis and dermatomyositis. N Engl J Med 1993; 328:1317.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?10/61/11223/abstract/25\">",
"      Bachman TR, Sawitzke AD, Perkins SL, et al. Methotrexate-associated lymphoma in patients with rheumatoid arthritis: report of two cases. Arthritis Rheum 1996; 39:325.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?10/61/11223/abstract/26\">",
"      Moseley AC, Lindsley HB, Skikne BS, Tawfik O. Reversible methotrexate associated lymphoproliferative disease evolving into Hodgkin's disease. J Rheumatol 2000; 27:810.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?10/61/11223/abstract/27\">",
"      Merrill JT, Shen C, Schreibman D, et al. Adenosine A1 receptor promotion of multinucleated giant cell formation by human monocytes: a mechanism for methotrexate-induced nodulosis in rheumatoid arthritis. Arthritis Rheum 1997; 40:1308.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?10/61/11223/abstract/28\">",
"      Pfeilschifter J, Diel IJ. Osteoporosis due to cancer treatment: pathogenesis and management. J Clin Oncol 2000; 18:1570.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?10/61/11223/abstract/29\">",
"      Schwartz AM, Leonidas JC. Methotrexate osteopathy. Skeletal Radiol 1984; 11:13.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?10/61/11223/abstract/30\">",
"      Buckley LM, Leib ES, Cartularo KS, et al. Effects of low dose methotrexate on the bone mineral density of patients with rheumatoid arthritis. J Rheumatol 1997; 24:1489.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?10/61/11223/abstract/31\">",
"      Ide M, Suzuki Y, Ichikawa Y, et al. Influence of long-term low-dose methotrexate therapy on periarticular and generalized osteoporosis in rheumatoid arthritis. Jap J Rheumatol 1999; 9:75.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?10/61/11223/abstract/32\">",
"      Turner SL, Slevin NJ, Gupta NK, Swindell R. Radical external beam radiotherapy for 333 squamous carcinomas of the oral cavity--evaluation of late morbidity and a watch policy for the clinically negative neck. Radiother Oncol 1996; 41:21.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?10/61/11223/abstract/33\">",
"      O'Dell J, Gilg J, Palmer W, et al. Pneumococcal vaccination in rheumatoid arthritis patients on methotrexate. (abstract) Arthritis Rheum 1992; 35:S197.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?10/61/11223/abstract/34\">",
"      Mease PJ, Ritchlin CT, Martin RW, et al. Pneumococcal vaccine response in psoriatic arthritis patients during treatment with etanercept. J Rheumatol 2004; 31:1356.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?10/61/11223/abstract/35\">",
"      Peponis V, Kyttaris VC, Chalkiadakis SE, et al. Ocular side effects of anti-rheumatic medications: what a rheumatologist should know. Lupus 2010; 19:675.",
"     </a>",
"    </li>",
"   </ol>",
"  </div>",
"  <div id=\"topicVersionRevision\">",
"   Topic 7509 Version 10.0",
"  </div>",
" </div>",
" <div id=\"footer\">",
"  <div id=\"supportFooter\">",
"   <span class=\"sfInfo\">",
"    &copy; 2013 UpToDate, Inc. All rights reserved.",
"   </span>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_footer\">",
"    Subscription and License Agreement",
"   </a>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Release: 21.6- C21.56",
"   </span>",
"   <br/>",
"   <span class=\"sfInfo\">",
"    Licensed to:",
"    <span class=\"emphasis\">",
"     AsanBook Dig. Med. Lib.",
"    </span>",
"   </span>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Support Tag: [1004-118.195.65.247-FCC50AAECF-S244013.14]",
"    <br/>",
"   </span>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f10_61_11223=[""].join("\n");
var outline_f10_61_11223=[" <div id=\"toggleOutline\">",
"  <a href=\"#\" title=\"Collapse Topic Outline\">",
"   <img alt=\"\" src=\"./../images/orange_arrow_left.myextg\"/>",
"  </a>",
" </div>",
" <div id=\"innerOutline\">",
"  <h1>",
"   TOPIC OUTLINE",
"  </h1>",
"  <div id=\"outline\">",
"   <ul>",
"    <li>",
"     <a class=\"sr_button\" href=\"#H12\" id=\"summRecButton\">",
"      <span>",
"       SUMMARY &amp; RECOMMENDATIONS",
"      </span>",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H1\">",
"      INTRODUCTION",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H2\">",
"      HEPATOTOXICITY",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H3\">",
"      PULMONARY TOXICITY",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H4\">",
"      MYELOSUPPRESSION",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H5\">",
"      NEPHROTOXICITY",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H6\">",
"      COMMON TOXICITIES",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H7\">",
"      Role of folate",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H14365930\">",
"      LYMPHOPROLIFERATIVE DISORDERS",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H8\">",
"      NODULOSIS",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H9\">",
"      PREGNANCY",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H10\">",
"      BONE",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H11\">",
"      OTHERS",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H12\">",
"      SUMMARY AND RECOMMENDATIONS",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a href=\"#references\">",
"      REFERENCES",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   RELATED TOPICS",
"  </h1>",
"  <div id=\"relatedTopics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?34/2/34857?source=related_link\">",
"      Crystal-induced acute kidney injury (acute renal failure)",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?0/11/184?source=related_link\">",
"      Disease outcome and functional capacity in rheumatoid arthritis",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?25/25/26009?source=related_link\">",
"      Hepatitis B virus reactivation associated with immunosuppression",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?31/24/32134?source=related_link\">",
"      Hepatotoxicity associated with chronic oral methotrexate for nonmalignant disease",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?9/5/9306?source=related_link\">",
"      Methotrexate-induced lung injury",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?37/22/38250?source=related_link\">",
"      Oral toxicity associated with chemotherapy",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?29/7/29815?source=related_link\">",
"      Rheumatoid nodules",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?29/0/29706?source=related_link\">",
"      Secondary immune deficiency induced by drugs and biologics",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?32/55/33658?source=related_link\">",
"      Therapeutic use and toxicity of high-dose methotrexate",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?37/59/38842?source=related_link\">",
"      Use of antiinflammatory and immunosuppressive drugs in rheumatic diseases during pregnancy and lactation",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?31/26/32169?source=related_link\">",
"      Use of methotrexate in the treatment of rheumatoid arthritis",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
" </div>"].join("\n");
var title_f10_61_11224="Dialysis issues prior to and after renal transplantation";
var content_f10_61_11224=[" <noscript>",
"  <div id=\"javascriptDisabled\">",
"   It seems to us that you have your JavaScript turned off on your browser. JavaScript is required in order for our site to behave correctly.  Please enable your JavaScript to continue use our site.",
"  </div>",
" </noscript>",
" <div id=\"printHeader\">",
"  <div id=\"printHeaderLogo\">",
"   <img alt=\"UpToDate\" src=\"./../images/UTD2_masthead.myextg\">",
"    <img align=\"right\" alt=\"Wolters Kluwer Health\" height=\"40\" src=\"./../images/logoWKH.myextg\" width=\"175\">",
"     <br>",
"      <div id=\"printHeaderText\">",
"       Official reprint from  UpToDate",
"       <sup>",
"        &reg;",
"       </sup>",
"       <br>",
"        <a href=\"file://www.uptodate.com\">",
"         www.uptodate.com",
"        </a>",
"        &copy;2013 UpToDate",
"        <sup>",
"         &reg;",
"        </sup>",
"       </br>",
"      </div>",
"     </br>",
"    </img>",
"   </img>",
"  </div>",
"  <div id=\"printHeaderLinks\">",
"   <a class=\"TOPIC\" href=\"#\" id=\"printHeaderPrint\" rel=\"2\" title=\"Click here to print\">",
"    Print",
"   </a>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a href=\"#\" id=\"printHeaderBack\" title=\"Back to normal view\">",
"    Back",
"   </a>",
"  </div>",
" </div>",
" <!-- TC:TOPIC_PAGE -->",
" <div id=\"topicContent\">",
"  <div id=\"topicTitle\">",
"   Dialysis issues prior to and after renal transplantation",
"  </div>",
"  <div id=\"topicContributors\">",
"   <div>",
"    <a id=\"authors\">",
"    </a>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"UTD.htm?10/61/11224/contributors\">",
"     Authors",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"UTD.htm?10/61/11224/contributors\">",
"     Vijaya Venkataraman, MD",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"UTD.htm?10/61/11224/contributors\">",
"     Daniel C Brennan, MD, FACP",
"    </a>",
"    <br/>",
"   </div>",
"   <div>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"UTD.htm?10/61/11224/contributors\">",
"     Section Editor",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"UTD.htm?10/61/11224/contributors\">",
"     Barbara Murphy, MB, BAO, BCh, FRCPI",
"    </a>",
"    <br/>",
"   </div>",
"   <div>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"UTD.htm?10/61/11224/contributors\">",
"     Deputy Editor",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"UTD.htm?10/61/11224/contributors\">",
"     Alice M Sheridan, MD",
"    </a>",
"    <br/>",
"   </div>",
"  </div>",
"  <div id=\"disclosures\">",
"   <a href=\"UTD.htm?10/61/11224/contributor-disclosure\" target=\"_blank\">",
"    Disclosures",
"   </a>",
"  </div>",
"  <div id=\"reviewProcess\">",
"   <span>",
"    All topics are updated as new evidence becomes available and our",
"   </span>",
"   <a href=\"/home/editorial-policy\" target=\"_blank\">",
"    peer review process",
"   </a>",
"   <span>",
"    is complete.",
"   </span>",
"  </div>",
"  <div id=\"literatureReviewDate\">",
"   <span class=\"emphasis\">",
"    Literature review current through:",
"   </span>",
"   Oct 2013.",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <span class=\"emphasis\">",
"    This topic last updated:",
"   </span>",
"   Mar 9, 2012.",
"  </div>",
"  <div id=\"topicText\">",
"   <p class=\"headingAnchor\" id=\"H1\">",
"    <span class=\"h1\">",
"     INTRODUCTION",
"    </span>",
"    &nbsp;&mdash;&nbsp;Survival benefits of renal transplantation over dialysis therapy are well established for patients with end-stage renal disease (ESRD). The most convincing evidence for this comes from comparisons of mortality between patients on the waiting list for transplantation and the recipients of a transplant. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?17/36/17992?source=see_link\">",
"     \"Patient survival after renal transplantation\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    An overview of the various issues related to dialysis and renal transplantation are discussed in this topic review. These include the issue of preemptive renal transplantation, the impact of dialysis vintage and choice of dialysis modality on transplant outcomes, and post-transplant dialysis topics.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H2\">",
"    <span class=\"h1\">",
"     PREEMPTIVE TRANSPLANTATION AND OUTCOMES",
"    </span>",
"    &nbsp;&mdash;&nbsp;Near doubling of death rates among waitlisted patients compared with transplant recipients argues against the routine strategy of placing ESRD patients on maintenance dialysis before consideration is given to renal transplantation. This leads to the question of whether transplantation of these patients prior to the initiation of dialysis (preemptive transplantation) would improve outcomes significantly.",
"   </p>",
"   <p>",
"    Results of previous studies examining this issue have been conflicting [",
"    <a class=\"abstract\" href=\"UTD.htm?10/61/11224/abstract/1-4\">",
"     1-4",
"    </a>",
"    ]. In addition, the increasing use of intensive dialysis regimens such as home or nocturnal hemodialysis may reduce the benefit of preemptive transplantation. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?18/44/19144?source=see_link\">",
"     \"Home hemodialysis\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?17/45/18137?source=see_link\">",
"     \"Short daily hemodialysis\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?3/24/3465?source=see_link\">",
"     \"Outcomes associated with nocturnal hemodialysis\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    However, several subsequent large analyses have demonstrated that preemptive transplantation leads to substantial improvements in patient and graft survival when compared to transplantation after a period of dialysis therapy [",
"    <a class=\"abstract\" href=\"UTD.htm?10/61/11224/abstract/5-8\">",
"     5-8",
"    </a>",
"    ]. Nevertheless, these studies are clearly limited due to lead-time bias. As examples:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      In a study of nearly 40,000 primary renal transplant recipients, those undergoing preemptive transplantation had 25 and 27 percent reductions in the relative risk for graft loss for deceased and live donor transplants, respectively [",
"      <a class=\"abstract\" href=\"UTD.htm?10/61/11224/abstract/5\">",
"       5",
"      </a>",
"      ]. Corresponding risks for patient death were also reduced by 16 and 31 percent.",
"     </li>",
"     <li>",
"      In a separate analysis of 73,103 patients registered in the United States Renal Data Systems (USRDS) database, a relative increase in mortality risk after transplantation of 21, 28, 41, 53, and 72 percent versus that observed with preemptive transplantation, was reported among those with waiting times of 6 to 12 months, 12 to 24 months, 24 to 36, 36 to 48, and over 48 months, respectively [",
"      <a class=\"abstract\" href=\"UTD.htm?10/61/11224/abstract/6\">",
"       6",
"      </a>",
"      ]. Similarly, relative to preemptive transplants, waiting times of 0 to 6 months, 6 to 12 months, 12 to 24 months, and over 24 months also conferred a 17, 37, 55, and 68 percent relative increase in risk for death-censored graft loss after transplantation, respectively.",
"     </li>",
"     <li>",
"      Another analysis of 8481 living donor transplant recipients showed that preemptive transplantation was associated with 52, 82, 86 percent reductions in the relative rate of allograft failure in the first, second, and third years after transplant, respectively [",
"      <a class=\"abstract\" href=\"UTD.htm?10/61/11224/abstract/7\">",
"       7",
"      </a>",
"      ].",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    In addition, a decision analytic stimulation model found that the patient survival benefit with preemptive transplantation compared with dialysis and waitlisting was approximately 7.5 to 9.9 years for 40-year-old patients and 4.3 to 6.0 years for 70-year-olds [",
"    <a class=\"abstract\" href=\"UTD.htm?10/61/11224/abstract/9\">",
"     9",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    The exact reasons for these improved outcomes with preemptive transplantation are unclear. The following factors may contribute:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Low solute clearances associated with dialysis therapy allow accumulation of a number of substances associated with adverse effects, such as accelerated atherosclerosis, malnutrition, and chronic inflammation. The cumulative burden of these processes with prolonged dialysis exposure, particularly increased cardiovascular disease, may predispose to adverse outcomes that are avoided with preemptive transplantation [",
"      <a class=\"abstract\" href=\"UTD.htm?10/61/11224/abstract/10\">",
"       10",
"      </a>",
"      ].",
"     </li>",
"     <li>",
"      Preemptive transplantation is associated with significantly lower rates of delayed graft function (DGF) compared with nonpreemptive transplantation for both deceased donor and living donor transplants.",
"     </li>",
"     <li>",
"      Rates of biopsy-confirmed acute rejection within six months of transplantation are also significantly lower for patients transplanted preemptively.",
"     </li>",
"     <li>",
"      Preemptive transplant recipients have associated socioeconomic and demographic features that predict better outcomes [",
"      <a class=\"abstract\" href=\"UTD.htm?10/61/11224/abstract/11\">",
"       11",
"      </a>",
"      ]. As an example, preemptive transplants are more likely among younger subjects, whites, patients with a college education, those able to work, and transplants with fewer HLA antigen mismatches.",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    DGF and acute rejection are well-known to have negative effects on graft survival, both independently and synergistically [",
"    <a class=\"abstract\" href=\"UTD.htm?10/61/11224/abstract/12,13\">",
"     12,13",
"    </a>",
"    ]. Thus, lower rates of occurrence of both of these adverse events with preemptive transplantation may contribute to the better outcomes. However, correlations between better graft survival and preemptive transplantation persist even after adjustments were made for the effects of DGF and acute rejection (except in the first year after transplantation). This implies that preemptive transplantation alone may have direct beneficial effects on graft survival.",
"   </p>",
"   <p>",
"    The issue of when to proceed with preemptive kidney transplantation in the patient with chronic kidney disease is unclear. Higher versus lower pretransplant glomerular filtration rate (GFR) does not appear to be associated with superior allograft survival posttransplant [",
"    <a class=\"abstract\" href=\"UTD.htm?10/61/11224/abstract/14,15\">",
"     14,15",
"    </a>",
"    ]. This was best shown by an analysis of 19,461 first-time pre-emptive kidney recipients reported to the United Network for Organ Sharing (UNOS) between 1995 and 2009 [",
"    <a class=\"abstract\" href=\"UTD.htm?10/61/11224/abstract/15\">",
"     15",
"    </a>",
"    ]. Analysis of this large cohort did not detect any difference in patient survival or death-censored graft survival among patients who were transplanted at estimated GFRs less than 10, between 10 to 15, between 15 to 20, and greater than 20",
"    <span class=\"nowrap\">",
"     mL/min",
"    </span>",
"    per 1.73 m2, respectively.",
"   </p>",
"   <p>",
"    We agree with the consensus guidelines from The Canadian Society of Transplantation that recommend that the procedure should not be performed in most patients unless the glomerular filtration rate (GFR) is less than 20",
"    <span class=\"nowrap\">",
"     mL/minute",
"    </span>",
"    and evidence exists of a progressive and irreversible decrease in renal function over the previous 6 to 12 months [",
"    <a class=\"abstract\" href=\"UTD.htm?10/61/11224/abstract/16\">",
"     16",
"    </a>",
"    ]. We usually calculate the GFR using the MDRD equation. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?35/45/36570?source=see_link\">",
"     \"Assessment of kidney function\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    In the United States, there is evidence that insurance type and minority status may adversely affect placement on the waiting list prior to the need for dialysis. This was shown in a study that analyzed the Scientific Registry of Transplant Recipients database to determine the factors underlying preemptive listing and duration of dialysis before listing [",
"    <a class=\"abstract\" href=\"UTD.htm?10/61/11224/abstract/17\">",
"     17",
"    </a>",
"    ]. Factors associated with a low rate of preemptive listing and increased duration of dialysis included Medicare insurance, member of a minority group, and low education level.",
"   </p>",
"   <p>",
"    In sum, there is compelling evidence for avoidance of dialysis and early preemptive transplantation of suitable patients with ESRD [",
"    <a class=\"abstract\" href=\"UTD.htm?10/61/11224/abstract/10\">",
"     10",
"    </a>",
"    ]. This strategy should be aggressively pursued, especially for the young patient with preserved functional status, low levels of sensitization, and no significant burden of comorbid disease.",
"   </p>",
"   <p>",
"    However, only approximately 20 percent of living donor and 5 percent of deceased donor transplants are performed preemptively in the United States. This, in large measure, is due to rapid expansion in the numbers of potential transplant candidates without parallel expansion of the donor pool. However, it also stems from the failure to recognize dialysis as a modifiable risk factor for relatively poor post-transplant outcomes.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H4\">",
"    <span class=\"h1\">",
"     DURATION OF PRETRANSPLANT DIALYSIS AND POST-TRANSPLANT OUTCOMES",
"    </span>",
"    &nbsp;&mdash;&nbsp;The adverse effects of dialysis therapy on post-transplant outcomes are duration dependent. Thus, increasing periods of exposure to dialysis prior to transplantation are associated with proportionately greater increases in the risk of graft loss and patient death after transplantation. As an example, a retrospective analysis from the USRDS database found that being on dialysis for 0 to 6 months prior to transplantation conferred a 17 percent increased risk for death-censored graft loss as compared with preemptive transplantation [",
"    <a class=\"abstract\" href=\"UTD.htm?10/61/11224/abstract/6\">",
"     6",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Since this risk increased linearly with incremental time on dialysis, being on maintenance dialysis for 36 months prior to transplantation resulted in the risk of graft loss being 68 percent higher than that observed with preemptive transplantation (",
"    <a class=\"graphic graphic_figure graphicRef61627 \" href=\"UTD.htm?2/21/2399\">",
"     figure 1",
"    </a>",
"    ). The same linear relationship was also seen between time on dialysis and patient death with a functioning graft. However, a statistically significant association could only be shown beyond six months of dialysis exposure (",
"    <a class=\"graphic graphic_figure graphicRef53436 \" href=\"UTD.htm?12/15/12543\">",
"     figure 2",
"    </a>",
"    ).",
"   </p>",
"   <p>",
"    In a separate analysis also utilizing the USRDS database, these same results were reproduced [",
"    <a class=\"abstract\" href=\"UTD.htm?10/61/11224/abstract/18\">",
"     18",
"    </a>",
"    ]. However, there was a statistically significant adverse association between ESRD duration and graft loss that was seen only after six months of dialysis therapy. In addition, the adverse association between ESRD duration and patient survival was seen only after one year of dialysis exposure [",
"    <a class=\"abstract\" href=\"UTD.htm?10/61/11224/abstract/18\">",
"     18",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Despite these differences, it remains that, although dialysis initiation at the appropriate time should not be deferred in favor of waiting for a kidney",
"    <strong>",
"     transplant",
"    </strong>",
"    , transplantation of suitable patients at the earliest time offers the best outcomes for patient and graft survival [",
"    <a class=\"abstract\" href=\"UTD.htm?10/61/11224/abstract/18\">",
"     18",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Although these data estimate the relative effects of increasing dialysis times on posttransplant patient and graft survival, they do not quantify the absolute adverse impact of ESRD duration on these outcomes. An objective estimate of this risk was obtained from the results of a retrospective analysis that examined 10 year adjusted graft survivals for deceased and living donor transplants as a function of the duration of pretransplant dialysis [",
"    <a class=\"abstract\" href=\"UTD.htm?10/61/11224/abstract/19\">",
"     19",
"    </a>",
"    ]. The following results were reported:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Ten year graft survival in deceased donor renal transplant recipients for those transplanted preemptively versus patients on dialysis for more than two years was 69 and 39 percent, respectively",
"     </li>",
"     <li>",
"      Ten year graft survivals for living donor transplants for those transplanted preemptively versus patients transplanted after two years of dialysis therapy was 75 and 49 percent, respectively.",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    In addition, for any given wait-time on dialysis, graft survival for living donor transplants is better than that with deceased donor transplants. However, this relative benefit is smaller in magnitude than the effect of waiting time. In this context, living donor transplants performed after prolonged dialysis exposure yield results similar to deceased donor transplants performed within six months of dialysis initiation.",
"   </p>",
"   <p>",
"    Similarly, deceased donor transplants performed after prolonged waiting times have by far the lowest long-term graft survival rates. Despite this, the long-term survival advantages of transplantation over dialysis are maintained even in this group of patients.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H5\">",
"    <span class=\"h1\">",
"     PRE-TRANSPLANT DIALYSIS MODALITY AND TRANSPLANT OUTCOMES",
"    </span>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H6\">",
"    <span class=\"h2\">",
"     Peritoneal dialysis versus hemodialysis",
"    </span>",
"    &nbsp;&mdash;&nbsp;The role of pretransplant dialysis modality in affecting post-transplant outcomes is controversial. The results of most studies examining this issue have been equivocal. Some have reported lower DGF rates with its attendant long-term benefits and decreased allograft and patient survival for those treated with peritoneal dialysis (PD), while others have shown worse outcomes related to excess graft thrombosis and infections for these patients [",
"    <a class=\"abstract\" href=\"UTD.htm?10/61/11224/abstract/4,20-27\">",
"     4,20-27",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Retrospective and prospective analyses of large numbers of patients have found similar risks of mortality with PD or hemodialysis prior to transplantation [",
"    <a class=\"abstract\" href=\"UTD.htm?10/61/11224/abstract/28,29\">",
"     28,29",
"    </a>",
"    ]. As an example, a large retrospective study of nearly 23,000 primary renal transplant recipients found comparable death risks and overall graft survivals with either modality [",
"    <a class=\"abstract\" href=\"UTD.htm?10/61/11224/abstract/28\">",
"     28",
"    </a>",
"    ]. However, patients treated with PD prior to transplantation had an unexpected 15 percent significantly greater risk of death-censored graft failure relative to those treated with hemodialysis. When analysis was restricted to the first three months of follow-up after transplantation, the risk for graft loss with peritoneal dialysis was even more pronounced and 33 percent higher than that for hemodialysis. In addition, adjusted Cox analyses that included only those patients whose grafts functioned for at least three months, found little effect of dialysis on outcomes, implying that the risk associated with peritoneal dialysis was confined to the early posttransplant period (",
"    <a class=\"graphic graphic_table graphicRef52161 \" href=\"UTD.htm?16/36/16971\">",
"     table 1",
"    </a>",
"    ).",
"   </p>",
"   <p>",
"    This observation was not clearly confirmed by a more recent analysis of combined data obtained from the Scientific Registry of Transplant Recipients and a list of individuals undergoing dialysis provided by a nation-wide outpatient dialysis facility from 2001 to 2006 [",
"    <a class=\"abstract\" href=\"UTD.htm?10/61/11224/abstract/30\">",
"     30",
"    </a>",
"    ]. Compared with hemodialysis, peritoneal dialysis was associated with a lower adjusted all-cause mortality (43 percent) and cardiovascular mortality (66 percent), but there was no difference between groups in adjusted death-censored graft function and DGF when considering relevant variables and the type of dialysis.",
"   </p>",
"   <p>",
"    The disparity between these observational studies may reflect differences in the eras in which patients were transplanted and shorter duration of dialysis prior to transplantation dialysis in the later study. In addition, the later study is limited by a relatively smaller number of patients, a shorter duration of follow-up and selection bias. As an example, patients on peritoneal dialysis were younger, more likely to be white, less likely to be diabetic, and more likely to have received kidneys from younger donors with fewer HLA mismatches.",
"   </p>",
"   <p>",
"    An important variable that was not measured in the later study was the amount of residual renal function and urine output.",
"   </p>",
"   <p>",
"    A significant increase in relative risk for graft loss that was observed in the 2002 study cited above [",
"    <a class=\"abstract\" href=\"UTD.htm?10/61/11224/abstract/28\">",
"     28",
"    </a>",
"    ] does not in itself indicate the magnitude of increase in graft loss. The latter depends upon both the actual rate of graft loss as well as the relative risk. As an example, the United States national average for graft survivals at three months posttransplantation for deceased donor kidneys is 94 percent [",
"    <a class=\"abstract\" href=\"UTD.htm?10/61/11224/abstract/31\">",
"     31",
"    </a>",
"    ]. Assuming that the remaining 6 percent graft loss occurred in patients previously on hemodialysis, the 33 percent higher risk for peritoneal dialysis would translate into an 8 percent risk of graft loss for this modality and an absolute difference of 2 percent between the two.",
"   </p>",
"   <p>",
"    The etiology of excess graft loss associated with pretransplant peritoneal dialysis, if present, is unclear. In a limited subset of patients in whom data for cause of graft loss were available, allograft thrombosis was found to be more frequent among peritoneal dialysis patients [",
"    <a class=\"abstract\" href=\"UTD.htm?10/61/11224/abstract/31\">",
"     31",
"    </a>",
"    ]. Although tentative due to the lack of complete data, these results have been substantiated by other reports associating prior peritoneal dialysis treatment with increased risk of allograft thrombosis [",
"    <a class=\"abstract\" href=\"UTD.htm?10/61/11224/abstract/24,32,33\">",
"     24,32,33",
"    </a>",
"    ]. The highest risks for renal vein thrombosis have been found in repeat transplant recipients treated with peritoneal dialysis.",
"   </p>",
"   <p>",
"    The mechanism by which peritoneal dialysis predisposes to allograft thrombosis is unknown. It may be related to an acquired thrombophilic state in peritoneal dialysis patients resulting from the loss of anticoagulant proteins in the dialysate, increased activity of plasma procoagulant factors and the accumulation of the highly thrombogenic moieties such as apolipoprotein(a). In a brief report, prophylactic use of low dose",
"    <a class=\"drug drug_general\" href=\"UTD.htm?24/7/24698?source=see_link\">",
"     aspirin",
"    </a>",
"    was noted to cause a significant reduction in the incidence of allograft thrombosis [",
"    <a class=\"abstract\" href=\"UTD.htm?10/61/11224/abstract/34\">",
"     34",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Systematic assessment of the risk of bleeding from",
"    <a class=\"drug drug_general\" href=\"UTD.htm?24/7/24698?source=see_link\">",
"     aspirin",
"    </a>",
"    therapy in patients undergoing vascular anastomosis, and posttransplant biopsies is essential before aspirin prophylaxis can be adopted as standard practice. Pending this change, given the disastrous consequences of allograft thrombosis, a reasonable strategy to follow may be to place all PD patients undergoing renal transplantation on low-dose aspirin, empirically, in the early perioperative period.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H7\">",
"    <span class=\"h2\">",
"     Biocompatible versus bioincompatible membranes",
"    </span>",
"    &nbsp;&mdash;&nbsp;Although patients on maintenance hemodialysis were found to have favorable early graft survival in comparison to those on peritoneal dialysis, exposure to hemodialysis in the 24-hour period immediately prior to transplantation has been implicated in slower graft recovery after transplantation. This effect is most pronounced when dialysis is performed using complement-activating or bioincompatible membrane (BICM) dialyzers (eg, cuprophane dialyzers) with concomitant ultrafiltration. As an example, in a study of 44 allograft recipients who were dialyzed within a 24 hour interval prior to transplantation, the",
"    <span class=\"nowrap\">",
"     T1/2",
"    </span>",
"    serum creatinine (defined as the time taken for the serum creatinine to decline to half the level at the time of transplantation) was significantly higher with a BICM dialyzer (9.3 days for patients undergoing ultrafiltration and dialysis using a BICM dialyzer in comparison with 1.7 + 0.8 days for those dialyzed without ultrafiltration using a biocompatible membrane) [",
"    <a class=\"abstract\" href=\"UTD.htm?10/61/11224/abstract/35\">",
"     35",
"    </a>",
"    ]. Recovery of graft function was somewhat more favorable for patients dialyzed using a BICM but without net fluid removal",
"    <span class=\"nowrap\">",
"     (T1/2",
"    </span>",
"    serum creatinine of 3.7 days), although it still remained significantly delayed relative to patients dialyzed with a biocompatible membrane in the absence of ultrafiltration.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H9\">",
"    <span class=\"h1\">",
"     DIALYSIS IMMEDIATELY POST-TRANSPLANTATION AND OUTCOMES",
"    </span>",
"    &nbsp;&mdash;&nbsp;The need for dialysis in the first postoperative week after transplantation (by convention termed delayed graft function [DGF]) has been independently associated with nearly two to threefold increase in patient death, graft failure and death-censored graft failure [",
"    <a class=\"abstract\" href=\"UTD.htm?10/61/11224/abstract/13,28,36\">",
"     13,28,36",
"    </a>",
"    ]. Although most commonly due to post-ischemic acute tubular necrosis, DGF may also be the result of rejection episodes, urinary obstruction, or allograft thrombosis. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?2/1/2072?source=see_link\">",
"     \"Differential diagnosis of renal allograft dysfunction\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    The nonspecific inflammation associated with acute tubular necrosis might lead to upregulation of adhesion molecules and enhanced MHC class I and II antigen expression, eventually resulting in acute rejection. In this context, a significant association has been noted between occurrence of DGF and the incidence of early acute rejections. In an analysis of 27,096 cadaveric renal transplants, a 25 percent acute rejection rate was reported in the presence of DGF versus only 8 percent without DGF [",
"    <a class=\"abstract\" href=\"UTD.htm?10/61/11224/abstract/13\">",
"     13",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    It has also been speculated that early renal injury associated with DGF may result in fewer functioning nephrons, leading to hyperfiltration injury and fibrosis; this may eventually have an adverse effect on graft survival. In the previously cited study, occurrence of DGF alone was noted to decrease allograft half-life from 14.2 years to 9.4 years [",
"    <a class=\"abstract\" href=\"UTD.htm?10/61/11224/abstract/13\">",
"     13",
"    </a>",
"    ]. When superimposed by acute rejection in the first six posttransplant months, this was further reduced to 6.2 years, indicating synergistic adverse effects of acute rejection and DGF on graft survival.",
"   </p>",
"   <p>",
"    When compared with the hemodialysis population, the incidence of DGF is significantly lower for peritoneal dialysis patients (adjusted risk 0.74) [",
"    <a class=\"abstract\" href=\"UTD.htm?10/61/11224/abstract/28\">",
"     28",
"    </a>",
"    ]. In addition, evolution of graft function (as determined by the",
"    <span class=\"nowrap\">",
"     T1/2",
"    </span>",
"    serum creatinine) is also much faster for peritoneal dialysis patients [",
"    <a class=\"abstract\" href=\"UTD.htm?10/61/11224/abstract/23\">",
"     23",
"    </a>",
"    ]. Despite these significant beneficial effects, pretransplant peritoneal dialysis therapy has been associated with a higher rate of early graft losses, as discussed previously.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H10\">",
"    <span class=\"h1\">",
"     RETURN TO DIALYSIS AFTER GRAFT LOSS",
"    </span>",
"    &nbsp;&mdash;&nbsp;Compared to those with continued allograft function, patient survival after graft loss is extremely poor [",
"    <a class=\"abstract\" href=\"UTD.htm?10/61/11224/abstract/37-39\">",
"     37-39",
"    </a>",
"    ]:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      In general, less than 40 percent of such patients survive 10 years as compared to more than 75 percent of patients with a functioning kidney transplant surviving beyond 10 years [",
"      <a class=\"abstract\" href=\"UTD.htm?10/61/11224/abstract/37\">",
"       37",
"      </a>",
"      ].",
"     </li>",
"     <li>",
"      Data obtained from the USRDS registry shows that the annual adjusted death rate for patients returning to dialysis is over three times higher than the death rate during transplant (9.42 versus 2.81 per 100 patient-years) [",
"      <a class=\"abstract\" href=\"UTD.htm?10/61/11224/abstract/37\">",
"       37",
"      </a>",
"      ]. More significantly, although these patients were originally on the transplant waiting list, their mortality posttransplant loss is 50 percent higher than the wait-listed group.",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    The exact reasons for this elevated mortality risk remain undefined. It is likely to be related at least in part to the recurrence of renal failure itself. In relation to this, decreased renal function at one year post-transplantation is associated in a dose dependent fashion with increased cardiovascular mortality in patients with functioning transplants [",
"    <a class=\"abstract\" href=\"UTD.htm?10/61/11224/abstract/38\">",
"     38",
"    </a>",
"    ]. This effect is even more pronounced when cardiovascular deaths after graft loss is included in the analysis, suggesting a continuum of increasing mortality with progressive worsening of renal function. In addition, although ESRD duration prior to transplantation is a powerful predictor of a risk of death after graft loss, the length of time with a functioning transplant has shown no dose-related association with mortality after graft loss [",
"    <a class=\"abstract\" href=\"UTD.htm?10/61/11224/abstract/37\">",
"     37",
"    </a>",
"    ]; this indicates a protective effect of the transplanted kidney alone on survival [",
"    <a class=\"abstract\" href=\"UTD.htm?10/61/11224/abstract/37\">",
"     37",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    As a result, patients returning to dialysis after graft loss represent a unique subgroup of the ESRD population which has accrued increased comorbidities and mortality risk. As per current USRDS data, they constitute an expanding subgroup of approximately 5 percent of the incident dialysis patients. Of these, approximately 10 percent are likely to get retransplanted while the majority will continue to remain on dialysis.",
"   </p>",
"   <p>",
"    The optimal dialysis modality after allograft loss in these patients is unclear. Similar survival rates have been reported with peritoneal dialysis and hemodialysis [",
"    <a class=\"abstract\" href=\"UTD.htm?10/61/11224/abstract/40,41\">",
"     40,41",
"    </a>",
"    ]. In addition, limited data suggest that patient survival and peritonitis-free survival is similar in those with failed allograft function who subsequently undergo peritoneal dialysis (PD) compared to those who undergo PD after the loss of native kidney function [",
"    <a class=\"abstract\" href=\"UTD.htm?10/61/11224/abstract/42\">",
"     42",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Surprisingly, an analysis of USRDS data showed a 36 percent higher risk of graft failure in patients undergoing preemptive retransplantation in comparison with those retransplanted after a period of dialysis [",
"    <a class=\"abstract\" href=\"UTD.htm?10/61/11224/abstract/43\">",
"     43",
"    </a>",
"    ]. At the same time, this study also found, as expected, that waiting time after graft loss had a negative association with recipient survival. This suggests that there is a currently undefined but optimal time on dialysis after allograft loss beyond which retransplantation should be pursued.",
"   </p>",
"   <p>",
"    Alternately and perhaps more likely, it is possible that we delay re-initiation of dialysis in patients with failing grafts, allowing them to get sicker and accrue more risk. To this end, initiation of dialysis after graft loss is often delayed till clearances have fallen well below targets recommended by the",
"    <span class=\"nowrap\">",
"     K/DOQI",
"    </span>",
"    workgroup [",
"    <a class=\"abstract\" href=\"UTD.htm?10/61/11224/abstract/44\">",
"     44",
"    </a>",
"    ]. Similarly, the mean serum albumin concentration and hematocrit level, both known to be markers for increased mortality and morbidity in the non-transplant ESRD population, are lower than recommended in the majority of patients returning to dialysis after transplantation [",
"    <a class=\"abstract\" href=\"UTD.htm?10/61/11224/abstract/45\">",
"     45",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H11\">",
"    <span class=\"h2\">",
"     Withdrawal of immunosuppression after return to dialysis",
"    </span>",
"    &nbsp;&mdash;&nbsp;There is no consensus or data from controlled trials on how best to withdraw immunosuppression after a return to dialysis. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?40/9/41111?source=see_link\">",
"     \"Withdrawal of immunosuppression after renal transplant failure\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    Aggressive management of comorbid conditions especially in the context of allograft dysfunction with appropriate timing of transfer to dialysis therapy are critical to optimizing survival in this group of patients and need to be consciously integrated into routine post-transplant care.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H33915669\">",
"    <span class=\"h1\">",
"     SUMMARY AND RECOMMENDATIONS",
"    </span>",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Preemptive transplantation leads to substantial improvements in patient and graft survival when compared to transplantation after a period of dialysis therapy. The reasons for improved outcomes are unclear but may include the decreased progression of cardiovascular disease and lower rates of delayed graft function and acute rejection. Socioeconomic and demographic features that are typically associated with preemptive transplant also predict better outcomes. (See",
"      <a class=\"local\" href=\"#H2\">",
"       'Preemptive transplantation and outcomes'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      The issue of when to proceed with preemptive kidney transplantation is unclear. Higher versus lower pretransplant glomerular filtration rate (GFR) does not appear to be associated with superior allograft survival posttransplant. We agree with recommendations from The Canadian Society of Transplantation that kidney transplantation should not be performed in most patients unless the glomerular filtration rate (GFR) is less than 20",
"      <span class=\"nowrap\">",
"       mL/minute",
"      </span>",
"      and evidence exists of a progressive and irreversible decrease in renal function over the previous 6 to 12 months. (See",
"      <a class=\"local\" href=\"#H2\">",
"       'Preemptive transplantation and outcomes'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      The adverse effects of dialysis therapy on post-transplant outcomes are duration dependent. Although for any given wait-time on dialysis, graft survival for living donor transplants is better than that with deceased donor transplants, this relative benefit is smaller than the effect of waiting time. Thus living donor transplants performed after prolonged dialysis exposure yield results similar to deceased donor transplants performed within six months of dialysis initiation. Deceased donor transplants performed after prolonged waiting times have by far the lowest long-term graft survival rates. (See",
"      <a class=\"local\" href=\"#H4\">",
"       'Duration of pretransplant dialysis and post-transplant outcomes'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      Most studies have found similar risks of mortality with peritoneal dialysis or hemodialysis prior to transplantation, although pretransplant peritoneal dialysis may be associated with increased graft loss related to allograft thrombosis. The prophylactic use of low dose",
"      <a class=\"drug drug_general\" href=\"UTD.htm?24/7/24698?source=see_link\">",
"       aspirin",
"      </a>",
"      may reduce the risk allograft thrombosis among such patients. However an assessment of the risk of bleeding from aspirin therapy in patients undergoing vascular anastomosis, and posttransplant biopsies is essential before aspirin prophylaxis can be adopted as standard practice. (See",
"      <a class=\"local\" href=\"#H6\">",
"       'Peritoneal dialysis versus hemodialysis'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      Compared to those with continued allograft function, and even to those on the transplant wait-listed group, patient survival after graft loss is poor. The exact reasons for the elevated mortality risk remain undefined, but are likely related, at least in part, to the recurrence of renal failure itself. (See",
"      <a class=\"local\" href=\"#H10\">",
"       'Return to dialysis after graft loss'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      Patients undergoing preemptive retransplantation have a higher risk of graft failure compared with those retransplanted after a period of dialysis, although waiting time after graft loss is still inversely associated with recipient survival. This likely means that re-initiation of dialysis is inappropriately delayed in many patients with failing grafts, allowing them to get sicker and accrue more risk. The appropriate timing of dialysis initiation and the aggressive management of comorbid conditions such as anemia are critical in optimizing survival in patients with a failing allograft and should be consciously integrated into routine post-transplant care. (See",
"      <a class=\"local\" href=\"#H11\">",
"       'Withdrawal of immunosuppression after return to dialysis'",
"      </a>",
"      above.)",
"     </li>",
"    </ul>",
"   </p>",
"  </div>",
"  <div id=\"topicAgreement\">",
"   Use of UpToDate is subject to the",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_in_page\" target=\"_blank\">",
"    Subscription and License Agreement",
"   </a>",
"   .",
"  </div>",
"  <div class=\"headingAnchor\" id=\"references\">",
"   <h1>",
"    REFERENCES",
"   </h1>",
"   <ol id=\"reference\">",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?10/61/11224/abstract/1\">",
"      Berthoux FC, Jones EH, Mehls O, Valderr&aacute;bano F. Transplantation Report. 2: Pre-emptive renal transplantation in adults aged over 15 years. The EDTA-ERA Registry. European Dialysis and Transplant Association-European Renal Association. Nephrol Dial Transplant 1996; 11 Suppl 1:41.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?10/61/11224/abstract/2\">",
"      John AG, Rao M, Jacob CK. Preemptive live-related renal transplantation. Transplantation 1998; 66:204.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?10/61/11224/abstract/3\">",
"      Papalois VE, Moss A, Gillingham KJ, et al. Pre-emptive transplants for patients with renal failure: an argument against waiting until dialysis. Transplantation 2000; 70:625.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?10/61/11224/abstract/4\">",
"      Vats AN, Donaldson L, Fine RN, Chavers BM. Pretransplant dialysis status and outcome of renal transplantation in North American children: a NAPRTCS Study. North American Pediatric Renal Transplant Cooperative Study. Transplantation 2000; 69:1414.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?10/61/11224/abstract/5\">",
"      Kasiske BL, Snyder JJ, Matas AJ, et al. Preemptive kidney transplantation: the advantage and the advantaged. J Am Soc Nephrol 2002; 13:1358.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?10/61/11224/abstract/6\">",
"      Meier-Kriesche HU, Port FK, Ojo AO, et al. Effect of waiting time on renal transplant outcome. Kidney Int 2000; 58:1311.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?10/61/11224/abstract/7\">",
"      Mange KC, Joffe MM, Feldman HI. Effect of the use or nonuse of long-term dialysis on the subsequent survival of renal transplants from living donors. N Engl J Med 2001; 344:726.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?10/61/11224/abstract/8\">",
"      Gill JS, Tonelli M, Johnson N, Pereira BJ. Why do preemptive kidney transplant recipients have an allograft survival advantage? Transplantation 2004; 78:873.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?10/61/11224/abstract/9\">",
"      Liem YS, Weimar W. Early living-donor kidney transplantation: a review of the associated survival benefit. Transplantation 2009; 87:317.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?10/61/11224/abstract/10\">",
"      Meier-Kriesche HU, Schold JD. The impact of pretransplant dialysis on outcomes in renal transplantation. Semin Dial 2005; 18:499.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?10/61/11224/abstract/11\">",
"      Butkus DE, Dottes AL, Meydrech EF, Barber WH. Effect of poverty and other socioeconomic variables on renal allograft survival. Transplantation 2001; 72:261.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?10/61/11224/abstract/12\">",
"      Matas AJ, Gillingham KJ, Payne WD, Najarian JS. The impact of an acute rejection episode on long-term renal allograft survival (t1/2). Transplantation 1994; 57:857.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?10/61/11224/abstract/13\">",
"      Shoskes DA, Cecka JM. Deleterious effects of delayed graft function in cadaveric renal transplant recipients independent of acute rejection. Transplantation 1998; 66:1697.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?10/61/11224/abstract/14\">",
"      Akkina SK, Connaire JJ, Snyder JJ, et al. Earlier is not necessarily better in preemptive kidney transplantation. Am J Transplant 2008; 8:2071.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?10/61/11224/abstract/15\">",
"      Grams ME, Massie AB, Coresh J, Segev DL. Trends in the timing of pre-emptive kidney transplantation. J Am Soc Nephrol 2011; 22:1615.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?10/61/11224/abstract/16\">",
"      Knoll G, Cockfield S, Blydt-Hansen T, et al. Canadian Society of Transplantation consensus guidelines on eligibility for kidney transplantation. CMAJ 2005; 173:1181.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?10/61/11224/abstract/17\">",
"      Keith D, Ashby VB, Port FK, Leichtman AB. Insurance type and minority status associated with large disparities in prelisting dialysis among candidates for kidney transplantation. Clin J Am Soc Nephrol 2008; 3:463.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?10/61/11224/abstract/18\">",
"      Goldfarb-Rumyantzev A, Hurdle JF, Scandling J, et al. Duration of end-stage renal disease and kidney transplant outcome. Nephrol Dial Transplant 2005; 20:167.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?10/61/11224/abstract/19\">",
"      Meier-Kriesche HU, Kaplan B. Waiting time on dialysis as the strongest modifiable risk factor for renal transplant outcomes: a paired donor kidney analysis. Transplantation 2002; 74:1377.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?10/61/11224/abstract/20\">",
"      Cosio FG, Alamir A, Yim S, et al. Patient survival after renal transplantation: I. The impact of dialysis pre-transplant. Kidney Int 1998; 53:767.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?10/61/11224/abstract/21\">",
"      Binaut R, Hazzan M, Pruvot FR, et al. Comparative study of chronic ambulatory peritoneal dialysis versus hemodialysis patients after kidney transplantation: clinical and financial assessment. Transplant Proc 1997; 29:2428.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?10/61/11224/abstract/22\">",
"      Van Biesen W, Vanholder R, Van Loo A, et al. Peritoneal dialysis favorably influences early graft function after renal transplantation compared to hemodialysis. Transplantation 2000; 69:508.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?10/61/11224/abstract/23\">",
"      Vanholder R, Heering P, Loo AV, et al. Reduced incidence of acute renal graft failure in patients treated with peritoneal dialysis compared with hemodialysis. Am J Kidney Dis 1999; 33:934.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?10/61/11224/abstract/24\">",
"      Ojo AO, Hanson JA, Wolfe RA, et al. Dialysis modality and the risk of allograft thrombosis in adult renal transplant recipients. Kidney Int 1999; 55:1952.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?10/61/11224/abstract/25\">",
"      Passalacqua JA, Wiland AM, Fink JC, et al. Increased incidence of postoperative infections associated with peritoneal dialysis in renal transplant recipients. Transplantation 1999; 68:535.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?10/61/11224/abstract/26\">",
"      Chalem Y, Ryckelynck JP, Tuppin P, et al. Access to, and outcome of, renal transplantation according to treatment modality of end-stage renal disease in France. Kidney Int 2005; 67:2448.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?10/61/11224/abstract/27\">",
"      Goldfarb-Rumyantzev AS, Hurdle JF, Scandling JD, et al. The role of pretransplantation renal replacement therapy modality in kidney allograft and recipient survival. Am J Kidney Dis 2005; 46:537.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?10/61/11224/abstract/28\">",
"      Snyder JJ, Kasiske BL, Gilbertson DT, Collins AJ. A comparison of transplant outcomes in peritoneal and hemodialysis patients. Kidney Int 2002; 62:1423.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?10/61/11224/abstract/29\">",
"      Inrig JK, Sun JL, Yang Q, et al. Mortality by dialysis modality among patients who have end-stage renal disease and are awaiting renal transplantation. Clin J Am Soc Nephrol 2006; 1:774.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?10/61/11224/abstract/30\">",
"      Molnar MZ, Mehrotra R, Duong U, et al. Dialysis modality and outcomes in kidney transplant recipients. Clin J Am Soc Nephrol 2012; 7:332.",
"     </a>",
"    </li>",
"    <li>",
"     Organ Procurement and Transplantation Network/Scientific Renal Transplant Registry. Annual data report 2003. Adjusted graft survival, deceased donor kidney transplants. www.unos.org (Accessed 3/11/05).",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?10/61/11224/abstract/32\">",
"      McDonald RA, Smith JM, Stablein D, Harmon WE. Pretransplant peritoneal dialysis and graft thrombosis following pediatric kidney transplantation: a NAPRTCS report. Pediatr Transplant 2003; 7:204.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?10/61/11224/abstract/33\">",
"      Murphy BG, Hill CM, Middleton D, et al. Increased renal allograft thrombosis in CAPD patients. Nephrol Dial Transplant 1994; 9:1166.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?10/61/11224/abstract/34\">",
"      Robertson AJ, Nargund V, Gray DW, Morris PJ. Low dose aspirin as prophylaxis against renal-vein thrombosis in renal-transplant recipients. Nephrol Dial Transplant 2000; 15:1865.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?10/61/11224/abstract/35\">",
"      Van Loo AA, Vanholder RC, Bernaert PR, et al. Pretransplantation hemodialysis strategy influences early renal graft function. J Am Soc Nephrol 1998; 9:473.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?10/61/11224/abstract/36\">",
"      Tapiawala SN, Tinckam KJ, Cardella CJ, et al. Delayed graft function and the risk for death with a functioning graft. J Am Soc Nephrol 2010; 21:153.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?10/61/11224/abstract/37\">",
"      Kaplan B, Meier-Kriesche HU. Death after graft loss: an important late study endpoint in kidney transplantation. Am J Transplant 2002; 2:970.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?10/61/11224/abstract/38\">",
"      Meier-Kriesche HU, Baliga R, Kaplan B. Decreased renal function is a strong risk factor for cardiovascular death after renal transplantation. Transplantation 2003; 75:1291.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?10/61/11224/abstract/39\">",
"      Rao PS, Schaubel DE, Jia X, et al. Survival on dialysis post-kidney transplant failure: results from the Scientific Registry of Transplant Recipients. Am J Kidney Dis 2007; 49:294.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?10/61/11224/abstract/40\">",
"      de Jonge H, Bammens B, Lemahieu W, et al. Comparison of peritoneal dialysis and haemodialysis after renal transplant failure. Nephrol Dial Transplant 2006; 21:1669.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?10/61/11224/abstract/41\">",
"      Perl J, Hasan O, Bargman JM, et al. Impact of dialysis modality on survival after kidney transplant failure. Clin J Am Soc Nephrol 2011; 6:582.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?10/61/11224/abstract/42\">",
"      Badve SV, Hawley CM, McDonald SP, et al. Effect of previously failed kidney transplantation on peritoneal dialysis outcomes in the Australian and New Zealand patient populations. Nephrol Dial Transplant 2006; 21:776.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?10/61/11224/abstract/43\">",
"      Goldfarb-Rumyantzev AS, Hurdle JF, Baird BC, et al. The role of pre-emptive re-transplant in graft and recipient outcome. Nephrol Dial Transplant 2006; 21:1355.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?10/61/11224/abstract/44\">",
"      Arias M, Escallada R, de Francisco AL, et al. Return to dialysis after renal transplantation. Which would be the best way? Kidney Int Suppl 2002; :85.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?10/61/11224/abstract/45\">",
"      Gill JS, Abichandani R, Khan S, et al. Opportunities to improve the care of patients with kidney transplant failure. Kidney Int 2002; 61:2193.",
"     </a>",
"    </li>",
"   </ol>",
"  </div>",
"  <div id=\"topicVersionRevision\">",
"   Topic 7334 Version 7.0",
"  </div>",
" </div>",
" <div id=\"footer\">",
"  <div id=\"supportFooter\">",
"   <span class=\"sfInfo\">",
"    &copy; 2013 UpToDate, Inc. All rights reserved.",
"   </span>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_footer\">",
"    Subscription and License Agreement",
"   </a>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Release: 21.6- C21.56",
"   </span>",
"   <br/>",
"   <span class=\"sfInfo\">",
"    Licensed to:",
"    <span class=\"emphasis\">",
"     AsanBook Dig. Med. Lib.",
"    </span>",
"   </span>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Support Tag: [0504-118.195.65.248-3A8E13EC2C-S244013.14]",
"    <br/>",
"   </span>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f10_61_11224=[""].join("\n");
var outline_f10_61_11224=[" <div id=\"toggleOutline\">",
"  <a href=\"#\" title=\"Collapse Topic Outline\">",
"   <img alt=\"\" src=\"./../images/orange_arrow_left.myextg\"/>",
"  </a>",
" </div>",
" <div id=\"innerOutline\">",
"  <h1>",
"   TOPIC OUTLINE",
"  </h1>",
"  <div id=\"outline\">",
"   <ul>",
"    <li>",
"     <a class=\"sr_button\" href=\"#H33915669\" id=\"summRecButton\">",
"      <span>",
"       SUMMARY &amp; RECOMMENDATIONS",
"      </span>",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H1\">",
"      INTRODUCTION",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H2\">",
"      PREEMPTIVE TRANSPLANTATION AND OUTCOMES",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H4\">",
"      DURATION OF PRETRANSPLANT DIALYSIS AND POST-TRANSPLANT OUTCOMES",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H5\">",
"      PRE-TRANSPLANT DIALYSIS MODALITY AND TRANSPLANT OUTCOMES",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H6\">",
"      Peritoneal dialysis versus hemodialysis",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H7\">",
"      Biocompatible versus bioincompatible membranes",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H9\">",
"      DIALYSIS IMMEDIATELY POST-TRANSPLANTATION AND OUTCOMES",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H10\">",
"      RETURN TO DIALYSIS AFTER GRAFT LOSS",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H11\">",
"      Withdrawal of immunosuppression after return to dialysis",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H33915669\">",
"      SUMMARY AND RECOMMENDATIONS",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a href=\"#references\">",
"      REFERENCES",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   <div class=\"openRelatedGraphics\" id=\"NEPH/7334\" rel=\"outline_link\">",
"    GRAPHICS",
"    <a class=\"graphics_icon\" href=\"#\" title=\"View All Related Graphics\">",
"     View All",
"    </a>",
"   </div>",
"  </h1>",
"  <div id=\"relatedGraphics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <div class=\"openRelatedGraphics\" id=\"NEPH/7334|FIG\">",
"      <a href=\"#\" title=\"FIGURES\">",
"       FIGURES",
"      </a>",
"     </div>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_figure\" href=\"UTD.htm?2/21/2399\" title=\"figure 1\">",
"      death censored graft Survival",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_figure\" href=\"UTD.htm?12/15/12543\" title=\"figure 2\">",
"      proportional hazard analysis",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <div class=\"openRelatedGraphics\" id=\"NEPH/7334|TAB\">",
"      <a href=\"#\" title=\"TABLES\">",
"       TABLES",
"      </a>",
"     </div>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_table\" href=\"UTD.htm?16/36/16971\" title=\"table 1\">",
"      Effects pretransplant dialysis",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   RELATED TOPICS",
"  </h1>",
"  <div id=\"relatedTopics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?35/45/36570?source=related_link\">",
"      Assessment of kidney function",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?2/1/2072?source=related_link\">",
"      Differential diagnosis of renal allograft dysfunction",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?18/44/19144?source=related_link\">",
"      Home hemodialysis",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?3/24/3465?source=related_link\">",
"      Outcomes associated with nocturnal hemodialysis",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?17/36/17992?source=related_link\">",
"      Patient survival after renal transplantation",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?17/45/18137?source=related_link\">",
"      Short daily hemodialysis",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?40/9/41111?source=related_link\">",
"      Withdrawal of immunosuppression after renal transplant failure",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
" </div>"].join("\n");
var title_f10_61_11225="Management of symptomatic (non-ruptured) and ruptured abdominal aortic aneurysm";
var content_f10_61_11225=[" <noscript>",
"  <div id=\"javascriptDisabled\">",
"   It seems to us that you have your JavaScript turned off on your browser. JavaScript is required in order for our site to behave correctly.  Please enable your JavaScript to continue use our site.",
"  </div>",
" </noscript>",
" <div id=\"printHeader\">",
"  <div id=\"printHeaderLogo\">",
"   <img alt=\"UpToDate\" src=\"./../images/UTD2_masthead.myextg\">",
"    <img align=\"right\" alt=\"Wolters Kluwer Health\" height=\"40\" src=\"./../images/logoWKH.myextg\" width=\"175\">",
"     <br>",
"      <div id=\"printHeaderText\">",
"       Official reprint from  UpToDate",
"       <sup>",
"        &reg;",
"       </sup>",
"       <br>",
"        <a href=\"file://www.uptodate.com\">",
"         www.uptodate.com",
"        </a>",
"        &copy;2013 UpToDate",
"        <sup>",
"         &reg;",
"        </sup>",
"       </br>",
"      </div>",
"     </br>",
"    </img>",
"   </img>",
"  </div>",
"  <div id=\"printHeaderLinks\">",
"   <a class=\"TOPIC\" href=\"#\" id=\"printHeaderPrint\" rel=\"3\" title=\"Click here to print\">",
"    Print",
"   </a>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a href=\"#\" id=\"printHeaderBack\" title=\"Back to normal view\">",
"    Back",
"   </a>",
"  </div>",
" </div>",
" <!-- TC:TOPIC_PAGE -->",
" <div id=\"topicContent\">",
"  <div id=\"topicTitle\">",
"   Management of symptomatic (non-ruptured) and ruptured abdominal aortic aneurysm",
"  </div>",
"  <div id=\"topicContributors\">",
"   <div>",
"    <a id=\"authors\">",
"    </a>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"UTD.htm?10/61/11225/contributors\">",
"     Authors",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"UTD.htm?10/61/11225/contributors\">",
"     Jeffrey Jim, MD",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"UTD.htm?10/61/11225/contributors\">",
"     Robert W Thompson, MD",
"    </a>",
"    <br/>",
"   </div>",
"   <div>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"UTD.htm?10/61/11225/contributors\">",
"     Section Editors",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"UTD.htm?10/61/11225/contributors\">",
"     Joseph L Mills, Sr, MD",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"UTD.htm?10/61/11225/contributors\">",
"     John F Eidt, MD",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"UTD.htm?10/61/11225/contributors\">",
"     Emile R Mohler III, MD",
"    </a>",
"    <br/>",
"   </div>",
"   <div>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"UTD.htm?10/61/11225/contributors\">",
"     Deputy Editor",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"UTD.htm?10/61/11225/contributors\">",
"     Kathryn A Collins, MD, PhD, FACS",
"    </a>",
"    <br/>",
"   </div>",
"  </div>",
"  <div id=\"disclosures\">",
"   <a href=\"UTD.htm?10/61/11225/contributor-disclosure\" target=\"_blank\">",
"    Disclosures",
"   </a>",
"  </div>",
"  <div id=\"reviewProcess\">",
"   <span>",
"    All topics are updated as new evidence becomes available and our",
"   </span>",
"   <a href=\"/home/editorial-policy\" target=\"_blank\">",
"    peer review process",
"   </a>",
"   <span>",
"    is complete.",
"   </span>",
"  </div>",
"  <div id=\"literatureReviewDate\">",
"   <span class=\"emphasis\">",
"    Literature review current through:",
"   </span>",
"   Oct 2013.",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <span class=\"emphasis\">",
"    This topic last updated:",
"   </span>",
"   Feb 12, 2013.",
"  </div>",
"  <div id=\"topicText\">",
"   <p class=\"headingAnchor\" id=\"H53322839\">",
"    <span class=\"h1\">",
"     INTRODUCTION",
"    </span>",
"    &nbsp;&mdash;&nbsp;Symptomatic abdominal aortic aneurysm (AAA) refers to any of a number of symptoms (eg, abdominal pain, limb ischemia) that can be attributed to the aneurysm. The presence of symptoms increases the risk for AAA rupture, and thus, for most patients with symptomatic AAA, repair should be performed. AAA rupture can also occur in the absence of intervening symptoms. In the United States, rupture of an abdominal aortic aneurysm occurs in about 15,000 patients per year [",
"    <a class=\"abstract\" href=\"UTD.htm?10/61/11225/abstract/1\">",
"     1",
"    </a>",
"    ]. Without repair, ruptured AAA is nearly always fatal. In spite of significant advances in intensive care unit management and surgical techniques, mortality following repair of ruptured AAA remains high [",
"    <a class=\"abstract\" href=\"UTD.htm?10/61/11225/abstract/2\">",
"     2",
"    </a>",
"    ]. Surgical outcomes may be improved using endovascular aneurysm repair (EVAR), but aortic endografting under emergency circumstances presents many challenges. Increasing numbers of institutions have initiated protocols for endovascular repair of ruptured AAA with promising results in small series, but not all institutions are equipped to treat ruptured AAAs using minimally-invasive technology.",
"   </p>",
"   <p>",
"    The management of symptomatic AAA, non-ruptured and ruptured, will be reviewed. The diagnosis and management of asymptomatic AAA and general technical issues of open surgical and endovascular aneurysm repair are discussed elsewhere. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?31/16/32010?source=see_link\">",
"     \"Clinical features and diagnosis of abdominal aortic aneurysm\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?30/27/31162?source=see_link\">",
"     \"Endovascular repair of abdominal aortic aneurysm\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?37/53/38746?source=see_link&amp;anchor=H611107773#H611107773\">",
"     \"Management of asymptomatic abdominal aortic aneurysm\", section on 'Introduction'",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H933032328\">",
"    <span class=\"h1\">",
"     ANEURYSM TERMINOLOGY",
"    </span>",
"    &nbsp;&mdash;&nbsp;An abdominal aorta with a maximal diameter &gt;3.0 cm is aneurysmal in most adult patients (",
"    <a class=\"graphic graphic_figure graphicRef51087 \" href=\"UTD.htm?42/14/43234\">",
"     figure 1",
"    </a>",
"    ). Abdominal aortic aneurysm (AAA) most often affects the segment of aorta between the renal and inferior mesenteric arteries (infrarenal) (",
"    <a class=\"graphic graphic_figure graphicRef60682 \" href=\"UTD.htm?9/29/9683\">",
"     figure 2",
"    </a>",
"    ); approximately 5 percent involve the renal (pararenal) or visceral arteries (suprarenal). Most AAAs produce no symptoms. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?31/16/32010?source=see_link&amp;anchor=H15830656#H15830656\">",
"     \"Clinical features and diagnosis of abdominal aortic aneurysm\", section on 'Asymptomatic AAA'",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Ruptured AAA &ndash; Aortic rupture is due to the weakening of the aortic wall leading to tearing of the aortic wall allowing blood to escape outside the confines of the aorta. (See",
"      <a class=\"medical medical_review\" href=\"UTD.htm?31/16/32010?source=see_link&amp;anchor=H15830929#H15830929\">",
"       \"Clinical features and diagnosis of abdominal aortic aneurysm\", section on 'Ruptured AAA'",
"      </a>",
"      .)",
"     </li>",
"     <li>",
"      Symptomatic (non-ruptured) AAA &ndash; Symptomatic AAA refers to any of a number of symptoms (eg,",
"      <span class=\"nowrap\">",
"       abdominal/back/flank",
"      </span>",
"      pain, limb ischemia) that can be attributed to the aneurysm. The presence of symptoms increases the risk for rupture [",
"      <a class=\"abstract\" href=\"UTD.htm?10/61/11225/abstract/3\">",
"       3",
"      </a>",
"      ]. (See",
"      <a class=\"medical medical_review\" href=\"UTD.htm?31/16/32010?source=see_link&amp;anchor=H15830889#H15830889\">",
"       \"Clinical features and diagnosis of abdominal aortic aneurysm\", section on 'Symptomatic (nonruptured) AAA'",
"      </a>",
"      .)",
"     </li>",
"    </ul>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H933041496\">",
"    <span class=\"h1\">",
"     INITIAL MANAGEMENT",
"    </span>",
"    &nbsp;&mdash;&nbsp;The initial management of the patient with symptomatic (non-ruptured) or ruptured AAA is guided by the hemodynamic status. Hemodynamically unstable patients who are candidates for repair are generally transferred directly from the emergency department to the operating room. Most patients with symptomatic (non-ruptured) AAA are hemodynamically stable but will require admission to definitely determine whether the AAA is the source of the symptoms. Until the AAA can be excluded as a source of symptoms, the patient should be observed in a monitored setting. For patients determined to have a symptomatic AAA, but for whom repair will be delayed to optimize associated medical conditions, we admit the patient to an intensive care unit setting. (See",
"    <a class=\"local\" href=\"#H933039132\">",
"     'Emergent versus delayed repair of symptomatic aneurysm'",
"    </a>",
"    below.)",
"   </p>",
"   <p>",
"    Two large bore peripheral intravenous catheters should be placed in all patients (symptomatic, non-ruptured, or ruptured AAA) for medication and fluid administration. In hemodynamically unstable patients with ruptured AAA, indirect evidence from the trauma population and one observational study in patients with AAA suggest that allowing a relatively low systolic blood pressure of 80 to 100 mmHg (permissive hypotension) may prevent further tearing of the aorta and limit blood loss [",
"    <a class=\"abstract\" href=\"UTD.htm?10/61/11225/abstract/4-6\">",
"     4-6",
"    </a>",
"    ]. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?13/20/13639?source=see_link\">",
"     \"Treatment of severe hypovolemia or hypovolemic shock in adults\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    Pain control is an important part of management. It is important to keep the patient comfortable, but consciousness should be maintained. In patients who remain severely hypertensive despite adequate pain control, short-acting intravenous beta-blockers (eg,",
"    <a class=\"drug drug_general\" href=\"UTD.htm?39/37/40536?source=see_link\">",
"     esmolol",
"    </a>",
"    ) can be use to titrate the blood pressure to normal values. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?39/61/40920?source=see_link\">",
"     \"Pain control in the critically ill adult patient\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    Laboratory studies including complete blood count, electrolytes, blood urea nitrogen, creatinine, liver function tests, prothrombin time, partial thromboplastin time, and a type and cross-match should be obtained. If AAA repair will be undertaken at the hospital to which the patient presented, packed red blood cells should be placed on hold for possible transfusion in the operating room. In patients with ruptured AAA, the patient should have at least 10 units of packed red blood cells available for transfusion, and the blood bank should be alerted to the potential need for massive transfusion. Similar to trauma patients with severe ongoing hemorrhage, patients with ruptured AAA requiring massive transfusion may require transfusion of unmatched blood, and may benefit from packed red blood cell: fresh frozen plasma ratios (PRBC:FFP) &le;2:1 rather than higher ratios. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?28/55/29562?source=see_link\">",
"     \"Initial evaluation and management of shock in adult trauma\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?37/25/38294?source=see_link&amp;anchor=H8#H8\">",
"     \"Massive blood transfusion\", section on 'FFP, platelets, and red cells in trauma patients'",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H933032592\">",
"    <span class=\"h1\">",
"     APPROACH TO AAA ASSOCIATED WITH SYMPTOMS",
"    </span>",
"    &nbsp;&mdash;&nbsp;Symptoms associated with AAA may or may not be due to AAA rupture. A presumptive diagnosis of ruptured AAA, which is a surgical emergency, can be made in patients known to have AAA or those with a newly diagnosed AAA who have hypotension and abdominal, flank, or back pain. Although most patients with symptomatic (non-ruptured) AAA will require AAA repair, the timing of and approach to repair differs depending upon the presenting symptoms which may be due to instability of the aneurysm (impending rupture, thromboembolism), rapid expansion of the aneurysm causing abdominal discomfort, or related to inflammatory or infected AAA causing systemic manifestations. The clinical and diagnostic features that distinguish these are discussed in detail elsewhere. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?31/16/32010?source=see_link&amp;anchor=H22317736#H22317736\">",
"     \"Clinical features and diagnosis of abdominal aortic aneurysm\", section on 'Clinical features'",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?31/16/32010?source=see_link&amp;anchor=H15828721#H15828721\">",
"     \"Clinical features and diagnosis of abdominal aortic aneurysm\", section on 'Diagnosis'",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H933041557\">",
"    <span class=\"h2\">",
"     Ruptured AAA",
"    </span>",
"    &nbsp;&mdash;&nbsp;Although there are rare reports of patient survival following a contained rupture of abdominal aortic aneurysm (AAA), in general, without repair, ruptured AAA is uniformly fatal, with death occurring usually within hours and certainly within a week of rupture [",
"    <a class=\"abstract\" href=\"UTD.htm?10/61/11225/abstract/7\">",
"     7",
"    </a>",
"    ]. Thus, when ruptured AAA is identified, repair should be undertaken emergently to give the patient the best chance for survival [",
"    <a class=\"abstract\" href=\"UTD.htm?10/61/11225/abstract/3,8\">",
"     3,8",
"    </a>",
"    ]. (See",
"    <a class=\"local\" href=\"#H933041496\">",
"     'Initial management'",
"    </a>",
"    above.)",
"   </p>",
"   <p>",
"    Although AAA repair should be offered to most patients with ruptured AAA, some patients may be at such high risk due to underlying comorbidities that comfort care is appropriate (See",
"    <a class=\"local\" href=\"#H933044420\">",
"     'Decision for comfort care'",
"    </a>",
"    below.)",
"   </p>",
"   <p>",
"    Hemodynamically unstable patients with known AAA who present with classic",
"    <span class=\"nowrap\">",
"     symptoms/signs",
"    </span>",
"    of rupture (hypotension,",
"    <span class=\"nowrap\">",
"     flank/back",
"    </span>",
"    pain, pulsatile mass) should be taken emergently to the operating room for immediate control of hemorrhage and repair of the aneurysm. Efforts to obtain proximal aortic control in the operating room should not be delayed waiting for type-specific blood components. For patients not previously known to have AAA, time may permit a focused ultrasound exam to confirm that an aneurysm is present prior to abdominal exploration, but this is not absolutely required (",
"    <a class=\"graphic graphic_algorithm graphicRef86821 \" href=\"UTD.htm?23/4/23631\">",
"     algorithm 1",
"    </a>",
"    ).",
"   </p>",
"   <p>",
"    For hemodynamically stable patients suspected of having a ruptured AAA, computed tomography (CT) of the abdomen confirms the rupture but is also important for evaluating whether an endovascular repair is feasible [",
"    <a class=\"abstract\" href=\"UTD.htm?10/61/11225/abstract/9\">",
"     9",
"    </a>",
"    ]. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?31/16/32010?source=see_link&amp;anchor=H22322988#H22322988\">",
"     \"Clinical features and diagnosis of abdominal aortic aneurysm\", section on 'Imaging symptomatic patients'",
"    </a>",
"    and",
"    <a class=\"local\" href=\"#H108751839\">",
"     'Aneurysm repair'",
"    </a>",
"    below.)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H933041795\">",
"    <span class=\"h3\">",
"     Impending rupture",
"    </span>",
"    &nbsp;&mdash;&nbsp;Some patients without overt rupture on imaging studies have clinical symptoms or other features on CT scan that may indicate that the aneurysm is rapidly changing in configuration (rapid expansion), or at risk for &ldquo;impending&rdquo; rupture. Good risk surgical candidates should generally be repaired in an urgent manner. Clinical features are discussed in detail elsewhere. &nbsp;(See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?31/16/32010?source=see_link&amp;anchor=H22317736#H22317736\">",
"     \"Clinical features and diagnosis of abdominal aortic aneurysm\", section on 'Clinical features'",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?31/16/32010?source=see_link&amp;anchor=H181166154#H181166154\">",
"     \"Clinical features and diagnosis of abdominal aortic aneurysm\", section on 'Ruptured versus nonruptured AAA'",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H933041788\">",
"    <span class=\"h2\">",
"     Symptomatic (non-ruptured) AAA",
"    </span>",
"    &nbsp;&mdash;&nbsp;Abdominal pain or other symptoms occurring in a patient known to have or newly diagnosed with AAA can present a clinical dilemma. In surgical series, between 5 and 22 percent of AAA are symptomatic [",
"    <a class=\"abstract\" href=\"UTD.htm?10/61/11225/abstract/8,10-14\">",
"     8,10-14",
"    </a>",
"    ]. Symptoms that may be related to AAA include abdominal pain or back pain, signs of acute thromboembolism, and fever. In the absence of rupture, pain or other symptoms attributable to AAA may indicate rapid expansion causing compression of adjacent structures, or an inflammatory or infected AAA [",
"    <a class=\"abstract\" href=\"UTD.htm?10/61/11225/abstract/8,14-17\">",
"     8,14-17",
"    </a>",
"    ]. In the absence of overt or impending rupture, the symptomatic patient should be assessed to determine whether their symptoms are related to the aneurysm, and although not well-studied, when no other cause is apparent, we agree with major society guidelines that suggest urgent repair, provided the patient does not have comorbidities that preclude repair [",
"    <a class=\"abstract\" href=\"UTD.htm?10/61/11225/abstract/3\">",
"     3",
"    </a>",
"    ] . (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?31/16/32010?source=see_link&amp;anchor=H22314616#H22314616\">",
"     \"Clinical features and diagnosis of abdominal aortic aneurysm\", section on 'Are symptoms related to AAA?'",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?31/16/32010?source=see_link&amp;anchor=H181166154#H181166154\">",
"     \"Clinical features and diagnosis of abdominal aortic aneurysm\", section on 'Ruptured versus nonruptured AAA'",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H933042774\">",
"    <span class=\"h3\">",
"     Abdominal/back/flank pain",
"    </span>",
"    &nbsp;&mdash;&nbsp;Patients presenting with",
"    <span class=\"nowrap\">",
"     abdominal/back/flank",
"    </span>",
"    pain in association with AAA should be admitted for further evaluation and monitoring. If an alternative diagnosis cannot be definitively established, symptoms should be presumed to be due to the AAA and a vascular surgical consultation should be obtained. The nature of the presenting symptoms should help determine whether the AAA is the source of the symptoms or simply an incidental finding during work-up of another disease process.",
"   </p>",
"   <p>",
"    Patients identified with another obvious source (eg, urinary calculi) for their symptoms, should undergo treatment of the other acute disease process and the AAA should be managed electively as an asymptomatic AAA. An inpatient vascular surgical consultation should nevertheless be obtained to confirm that the symptoms are not related to the AAA and to evaluate the need for and timing of AAA repair depending upon the resolution of the acute process. The determination of whether to proceed with elective repair depends upon the rupture risk, which is primarily determined by aortic diameter. The presence of very large AAA (&gt;6.0 cm) may warrant admission even if the aneurysm is not felt to be the source of symptoms. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?37/53/38746?source=see_link&amp;anchor=H431203144#H431203144\">",
"     \"Management of asymptomatic abdominal aortic aneurysm\", section on 'Aneurysm diameter and rupture risk'",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?37/53/38746?source=see_link&amp;anchor=H3592638#H3592638\">",
"     \"Management of asymptomatic abdominal aortic aneurysm\", section on 'Very large aneurysm'",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H933042786\">",
"    <span class=\"h3\">",
"     Thromboembolism",
"    </span>",
"    &nbsp;&mdash;&nbsp;Patients with symptoms and signs of acute thromboembolism should be managed according to the severity of symptoms (acute, subacute, or chronic limb ischemia). If thromboembolism is associated with abdominal pain, for which there is no other conceivable source, the embolus may have originated from a tear in the aortic wall and may be a sign of overt or impending aortic rupture. In the event of AAA rupture, thrombectomy can be performed concurrently with AAA repair.",
"   </p>",
"   <p>",
"    In the presence of AAA, a full evaluation should be performed to determine the source of the thromboemboli, and should include an electrocardiogram, echocardiogram, contrast-enhanced CT of the aorta from the aortic valve to the iliac bifurcation, and peripheral duplex ultrasound since distal embolization can also be related to concurrent large vessel aneurysm (eg, popliteal artery aneurysm). If the clinical evaluation does not identify an alternative source for thromboembolism, the AAA should be presumed to be the source.",
"   </p>",
"   <p>",
"    In the absence of AAA rupture, acute ischemic symptoms due to lower extremity thromboembolism from the AAA should be managed with anticoagulation, and thrombectomy (or lysis) as needed. If a lower extremity revascularization procedure is needed, consideration should be given to concurrent AAA repair. Under some circumstances AAA repair can be delayed; however, the risk of recurrent thromboembolism remains until the AAA is repaired. &nbsp;(See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?13/3/13368?source=see_link\">",
"     \"Acute arterial occlusion of the lower extremities (acute limb ischemia)\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H933042815\">",
"    <span class=\"h3\">",
"     Aortic infection",
"    </span>",
"    &nbsp;&mdash;&nbsp;Patients with fever and other systemic manifestations that suggest infected aortic aneurysm should be treated with urgent surgical debridement and vascular reconstruction. The clinical manifestations and treatment of infected aneurysm are discussed elsewhere. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?34/17/35098?source=see_link\">",
"     \"Overview of infected (mycotic) arterial aneurysm\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H933043282\">",
"    <span class=\"h3\">",
"     Inflammatory aneurysm",
"    </span>",
"    &nbsp;&mdash;&nbsp;A triad of chronic abdominal pain, weight loss, and elevated erythrocyte sedimentation rate in a patient with an AAA is highly suggestive of an inflammatory aneurysm. Patients with inflammatory aneurysms are often more symptomatic than patients with the more typical AAAs, but the incidence of actual rupture may be lower [",
"    <a class=\"abstract\" href=\"UTD.htm?10/61/11225/abstract/18\">",
"     18",
"    </a>",
"    ]. In patients who present with symptoms, repair should be undertaken regardless of aneurysm diameter. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?31/16/32010?source=see_link&amp;anchor=H22323992#H22323992\">",
"     \"Clinical features and diagnosis of abdominal aortic aneurysm\", section on 'Infected versus inflammatory AAA'",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H108751839\">",
"    <span class=\"h1\">",
"     ANEURYSM REPAIR",
"    </span>",
"    &nbsp;&mdash;&nbsp;Urgent or emergent AAA repair is generally indicated for patients with ruptured AAA and symptomatic (non-ruptured) AAA, provided the risk for repair is not prohibitive [",
"    <a class=\"abstract\" href=\"UTD.htm?10/61/11225/abstract/3,8\">",
"     3,8",
"    </a>",
"    ]. The decision of whether or not to offer repair to high-risk patients is discussed below. (See",
"    <a class=\"local\" href=\"#H933044420\">",
"     'Decision for comfort care'",
"    </a>",
"    below.)",
"   </p>",
"   <p>",
"    Two methods of aneurysm repair are currently available: open surgery and endovascular aneurysm repair (EVAR).",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Open AAA repair &ndash; Open aneurysm repair involves replacement of the diseased aortic segment with a tube or bifurcated prosthetic graft through a midline abdominal or retroperitoneal incision.",
"     </li>",
"     <li>",
"      EVAR &ndash; EVAR involves the placement of modular graft components delivered via the iliac or femoral arteries, which line the aorta and exclude the aneurysm sac from the circulation.",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    Endovascular aneurysm repair reduces perioperative (30-day) morbidity and mortality following elective AAA repair [",
"    <a class=\"abstract\" href=\"UTD.htm?10/61/11225/abstract/19-24\">",
"     19-24",
"    </a>",
"    ], and there is accumulating evidence that morbidity and mortality following repair of symptomatic [",
"    <a class=\"abstract\" href=\"UTD.htm?10/61/11225/abstract/25\">",
"     25",
"    </a>",
"    ] or ruptured AAA may also be reduced [",
"    <a class=\"abstract\" href=\"UTD.htm?10/61/11225/abstract/2,7,26-31\">",
"     2,7,26-31",
"    </a>",
"    ]. A systematic review identified 23 observational studies with 7040 urgent or emergent open (n = 6300) or endovascular (n = 740) AAA repairs in patients with symptomatic (non-ruptured) or ruptured AAA [",
"    <a class=\"abstract\" href=\"UTD.htm?10/61/11225/abstract/25\">",
"     25",
"    </a>",
"    ]. Emergency EVAR was associated with a significantly reduced perioperative (30-day) mortality risk relative to open repair (pooled odds ratio [OR] 0.62, 95% CI 0.52-0.75).",
"   </p>",
"   <p>",
"    To perform emergent endovascular AAA repair, the patient&rsquo;s aneurysm must meet anatomic criteria for EVAR and the institution must have a defined program for emergency endovascular surgery. Abdominal CT, which is obtained in hemodynamically stable patients, will determine whether the patient with symptomatic (non-ruptured) or ruptured AAA is anatomically suited to endovascular aneurysm repair (EVAR). Although up to 70 percent of patients may be candidates for EVAR, ruptured AAA is more often repaired with open surgical techniques, due to the limited number of centers available to perform emergency EVAR. Transfer to a vascular center is appropriate for hemodynamically stable patients who are anatomically suited to EVAR, particularly if the risk for open repair is high. (See",
"    <a class=\"local\" href=\"#H933044413\">",
"     'Decision for patient transfer'",
"    </a>",
"    below and",
"    <a class=\"local\" href=\"#H933044043\">",
"     'Risk assessment'",
"    </a>",
"    below.)",
"   </p>",
"   <p>",
"    The anatomic requirements for endovascular repair for non-ruptured and ruptured AAA are discussed elsewhere. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?30/27/31162?source=see_link&amp;anchor=H440175#H440175\">",
"     \"Endovascular repair of abdominal aortic aneurysm\", section on 'Anatomic suitability'",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?30/11/30904?source=see_link&amp;anchor=H273857002#H273857002\">",
"     \"Surgical and endovascular repair of ruptured abdominal aortic aneurysm\", section on 'Criteria for endovascular repair'",
"    </a>",
"    .) &nbsp;",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H933044043\">",
"    <span class=\"h2\">",
"     Risk assessment",
"    </span>",
"    &nbsp;&mdash;&nbsp;The general assessment of perioperative risk for",
"    <span class=\"nowrap\">",
"     urgent/emergent",
"    </span>",
"    repair of abdominal aortic aneurysm is similar to that of elective AAA repair; however, the urgency of the clinical situation often precludes a comprehensive evaluation. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?37/53/38746?source=see_link&amp;anchor=H3585830#H3585830\">",
"     \"Management of asymptomatic abdominal aortic aneurysm\", section on 'Medical risk assessment'",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    There have been many attempts to quantify the mortality risk associated with ruptured AAA. Unfortunately, no one system or variable has proven to be reliable in predicting mortality with certainty [",
"    <a class=\"abstract\" href=\"UTD.htm?10/61/11225/abstract/32\">",
"     32",
"    </a>",
"    ]. Factors that are associated with increased mortality following",
"    <strong>",
"     open",
"    </strong>",
"    repair of ruptured AAA include hypotension with a systolic blood pressure &lt;80 mmHg, advanced age (&gt;80 years), cardiac arrest, loss of consciousness, creatinine &gt;1.3 on admission, ischemic heart disease, female sex, and hemoglobin &lt;9.0 on admission [",
"    <a class=\"abstract\" href=\"UTD.htm?10/61/11225/abstract/2,33-43\">",
"     2,33-43",
"    </a>",
"    ]. There are no equivalent studies assessing preoperative risk factors and endovascular aneurysm repair of ruptured AAA. One risk prediction model based upon a population of United States Medicare beneficiaries (ie, &gt;65 years of age), found that mortality following elective AAA repair is predicted by comorbidities, gender, and age with no differential predictors between open or endovascular repair [",
"    <a class=\"abstract\" href=\"UTD.htm?10/61/11225/abstract/44\">",
"     44",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    For patients with several prognostic factors for poor outcome, the incidence of serious morbidity, such as dialysis dependence, colonic ischemia, and myocardial infarction, is high and the need for surgery related to a complication is also high. The presence of &gt;3 prognostic factors increases the likelihood that the patient will require extended care. For the patient who is older than 80, with renal dysfunction, loss of consciousness, and hemoglobin &lt;9, the chance of survival following open repair of ruptured AAA is almost zero [",
"    <a class=\"abstract\" href=\"UTD.htm?10/61/11225/abstract/32\">",
"     32",
"    </a>",
"    ]. The presence of multiple risk factors for poor outcome in a patient of advanced age, especially those with a &ldquo;Do Not Resuscitate&rdquo; advanced directive or a history of AAA repair refusal should lead to consideration for comfort care. (See",
"    <a class=\"local\" href=\"#H933044420\">",
"     'Decision for comfort care'",
"    </a>",
"    below.)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H933039132\">",
"    <span class=\"h2\">",
"     Emergent versus delayed repair of symptomatic aneurysm",
"    </span>",
"    &nbsp;&mdash;&nbsp;The timing of AAA repair for hemodynamically stable patients with symptomatic (non-ruptured) AAA remains a clinical challenge. Some patients may benefit from optimization of their medical status prior to repair; however, a definitive recommendation that would suit every clinical situation is not possible.",
"   </p>",
"   <p>",
"    Several retrospective case series comparing open AAA repair under elective versus emergent circumstances for symptomatic (non-ruptured) AAA have found significantly higher overall rates of perioperative morbidity and mortality for emergent compared with urgent repair (overall 18 to 26 percent versus 4 to 5 percent) [",
"    <a class=\"abstract\" href=\"UTD.htm?10/61/11225/abstract/8,45,46\">",
"     8,45,46",
"    </a>",
"    ]. Another series found no deaths from rupture in patients with symptomatic AAA whose operations were delayed and performed semi-electively [",
"    <a class=\"abstract\" href=\"UTD.htm?10/61/11225/abstract/14\">",
"     14",
"    </a>",
"    ]. The potential impact of endovascular repair in this subset of patients is unknown, but is unlikely to alter the need for preoperative medical optimization that appears to be beneficial for some patients.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H108721404\">",
"    <span class=\"h1\">",
"     MORBIDITY AND MORTALITY",
"    </span>",
"    &nbsp;&mdash;&nbsp;For symptomatic, non-ruptured AAAs, perioperative mortality rates are similar to those of elective repair; however, the rates of postoperative complications and late survival are intermediate compared with elective or ruptured AAA repair [",
"    <a class=\"abstract\" href=\"UTD.htm?10/61/11225/abstract/47\">",
"     47",
"    </a>",
"    ]. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?37/53/38746?source=see_link&amp;anchor=H1191821755#H1191821755\">",
"     \"Management of asymptomatic abdominal aortic aneurysm\", section on 'AAA repair'",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?30/27/31162?source=see_link&amp;anchor=H433042#H433042\">",
"     \"Endovascular repair of abdominal aortic aneurysm\", section on 'Perioperative morbidity and mortality'",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    The mortality associated with ruptured AAA may be as high as 90 percent when patients who die at home or upon arrival to the hospital are taken into account. In spite of obvious improvements in pre-hospital care, cardiovascular anesthesia, and critical care, surgical mortality following open repair of ruptured AAA has changed very little, remaining about 30 to 50 percent [",
"    <a class=\"abstract\" href=\"UTD.htm?10/61/11225/abstract/48,49\">",
"     48,49",
"    </a>",
"    ]. Although endovascular aneurysm repair may improve survival following AAA rupture, this has not been definitively established. The complications of aneurysm repair and mortality associated with ruptured AAA are discussed in detail elsewhere. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?30/11/30904?source=see_link&amp;anchor=H108749287#H108749287\">",
"     \"Surgical and endovascular repair of ruptured abdominal aortic aneurysm\", section on 'Complications'",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?30/11/30904?source=see_link&amp;anchor=H108753418#H108753418\">",
"     \"Surgical and endovascular repair of ruptured abdominal aortic aneurysm\", section on 'Mortality'",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H933044413\">",
"    <span class=\"h1\">",
"     DECISION FOR PATIENT TRANSFER",
"    </span>",
"    &nbsp;&mdash;&nbsp;Patients with AAA who require emergent or urgent aortic surgery for ruptured or symptomatic (non-ruptured) AAA should be treated at a facility where surgical expertise",
"    <span class=\"nowrap\">",
"     and/or",
"    </span>",
"    the perioperative resources necessary for major aortic surgery are available (eg, operating room personnel, an appropriately-trained surgeon, perioperative intensive care) [",
"    <a class=\"abstract\" href=\"UTD.htm?10/61/11225/abstract/50\">",
"     50",
"    </a>",
"    ]. For patients who present to a facility where these are not available, transfer to a vascular center is appropriate.",
"   </p>",
"   <p>",
"    Improved outcomes for open surgical repair of ruptured AAA are correlated with surgeon experience with a higher annual caseload of open aneurysm repair per year (non-ruptured and ruptured) correlating with improved outcomes [",
"    <a class=\"abstract\" href=\"UTD.htm?10/61/11225/abstract/51\">",
"     51",
"    </a>",
"    ]. The shift toward endovascular therapies has reduced the exposure of the general surgeon-in-training to open surgical repair of AAA. As a result, the number of general surgeons in the community experienced with open repair of ruptured AAA is declining. If an appropriate level of surgical care is not available at the institution to which the patients initially presented, the patient should be transferred [",
"    <a class=\"abstract\" href=\"UTD.htm?10/61/11225/abstract/50\">",
"     50",
"    </a>",
"    ]. If transfer is chosen, the patient and their family should be informed of the potential risk of deterioration during transfer, and the transfer should be accomplished as quickly as possible.",
"   </p>",
"   <p>",
"    Patients who have a high-risk for open AAA repair may be candidates for endovascular repair. However, for endovascular repair to be undertaken, in addition to having appropriate hospital personnel in place, the institution must have systems in place to support the endeavor. Resources that are needed include:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Rapid availability of high-quality computed tomography",
"     </li>",
"     <li>",
"      Availability of trained support staff (nursing, scrub technicians, radiology technologists, anesthesia)",
"     </li>",
"     <li>",
"      Stock of available endovascular prostheses in a wide range of sizes, which are replenished continuously",
"     </li>",
"     <li>",
"      Available vascular surgeon appropriately-trained in advanced endovascular techniques",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    For most small hospitals and low-volume facilities, these requirements cannot be met. If an institution is not able to perform emergency EVAR, an alternative approach is to provide open repair for hemodynamically unstable patients and transfer for hemodynamically stable patients to an appropriate vascular center.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H933044420\">",
"    <span class=\"h1\">",
"     DECISION FOR COMFORT CARE",
"    </span>",
"    &nbsp;&mdash;&nbsp;Some patients may refuse repair of a ruptured AAA, or are such poor candidates for repair that they are not likely to survive or have a meaningful quality of life even if they recover from the procedure. Although it remains disputed whether endovascular repair decreases mortality in patients with ruptured AAA, patients who have factors associated with a poor prognosis for open AAA repair may have lower rates of morbidity and mortality following EVAR for ruptured AAA, when repair is chosen. (See",
"    <a class=\"local\" href=\"#H933044043\">",
"     'Risk assessment'",
"    </a>",
"    above.)",
"   </p>",
"   <p>",
"    A decision must be made according to the wishes of the patient (if known) and family whether to proceed with repair or provide comfort measures. Patients who will not undergo repair are kept pain-free and allowed to expire. In one study of 21 patients, the average time to death following ruptured AAA without repair was seven hours [",
"    <a class=\"abstract\" href=\"UTD.htm?10/61/11225/abstract/52\">",
"     52",
"    </a>",
"    ]. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?12/37/12890?source=see_link\">",
"     \"Pain assessment and management in the last weeks of life\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H1345122119\">",
"    <span class=\"h1\">",
"     SUMMARY AND RECOMMENDATIONS",
"    </span>",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Symptomatic abdominal aortic aneurysm (AAA) refers to any of a number of symptoms (eg,",
"      <span class=\"nowrap\">",
"       abdominal/back/flank",
"      </span>",
"      pain, limb ischemia) that can be attributed to the aneurysm. In the absence of overt rupture (defined as aortic wall disruption leading to escape of blood outside the confines of the aorta), the presence of symptoms increases the risk for AAA rupture. AAA rupture can also occur in the absence of any intervening symptoms. Without repair, ruptured AAA is nearly uniformly fatal. Of the 50 percent of patients with ruptured AAA who reach the hospital for treatment, between 30 and 50 percent will die in the hospital in spite of significant advances in intensive care unit management and surgical techniques. (See",
"      <a class=\"local\" href=\"#H53322839\">",
"       'Introduction'",
"      </a>",
"      above and",
"      <a class=\"local\" href=\"#H108721404\">",
"       'Morbidity and mortality'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      Initial management of patients with symptomatic (non-ruptured) and ruptured AAA includes the placement of large bore peripheral intravenous catheters for medication and fluid administration, pain management, and preparation for surgery. For patients with ruptured AAA, we suggest maintaining the systolic blood pressure between 80 and 100 mmHg (permissive hypotension) rather than at higher levels prior to repair (",
"      <a class=\"grade\" href=\"._grade_6?title=Grade 2C\">",
"       Grade 2C",
"      </a>",
"      ). Permissive hypotension may minimize further tearing of the aorta and reduce blood loss. (See",
"      <a class=\"local\" href=\"#H933041496\">",
"       'Initial management'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      Although there are rare reports of patient survival following ruptured AAA without repair, in general, expectant management of ruptured AAA is nearly uniformly fatal. Thus, when ruptured AAA is identified, repair should be undertaken emergently to give the patient the best chance for survival. (See",
"      <a class=\"local\" href=\"#H933041557\">",
"       'Ruptured AAA'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      For patients with symptomatic (non-ruptured) AAA of any size or configuration who do not have a prohibitive risk for repair, we agree with major society guidelines that suggest urgent AAA repair (open or endovascular), rather than no repair (",
"      <a class=\"grade\" href=\"._grade_6?title=Grade 2C\">",
"       Grade 2C",
"      </a>",
"      ). In the absence of rupture, symptoms may indicate that the aneurysm is rapidly changing, increasing the risk of rupture. Symptoms may include",
"      <span class=\"nowrap\">",
"       abdominal/back/flank",
"      </span>",
"      pain, signs of thromboembolism, or systemic symptoms related to infected or inflammatory aneurysm. &nbsp;(See",
"      <a class=\"local\" href=\"#H933041788\">",
"       'Symptomatic (non-ruptured) AAA'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      Hemodynamically unstable patients with known AAA who present with classic",
"      <span class=\"nowrap\">",
"       symptoms/signs",
"      </span>",
"      of rupture (hypotension,",
"      <span class=\"nowrap\">",
"       flank/back",
"      </span>",
"      pain, pulsatile mass) should be taken directly to the operating room for immediate control of hemorrhage and repair of the aneurysm (",
"      <a class=\"graphic graphic_algorithm graphicRef86821 \" href=\"UTD.htm?23/4/23631\">",
"       algorithm 1",
"      </a>",
"      ). Efforts to obtain proximal aortic control in the operating room should not be delayed waiting for type-specific blood components. For hemodynamically unstable patients not previously known to have AAA, time may permit a focused ultrasound exam to confirm that an aneurysm is present prior to abdominal exploration, but this is not absolutely required. For patients with symptomatic (non-ruptured) or ruptured AAA who are hemodynamically stable, computed tomography (CT) of the abdomen should be obtained to evaluate whether an endovascular repair is feasible. (See",
"      <a class=\"local\" href=\"#H933041557\">",
"       'Ruptured AAA'",
"      </a>",
"      above and",
"      <a class=\"medical medical_review\" href=\"UTD.htm?31/16/32010?source=see_link&amp;anchor=H22322988#H22322988\">",
"       \"Clinical features and diagnosis of abdominal aortic aneurysm\", section on 'Imaging symptomatic patients'",
"      </a>",
"      .)",
"     </li>",
"     <li>",
"      Although many factors are associated with poor outcomes following repair of ruptured AAA, no scoring system or variable has proven reliable in predicting mortality of ruptured AAA with certainty. Factors on admission that are associated with increased mortality following open repair of ruptured AAA include hypotension, elevated creatinine, low hematocrit, advanced age, and cardiac arrest. For older patients (&gt;80 years) with multiple risk factors in whom EVAR is not feasible, comfort care should be discussed with the patient",
"      <span class=\"nowrap\">",
"       and/or",
"      </span>",
"      family as a possible care option. (See",
"      <a class=\"local\" href=\"#H933044043\">",
"       'Risk assessment'",
"      </a>",
"      above and",
"      <a class=\"local\" href=\"#H933044420\">",
"       'Decision for comfort care'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      For patients with ruptured AAA, where appropriate facilities, personnel, equipment, and expertise are available for endovascular aneurysm repair (EVAR), we suggest EVAR rather than open AAA repair, provided it is anatomically feasible (",
"      <a class=\"grade\" href=\"._grade_6?title=Grade 2C\">",
"       Grade 2C",
"      </a>",
"      ). In appropriately selected patients, endovascular repair of ruptured AAA appears to be associated with lower perioperative (30-day) morbidity and mortality. For patients with symptomatic but non-ruptured AAA who have multiple risk factors for poor prognosis, we also suggest EVAR rather than open repair (",
"      <a class=\"grade\" href=\"._grade_6?title=Grade 2C\">",
"       Grade 2C",
"      </a>",
"      ). Where endovascular aneurysm repair for emergency AAA repair is not an option (eg, not anatomically feasible, lack of facilities or expertise), open repair at the initial facility by a surgeon experienced with aortic surgery is appropriate. If no such surgeon is available, or the patient is a poor candidate for open repair, transfer to a vascular center is appropriate. (See",
"      <a class=\"local\" href=\"#H933044413\">",
"       'Decision for patient transfer'",
"      </a>",
"      above and",
"      <a class=\"local\" href=\"#H108751839\">",
"       'Aneurysm repair'",
"      </a>",
"      above and",
"      <a class=\"medical medical_review\" href=\"UTD.htm?30/11/30904?source=see_link&amp;anchor=H108751558#H108751558\">",
"       \"Surgical and endovascular repair of ruptured abdominal aortic aneurysm\", section on 'Open surgical versus endovascular repair'",
"      </a>",
"      .) &nbsp;",
"     </li>",
"    </ul>",
"   </p>",
"  </div>",
"  <div id=\"topicAgreement\">",
"   Use of UpToDate is subject to the",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_in_page\" target=\"_blank\">",
"    Subscription and License Agreement",
"   </a>",
"   .",
"  </div>",
"  <div class=\"headingAnchor\" id=\"references\">",
"   <h1>",
"    REFERENCES",
"   </h1>",
"   <ol id=\"reference\">",
"    <li>",
"     file://hcupnet.ahrq.gov/HCUPnet (Accessed on May 11, 2012).",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?10/61/11225/abstract/2\">",
"      Dillavou ED, Muluk SC, Makaroun MS. A decade of change in abdominal aortic aneurysm repair in the United States: Have we improved outcomes equally between men and women? J Vasc Surg 2006; 43:230.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?10/61/11225/abstract/3\">",
"      Chaikof EL, Brewster DC, Dalman RL, et al. The care of patients with an abdominal aortic aneurysm: the Society for Vascular Surgery practice guidelines. J Vasc Surg 2009; 50:S2.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?10/61/11225/abstract/4\">",
"      IMPROVE Trial, Powell JT, Thompson SG, et al. The Immediate Management of the Patient with Rupture: Open Versus Endovascular repair (IMPROVE) aneurysm trial--ISRCTN 48334791 IMPROVE trialists. Acta Chir Belg 2009; 109:678.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?10/61/11225/abstract/5\">",
"      Reimerink JJ, Hoornweg LL, Vahl AC, et al. Controlled hypotension in patients suspected of a ruptured abdominal aortic aneurysm: feasibility during transport by ambulance services and possible harm. Eur J Vasc Endovasc Surg 2010; 40:54.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?10/61/11225/abstract/6\">",
"      Dick F, Erdoes G, Opfermann P, et al. Delayed volume resuscitation during initial management of ruptured abdominal aortic aneurysm. J Vasc Surg 2013; 57:943.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?10/61/11225/abstract/7\">",
"      Lesperance K, Andersen C, Singh N, et al. Expanding use of emergency endovascular repair for ruptured abdominal aortic aneurysms: disparities in outcomes from a nationwide perspective. J Vasc Surg 2008; 47:1165.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?10/61/11225/abstract/8\">",
"      Sullivan CA, Rohrer MJ, Cutler BS. Clinical management of the symptomatic but unruptured abdominal aortic aneurysm. J Vasc Surg 1990; 11:799.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?10/61/11225/abstract/9\">",
"      Siegel CL, Cohan RH, Korobkin M, et al. Abdominal aortic aneurysm morphology: CT features in patients with ruptured and nonruptured aneurysms. AJR Am J Roentgenol 1994; 163:1123.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?10/61/11225/abstract/10\">",
"      Nevala T, Per&auml;l&auml; J, Aho P, et al. Outcome of symptomatic, unruptured abdominal aortic aneurysms after endovascular repair with the Zenith stent-graft system. Scand Cardiovasc J 2008; 42:178.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?10/61/11225/abstract/11\">",
"      Franks S, Lloyd G, Fishwick G, et al. Endovascular treatment of ruptured and symptomatic abdominal aortic aneurysms. Eur J Vasc Endovasc Surg 2006; 31:345.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?10/61/11225/abstract/12\">",
"      Antonello M, Lepidi S, Kechagias A, et al. Glasgow aneurysm score predicts the outcome after emergency open repair of symptomatic, unruptured abdominal aortic aneurysms. Eur J Vasc Endovasc Surg 2007; 33:272.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?10/61/11225/abstract/13\">",
"      Shifrin EG, Pizov R, Perel A, et al. Urgent abdominal aortic aneurysm repair in patients over the age 80. J Cardiovasc Surg (Torino) 1987; 28:167.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?10/61/11225/abstract/14\">",
"      Cambria RA, Gloviczki P, Stanson AW, et al. Symptomatic, nonruptured abdominal aortic aneurysms: are emergent operations necessary? Ann Vasc Surg 1994; 8:121.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?10/61/11225/abstract/15\">",
"      Adam DJ, Haggart PC, Ludlam CA, Bradbury AW. Hemostatic markers before operation in patients with acutely symptomatic nonruptured and ruptured infrarenal abdominal aortic aneurysm. J Vasc Surg 2002; 35:661.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?10/61/11225/abstract/16\">",
"      Soisalon-Soininen S, Salo JA, Perhoniemi V, Mattila S. Emergency surgery of non-ruptured abdominal aortic aneurysm. Ann Chir Gynaecol 1999; 88:38.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?10/61/11225/abstract/17\">",
"      Leo E, Biancari F, Kechagias A, et al. Outcome after emergency repair of symptomatic, unruptured abdominal aortic aneurysm: results in 42 patients and review of the literature. Scand Cardiovasc J 2005; 39:91.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?10/61/11225/abstract/18\">",
"      Lindblad B, Almgren B, Bergqvist D, et al. Abdominal aortic aneurysm with perianeurysmal fibrosis: experience from 11 Swedish vascular centers. J Vasc Surg 1991; 13:231.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?10/61/11225/abstract/19\">",
"      Mehta M, Byrne J, Darling RC 3rd, et al. Endovascular repair of ruptured infrarenal abdominal aortic aneurysm is associated with lower 30-day mortality and better 5-year survival rates than open surgical repair. J Vasc Surg 2013; 57:368.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?10/61/11225/abstract/20\">",
"      Nedeau AE, Pomposelli FB, Hamdan AD, et al. Endovascular vs open repair for ruptured abdominal aortic aneurysm. J Vasc Surg 2012; 56:15.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?10/61/11225/abstract/21\">",
"      Alsac JM, Kobeiter H, Becquemin JP, Desgranges P. Endovascular repair for ruptured AAA: a literature review. Acta Chir Belg 2005; 105:134.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?10/61/11225/abstract/22\">",
"      Brady AR, Fowkes FG, Greenhalgh RM, et al. Risk factors for postoperative death following elective surgical repair of abdominal aortic aneurysm: results from the UK Small Aneurysm Trial. On behalf of the UK Small Aneurysm Trial participants. Br J Surg 2000; 87:742.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?10/61/11225/abstract/23\">",
"      Dillavou ED, Muluk SC, Makaroun MS. Improving aneurysm-related outcomes: nationwide benefits of endovascular repair. J Vasc Surg 2006; 43:446.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?10/61/11225/abstract/24\">",
"      Lee WA, Carter JW, Upchurch G, et al. Perioperative outcomes after open and endovascular repair of intact abdominal aortic aneurysms in the United States during 2001. J Vasc Surg 2004; 39:491.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?10/61/11225/abstract/25\">",
"      Sadat U, Boyle JR, Walsh SR, et al. Endovascular vs open repair of acute abdominal aortic aneurysms--a systematic review and meta-analysis. J Vasc Surg 2008; 48:227.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?10/61/11225/abstract/26\">",
"      Veith FJ, Lachat M, Mayer D, et al. Collected world and single center experience with endovascular treatment of ruptured abdominal aortic aneurysms. Ann Surg 2009; 250:818.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?10/61/11225/abstract/27\">",
"      Starnes BW, Quiroga E, Hutter C, et al. Management of ruptured abdominal aortic aneurysm in the endovascular era. J Vasc Surg 2010; 51:9.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?10/61/11225/abstract/28\">",
"      McPhee J, Eslami MH, Arous EJ, et al. Endovascular treatment of ruptured abdominal aortic aneurysms in the United States (2001-2006): a significant survival benefit over open repair is independently associated with increased institutional volume. J Vasc Surg 2009; 49:817.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?10/61/11225/abstract/29\">",
"      Chagpar RB, Harris JR, Lawlor DK, et al. Early mortality following endovascular versus open repair of ruptured abdominal aortic aneurysms. Vasc Endovascular Surg 2010; 44:645.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?10/61/11225/abstract/30\">",
"      Mureebe L, Egorova N, Giacovelli JK, et al. National trends in the repair of ruptured abdominal aortic aneurysms. J Vasc Surg 2008; 48:1101.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?10/61/11225/abstract/31\">",
"      Davenport DL, O'Keeffe SD, Minion DJ, et al. Thirty-day NSQIP database outcomes of open versus endoluminal repair of ruptured abdominal aortic aneurysms. J Vasc Surg 2010; 51:305.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?10/61/11225/abstract/32\">",
"      Tambyraja AL, Murie JA, Chalmers RT. Prediction of outcome after abdominal aortic aneurysm rupture. J Vasc Surg 2008; 47:222.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?10/61/11225/abstract/33\">",
"      Johnston KW. Ruptured abdominal aortic aneurysm: six-year follow-up results of a multicenter prospective study. Canadian Society for Vascular Surgery Aneurysm Study Group. J Vasc Surg 1994; 19:888.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?10/61/11225/abstract/34\">",
"      Sarac TP, Bannazadeh M, Rowan AF, et al. Comparative predictors of mortality for endovascular and open repair of ruptured infrarenal abdominal aortic aneurysms. Ann Vasc Surg 2011; 25:461.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?10/61/11225/abstract/35\">",
"      Biancari F, Venermo M, Finnish Arterial Disease Investigators. Open repair of ruptured abdominal aortic aneurysm in patients aged 80 years and older. Br J Surg 2011; 98:1713.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?10/61/11225/abstract/36\">",
"      Biancari F, Leo E, Yl&ouml;nen K, et al. Value of the Glasgow Aneurysm Score in predicting the immediate and long-term outcome after elective open repair of infrarenal abdominal aortic aneurysm. Br J Surg 2003; 90:838.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?10/61/11225/abstract/37\">",
"      Biancari F, Hobo R, Juvonen T. Glasgow Aneurysm Score predicts survival after endovascular stenting of abdominal aortic aneurysm in patients from the EUROSTAR registry. Br J Surg 2006; 93:191.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?10/61/11225/abstract/38\">",
"      Korhonen SJ, Yl&ouml;nen K, Biancari F, et al. Glasgow Aneurysm Score as a predictor of immediate outcome after surgery for ruptured abdominal aortic aneurysm. Br J Surg 2004; 91:1449.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?10/61/11225/abstract/39\">",
"      Karkos CD, Sutton AJ, Bown MJ, Sayers RD. A meta-analysis and metaregression analysis of factors influencing mortality after endovascular repair of ruptured abdominal aortic aneurysms. Eur J Vasc Endovasc Surg 2011; 42:775.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?10/61/11225/abstract/40\">",
"      Pol RA, Reijnen MM, Zeebregts CJ. Outcome after open repair of ruptured abdominal aortic aneurysm in patients &gt;80 years old: a systematic review and meta-analysis. World J Surg 2011; 35:2575.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?10/61/11225/abstract/41\">",
"      Opfermann P, von Allmen R, Diehm N, et al. Repair of ruptured abdominal aortic aneurysm in octogenarians. Eur J Vasc Endovasc Surg 2011; 42:475.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?10/61/11225/abstract/42\">",
"      Scarcello E, Ferrari M, Rossi G, et al. A new preoperative predictor of outcome in ruptured abdominal aortic aneurysms: the time before shock (TBS). Ann Vasc Surg 2010; 24:315.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?10/61/11225/abstract/43\">",
"      McPhee JT, Hill JS, Eslami MH. The impact of gender on presentation, therapy, and mortality of abdominal aortic aneurysm in the United States, 2001-2004. J Vasc Surg 2007; 45:891.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?10/61/11225/abstract/44\">",
"      Giles KA, Schermerhorn ML, O'Malley AJ, et al. Risk prediction for perioperative mortality of endovascular vs open repair of abdominal aortic aneurysms using the Medicare population. J Vasc Surg 2009; 50:256.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?10/61/11225/abstract/45\">",
"      Haug ES, Romundstad P, Aadahl P, Myhre HO. Emergency non-ruptured abdominal aortic aneurysm. Eur J Vasc Endovasc Surg 2004; 28:612.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?10/61/11225/abstract/46\">",
"      Tambyraja AL, Raza Z, Stuart WP, et al. Does immediate operation for symptomatic non-ruptured abdominal aortic aneurysm compromise outcome? Eur J Vasc Endovasc Surg 2004; 28:543.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?10/61/11225/abstract/47\">",
"      De Martino RR, Nolan BW, Goodney PP, et al. Outcomes of symptomatic abdominal aortic aneurysm repair. J Vasc Surg 2010; 52:5.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?10/61/11225/abstract/48\">",
"      Bown MJ, Sutton AJ, Bell PR, Sayers RD. A meta-analysis of 50 years of ruptured abdominal aortic aneurysm repair. Br J Surg 2002; 89:714.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?10/61/11225/abstract/49\">",
"      Hoornweg LL, Storm-Versloot MN, Ubbink DT, et al. Meta analysis on mortality of ruptured abdominal aortic aneurysms. Eur J Vasc Endovasc Surg 2008; 35:558.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?10/61/11225/abstract/50\">",
"      Maybury RS, Chang DC, Freischlag JA. Rural hospitals face a higher burden of ruptured abdominal aortic aneurysm and are more likely to transfer patients for emergent repair. J Am Coll Surg 2011; 212:1061.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?10/61/11225/abstract/51\">",
"      Cho JS, Kim JY, Rhee RY, et al. Contemporary results of open repair of ruptured abdominal aortoiliac aneurysms: effect of surgeon volume on mortality. J Vasc Surg 2008; 48:10.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?10/61/11225/abstract/52\">",
"      Boyle JR, Gibbs PJ, Kruger A, et al. Existing delays following the presentation of ruptured abdominal aortic aneurysm allow sufficient time to assess patients for endovascular repair. Eur J Vasc Endovasc Surg 2005; 29:505.",
"     </a>",
"    </li>",
"   </ol>",
"  </div>",
"  <div id=\"topicVersionRevision\">",
"   Topic 15191 Version 5.0",
"  </div>",
" </div>",
" <div id=\"footer\">",
"  <div id=\"supportFooter\">",
"   <span class=\"sfInfo\">",
"    &copy; 2013 UpToDate, Inc. All rights reserved.",
"   </span>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_footer\">",
"    Subscription and License Agreement",
"   </a>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Release: 21.6- C21.56",
"   </span>",
"   <br/>",
"   <span class=\"sfInfo\">",
"    Licensed to:",
"    <span class=\"emphasis\">",
"     AsanBook Dig. Med. Lib.",
"    </span>",
"   </span>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Support Tag: [0504-202.43.93.2-77D3A94D3A-S244013.14]",
"    <br/>",
"   </span>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f10_61_11225=[""].join("\n");
var outline_f10_61_11225=[" <div id=\"toggleOutline\">",
"  <a href=\"#\" title=\"Collapse Topic Outline\">",
"   <img alt=\"\" src=\"./../images/orange_arrow_left.myextg\"/>",
"  </a>",
" </div>",
" <div id=\"innerOutline\">",
"  <h1>",
"   TOPIC OUTLINE",
"  </h1>",
"  <div id=\"outline\">",
"   <ul>",
"    <li>",
"     <a class=\"sr_button\" href=\"#H1345122119\" id=\"summRecButton\">",
"      <span>",
"       SUMMARY &amp; RECOMMENDATIONS",
"      </span>",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H53322839\">",
"      INTRODUCTION",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H933032328\">",
"      ANEURYSM TERMINOLOGY",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H933041496\">",
"      INITIAL MANAGEMENT",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H933032592\">",
"      APPROACH TO AAA ASSOCIATED WITH SYMPTOMS",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H933041557\">",
"      Ruptured AAA",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H933041795\">",
"      - Impending rupture",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H933041788\">",
"      Symptomatic (non-ruptured) AAA",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H933042774\">",
"      - Abdominal/back/flank pain",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H933042786\">",
"      - Thromboembolism",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H933042815\">",
"      - Aortic infection",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H933043282\">",
"      - Inflammatory aneurysm",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H108751839\">",
"      ANEURYSM REPAIR",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H933044043\">",
"      Risk assessment",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H933039132\">",
"      Emergent versus delayed repair of symptomatic aneurysm",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H108721404\">",
"      MORBIDITY AND MORTALITY",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H933044413\">",
"      DECISION FOR PATIENT TRANSFER",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H933044420\">",
"      DECISION FOR COMFORT CARE",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H1345122119\">",
"      SUMMARY AND RECOMMENDATIONS",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a href=\"#references\">",
"      REFERENCES",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   <div class=\"openRelatedGraphics\" id=\"SURG/15191\" rel=\"outline_link\">",
"    GRAPHICS",
"    <a class=\"graphics_icon\" href=\"#\" title=\"View All Related Graphics\">",
"     View All",
"    </a>",
"   </div>",
"  </h1>",
"  <div id=\"relatedGraphics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <div class=\"openRelatedGraphics\" id=\"SURG/15191|ALG\">",
"      <a href=\"#\" title=\"ALGORITHMS\">",
"       ALGORITHMS",
"      </a>",
"     </div>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_algorithm\" href=\"UTD.htm?23/4/23631\" title=\"algorithm 1\">",
"      Algorithm for the diagnosis of abdominal aortic aneurysm",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <div class=\"openRelatedGraphics\" id=\"SURG/15191|FIG\">",
"      <a href=\"#\" title=\"FIGURES\">",
"       FIGURES",
"      </a>",
"     </div>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_figure\" href=\"UTD.htm?42/14/43234\" title=\"figure 1\">",
"      Normal abdominal aorta",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_figure\" href=\"UTD.htm?9/29/9683\" title=\"figure 2\">",
"      Anatomy abdominal aortic aneurysm",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   RELATED TOPICS",
"  </h1>",
"  <div id=\"relatedTopics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?13/3/13368?source=related_link\">",
"      Acute arterial occlusion of the lower extremities (acute limb ischemia)",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?31/16/32010?source=related_link\">",
"      Clinical features and diagnosis of abdominal aortic aneurysm",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?30/27/31162?source=related_link\">",
"      Endovascular repair of abdominal aortic aneurysm",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?28/55/29562?source=related_link\">",
"      Initial evaluation and management of shock in adult trauma",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?37/53/38746?source=related_link\">",
"      Management of asymptomatic abdominal aortic aneurysm",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?37/25/38294?source=related_link\">",
"      Massive blood transfusion",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?34/17/35098?source=related_link\">",
"      Overview of infected (mycotic) arterial aneurysm",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?12/37/12890?source=related_link\">",
"      Pain assessment and management in the last weeks of life",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?39/61/40920?source=related_link\">",
"      Pain control in the critically ill adult patient",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?30/11/30904?source=related_link\">",
"      Surgical and endovascular repair of ruptured abdominal aortic aneurysm",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?13/20/13639?source=related_link\">",
"      Treatment of severe hypovolemia or hypovolemic shock in adults",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
" </div>"].join("\n");
var title_f10_61_11226="Bipolar disorder in adults: Teratogenic and postnatal risks of pharmacotherapy";
var content_f10_61_11226=[" <noscript>",
"  <div id=\"javascriptDisabled\">",
"   It seems to us that you have your JavaScript turned off on your browser. JavaScript is required in order for our site to behave correctly.  Please enable your JavaScript to continue use our site.",
"  </div>",
" </noscript>",
" <div id=\"printHeader\">",
"  <div id=\"printHeaderLogo\">",
"   <img alt=\"UpToDate\" src=\"./../images/UTD2_masthead.myextg\">",
"    <img align=\"right\" alt=\"Wolters Kluwer Health\" height=\"40\" src=\"./../images/logoWKH.myextg\" width=\"175\">",
"     <br>",
"      <div id=\"printHeaderText\">",
"       Official reprint from  UpToDate",
"       <sup>",
"        &reg;",
"       </sup>",
"       <br>",
"        <a href=\"file://www.uptodate.com\">",
"         www.uptodate.com",
"        </a>",
"        &copy;2013 UpToDate",
"        <sup>",
"         &reg;",
"        </sup>",
"       </br>",
"      </div>",
"     </br>",
"    </img>",
"   </img>",
"  </div>",
"  <div id=\"printHeaderLinks\">",
"   <a class=\"TOPIC\" href=\"#\" id=\"printHeaderPrint\" rel=\"7\" title=\"Click here to print\">",
"    Print",
"   </a>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a href=\"#\" id=\"printHeaderBack\" title=\"Back to normal view\">",
"    Back",
"   </a>",
"  </div>",
" </div>",
" <!-- TC:TOPIC_PAGE -->",
" <div id=\"topicContent\">",
"  <div id=\"topicTitle\">",
"   Bipolar disorder in adults: Teratogenic and postnatal risks of pharmacotherapy",
"  </div>",
"  <div id=\"topicContributors\">",
"   <div>",
"    <a id=\"authors\">",
"    </a>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"UTD.htm?10/61/11226/contributors\">",
"     Author",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"UTD.htm?10/61/11226/contributors\">",
"     Victoria Hendrick, MD",
"    </a>",
"    <br/>",
"   </div>",
"   <div>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"UTD.htm?10/61/11226/contributors\">",
"     Section Editor",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"UTD.htm?10/61/11226/contributors\">",
"     Paul Keck, MD",
"    </a>",
"    <br/>",
"   </div>",
"   <div>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"UTD.htm?10/61/11226/contributors\">",
"     Deputy Editor",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"UTD.htm?10/61/11226/contributors\">",
"     David Solomon, MD",
"    </a>",
"    <br/>",
"   </div>",
"  </div>",
"  <div id=\"disclosures\">",
"   <a href=\"UTD.htm?10/61/11226/contributor-disclosure\" target=\"_blank\">",
"    Disclosures",
"   </a>",
"  </div>",
"  <div id=\"reviewProcess\">",
"   <span>",
"    All topics are updated as new evidence becomes available and our",
"   </span>",
"   <a href=\"/home/editorial-policy\" target=\"_blank\">",
"    peer review process",
"   </a>",
"   <span>",
"    is complete.",
"   </span>",
"  </div>",
"  <div id=\"literatureReviewDate\">",
"   <span class=\"emphasis\">",
"    Literature review current through:",
"   </span>",
"   Oct 2013.",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <span class=\"emphasis\">",
"    This topic last updated:",
"   </span>",
"   Apr 3, 2013.",
"  </div>",
"  <div id=\"topicText\">",
"   <p class=\"headingAnchor\" id=\"H1564395\">",
"    <span class=\"h1\">",
"     INTRODUCTION",
"    </span>",
"    &nbsp;&mdash;&nbsp;Among women with an established pregnancy, surveys estimate that psychotropic drugs are taken by 21 to 33 percent [",
"    <a class=\"abstract\" href=\"UTD.htm?10/61/11226/abstract/1,2\">",
"     1,2",
"    </a>",
"    ]. Although these medications are often necessary to control a psychiatric illness that predates or emerges during pregnancy, pharmacotherapy entails risks of structural malformations, neonatal toxicity and withdrawal, and adverse developmental effects.",
"   </p>",
"   <p>",
"    This topic reviews the teratogenic and postnatal effects of pharmacotherapy for bipolar disorder. The principles of teratology; treatment of mania, hypomania, major depression, and mixed episodes during pregnancy; preconception and prenatal maintenance pharmacotherapy for bipolar patients; and preconception counseling for patients with bipolar disorder are discussed separately:",
"   </p>",
"   <p>",
"    <ul class=\"bulletCompact-block\">",
"     <li>",
"      (See",
"      <a class=\"medical medical_review\" href=\"UTD.htm?19/7/19574?source=see_link\">",
"       \"Principles of teratology\"",
"      </a>",
"      .)",
"     </li>",
"     <li>",
"      (See",
"      <a class=\"medical medical_review\" href=\"UTD.htm?4/16/4362?source=see_link\">",
"       \"Bipolar disorder in pregnant women: Treatment of mania, hypomania, and mixed episodes\"",
"      </a>",
"      .)",
"     </li>",
"     <li>",
"      (See",
"      <a class=\"medical medical_review\" href=\"UTD.htm?37/22/38248?source=see_link\">",
"       \"Bipolar disorder in pregnant women: Treatment of major depression\"",
"      </a>",
"      .)",
"     </li>",
"     <li>",
"      (See",
"      <a class=\"medical medical_review\" href=\"UTD.htm?2/51/2874?source=see_link\">",
"       \"Bipolar disorder in women: Preconception and prenatal maintenance pharmacotherapy\"",
"      </a>",
"      .)",
"     </li>",
"     <li>",
"      (See",
"      <a class=\"medical medical_review\" href=\"UTD.htm?39/24/40329?source=see_link\">",
"       \"Bipolar disorder in women: Contraception and preconception assessment and counseling\"",
"      </a>",
"      .)",
"     </li>",
"    </ul>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H1564402\">",
"    <span class=\"h1\">",
"     DEFINITIONS",
"    </span>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H1564410\">",
"    <span class=\"h2\">",
"     Bipolar disorder",
"    </span>",
"    &nbsp;&mdash;&nbsp;Bipolar disorder is a mood disorder that is characterized by episodes of mania (",
"    <a class=\"graphic graphic_table graphicRef81976 \" href=\"UTD.htm?3/53/3932\">",
"     table 1",
"    </a>",
"    ), hypomania (",
"    <a class=\"graphic graphic_table graphicRef70757 \" href=\"UTD.htm?22/39/23164\">",
"     table 2",
"    </a>",
"    ), and major depression (",
"    <a class=\"graphic graphic_table graphicRef70852 \" href=\"UTD.htm?17/21/17756\">",
"     table 3",
"    </a>",
"    ), as well as mixed episodes (major depression concurrent with mania) [",
"    <a class=\"abstract\" href=\"UTD.htm?10/61/11226/abstract/3\">",
"     3",
"    </a>",
"    ]. The subtypes of bipolar disorder include bipolar I and bipolar II. Patients with bipolar I disorder experience manic and mixed episodes, and nearly always experience major depressive and hypomanic episodes. Bipolar II disorder is marked by at least one hypomanic episode, at least one major depressive episode, and the absence of manic and mixed episodes. Additional information about the clinical features and diagnosis of bipolar disorder is discussed separately. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?19/11/19639?source=see_link&amp;anchor=H4#H4\">",
"     \"Bipolar disorder in adults: Epidemiology and diagnosis\", section on 'Clinical manifestations and diagnostic criteria'",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H1564418\">",
"    <span class=\"h2\">",
"     Teratogen",
"    </span>",
"    &nbsp;&mdash;&nbsp;Teratogens are factors that can alter normal intrauterine development of fetal growth, anatomic structures, physical functioning, and postnatal development. This definition encompasses environmental exposures, maternal medical disorders, infectious agents, and genetic conditions. Most discussions of teratogens usually center on drug exposures. In determining whether a drug is a teratogen, many authorities stipulate that the exposure causes a pattern of defects [",
"    <a class=\"abstract\" href=\"UTD.htm?10/61/11226/abstract/4\">",
"     4",
"    </a>",
"    ]. Thus, if exposure is associated with an increase in birth defects greater than that expected in the general population, but the defects vary and there is no discernible pattern, the drug is generally not considered teratogenic. The principles of teratology are discussed separately. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?19/7/19574?source=see_link\">",
"     \"Principles of teratology\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H1564426\">",
"    <span class=\"h1\">",
"     GENERAL PRINCIPLES",
"    </span>",
"    &nbsp;&mdash;&nbsp;All psychotropic drugs presumably cross the placenta and are present in the amniotic fluid [",
"    <a class=\"abstract\" href=\"UTD.htm?10/61/11226/abstract/5\">",
"     5",
"    </a>",
"    ]. Embryonic and fetal exposure to maternal pharmacotherapy can cause [",
"    <a class=\"abstract\" href=\"UTD.htm?10/61/11226/abstract/2,6-8\">",
"     2,6-8",
"    </a>",
"    ]:",
"   </p>",
"   <p>",
"    <ul class=\"bulletCompact-block\">",
"     <li>",
"      Miscarriage",
"     </li>",
"     <li>",
"      Major and minor structural malformations",
"     </li>",
"     <li>",
"      Fetal growth restriction and low birth weight",
"     </li>",
"     <li>",
"      Preterm delivery",
"     </li>",
"     <li>",
"      Neonatal toxicity and withdrawal",
"     </li>",
"     <li>",
"      Postnatal developmental effects upon behavior, cognition, and emotional regulation",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    Medication effects upon the fetus vary according to gestational age [",
"    <a class=\"abstract\" href=\"UTD.htm?10/61/11226/abstract/2,6,8\">",
"     2,6,8",
"    </a>",
"    ]. As an example, the fetus is most vulnerable to major morphologic teratogenesis during organogenesis in the embryonic period of the first trimester, between the third and eighth week of gestation (weeks of gestation are counted from the first day of the last menstrual period) (",
"    <a class=\"graphic graphic_figure graphicRef65816 \" href=\"UTD.htm?32/30/33261\">",
"     figure 1",
"    </a>",
"    and",
"    <a class=\"graphic graphic_figure graphicRef56642 \" href=\"UTD.htm?22/46/23272\">",
"     figure 2",
"    </a>",
"    ). Organogenesis occurs 5 to 10 weeks from the first day of the last menstrual period, or 3 to 8 weeks from conception (conception occurs approximately two weeks after the first day of the last menstrual period). By contrast, neonatal toxicity and withdrawal are the result of third trimester exposure.",
"   </p>",
"   <p>",
"    The estimated risk of major congenital malformations appears to vary among the medications that are most commonly used to treat bipolar disorder. The rank order from greatest to least teratogenic risk is [",
"    <a class=\"abstract\" href=\"UTD.htm?10/61/11226/abstract/9-14\">",
"     9-14",
"    </a>",
"    ]:",
"   </p>",
"   <p>",
"    <ul class=\"bulletCompact-block\">",
"     <li>",
"      <a class=\"drug drug_general\" href=\"UTD.htm?25/11/25785?source=see_link\">",
"       Valproate",
"      </a>",
"     </li>",
"     <li>",
"      <a class=\"drug drug_general\" href=\"UTD.htm?25/10/25770?source=see_link\">",
"       Carbamazepine",
"      </a>",
"     </li>",
"     <li>",
"      <a class=\"drug drug_general\" href=\"UTD.htm?23/11/23736?source=see_link\">",
"       Lithium",
"      </a>",
"     </li>",
"     <li>",
"      <a class=\"drug drug_general\" href=\"UTD.htm?6/28/6602?source=see_link\">",
"       Lamotrigine",
"      </a>",
"     </li>",
"     <li>",
"      Antipsychotics",
"     </li>",
"     <li>",
"      Antidepressants",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    In discussing teratogenic effects, patients should be informed that the base rate for congenital defects in the general population is approximately two to five percent [",
"    <a class=\"abstract\" href=\"UTD.htm?10/61/11226/abstract/15-18\">",
"     15-18",
"    </a>",
"    ]. The incidence of defects is two to three percent at birth but increases to five to six percent after one year when hidden defects are discovered.",
"   </p>",
"   <p>",
"    The estimated risks of congenital defects from pharmacotherapy are typically based upon birth registry and observational studies [",
"    <a class=\"abstract\" href=\"UTD.htm?10/61/11226/abstract/7\">",
"     7",
"    </a>",
"    ]. Although these studies probably provide the best evidence of the risks, the accuracy of these estimates is uncertain due to ascertainment bias. In addition, information about teratogenic effects is usually presented in terms of monotherapy, whereas many studies are confounded due to concomitant exposure to multiple psychotropic and nonpsychotropic medications [",
"    <a class=\"abstract\" href=\"UTD.htm?10/61/11226/abstract/19\">",
"     19",
"    </a>",
"    ], and acutely ill pregnant bipolar patients often require medication combinations [",
"    <a class=\"abstract\" href=\"UTD.htm?10/61/11226/abstract/20-23\">",
"     20-23",
"    </a>",
"    ]. Further, it is often not possible to separate the effects of drugs from the psychiatric illness itself, and studies often do not control for comorbid substance use disorder, maternal age, maternal body mass index, and prior miscarriages.",
"   </p>",
"   <p>",
"    Although a drug may significantly increase the risk of a congenital anomaly, the absolute risk may be low [",
"    <a class=\"abstract\" href=\"UTD.htm?10/61/11226/abstract/24\">",
"     24",
"    </a>",
"    ]. As an example, the estimated risk of Ebstein&rsquo;s anomaly (abnormalities of the tricuspid valve and right ventricle) in the general population is 1 in 20,000 live births [",
"    <a class=\"abstract\" href=\"UTD.htm?10/61/11226/abstract/25-27\">",
"     25-27",
"    </a>",
"    ]. Following first-trimester exposure to",
"    <a class=\"drug drug_general\" href=\"UTD.htm?23/11/23736?source=see_link\">",
"     lithium",
"    </a>",
"    , the risk increases 20-fold to approximately 1 in 1000, which many authorities consider low [",
"    <a class=\"abstract\" href=\"UTD.htm?10/61/11226/abstract/6,24,28\">",
"     6,24,28",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H1561478\">",
"    <span class=\"h2\">",
"     Resources",
"    </span>",
"    &nbsp;&mdash;&nbsp;Current information about the possible teratogenic effects of medications is available from several resources; these are discussed separately. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?19/7/19574?source=see_link&amp;anchor=H12#H12\">",
"     \"Principles of teratology\", section on 'Resources'",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    In addition, the possible teratogenic effects of drugs and suggestions for managing them can be found for all drugs included in the UpToDate drug database: search on the drug name, choose the drug information topic for that drug, and click on the &ldquo;Pregnancy Implications&rdquo; section of the topic outline. Clicking on the name of a drug cited within any UpToDate topic will also bring you to the drug information topic.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H1564785\">",
"    <span class=\"h1\">",
"     ANTIPARKINSONIAN DRUGS USED FOR TREATING EXTRAPYRAMIDAL SYMPTOMS",
"    </span>",
"    &nbsp;&mdash;&nbsp;Among the antiparkinsonian drugs that are used to treat extrapyramidal symptoms secondary to antipsychotics, reviews suggest that the risk of teratogenicity with antihistamines (eg,",
"    <a class=\"drug drug_general\" href=\"UTD.htm?33/2/33824?source=see_link\">",
"     diphenhydramine",
"    </a>",
"    ) appears to be low [",
"    <a class=\"abstract\" href=\"UTD.htm?10/61/11226/abstract/29\">",
"     29",
"    </a>",
"    ], and that organ malformation appears to be less likely with diphenhydramine than",
"    <a class=\"drug drug_general\" href=\"UTD.htm?12/46/13031?source=see_link\">",
"     amantadine",
"    </a>",
"    ,",
"    <a class=\"drug drug_general\" href=\"UTD.htm?3/55/3958?source=see_link\">",
"     benztropine",
"    </a>",
"    , and",
"    <a class=\"drug drug_general\" href=\"UTD.htm?6/1/6165?source=see_link\">",
"     trihexyphenidyl",
"    </a>",
"    [",
"    <a class=\"abstract\" href=\"UTD.htm?10/61/11226/abstract/24,30\">",
"     24,30",
"    </a>",
"    ]. As an example, a study of 270 infants exposed to diphenhydramine during the first trimester found no association with congenital defects [",
"    <a class=\"abstract\" href=\"UTD.htm?10/61/11226/abstract/31\">",
"     31",
"    </a>",
"    ]. However, studies have found that prenatal use of diphenhydramine was associated with congenital malformations [",
"    <a class=\"abstract\" href=\"UTD.htm?10/61/11226/abstract/5\">",
"     5",
"    </a>",
"    ], including a case-control study in which prenatal exposure to diphenhydramine was significantly greater among children with oral clefts (N = 599) than controls (N = 500) [",
"    <a class=\"abstract\" href=\"UTD.htm?10/61/11226/abstract/32\">",
"     32",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H1561485\">",
"    <span class=\"h1\">",
"     ANTIDEPRESSANTS",
"    </span>",
"    &nbsp;&mdash;&nbsp;Nearly all of the evidence about the teratogenic and postnatal developmental effects of antidepressants is based upon treatment of pregnant patients with unipolar major depression. Most studies have not found that selective serotonin reuptake inhibitors (SSRIs) in the first trimester increase the risk of birth defects, with the possible exception of",
"    <a class=\"drug drug_general\" href=\"UTD.htm?14/50/15146?source=see_link\">",
"     paroxetine",
"    </a>",
"    [",
"    <a class=\"abstract\" href=\"UTD.htm?10/61/11226/abstract/33\">",
"     33",
"    </a>",
"    ]. In addition, tricyclic antidepressants [",
"    <a class=\"abstract\" href=\"UTD.htm?10/61/11226/abstract/24,34,35\">",
"     24,34,35",
"    </a>",
"    ],",
"    <a class=\"drug drug_general\" href=\"UTD.htm?25/29/26073?source=see_link\">",
"     bupropion",
"    </a>",
"    [",
"    <a class=\"abstract\" href=\"UTD.htm?10/61/11226/abstract/36\">",
"     36",
"    </a>",
"    ],",
"    <a class=\"drug drug_general\" href=\"UTD.htm?31/41/32408?source=see_link\">",
"     mirtazapine",
"    </a>",
"    [",
"    <a class=\"abstract\" href=\"UTD.htm?10/61/11226/abstract/37\">",
"     37",
"    </a>",
"    ],",
"    <a class=\"drug drug_general\" href=\"UTD.htm?2/0/2057?source=see_link\">",
"     nefazodone",
"    </a>",
"    [",
"    <a class=\"abstract\" href=\"UTD.htm?10/61/11226/abstract/38\">",
"     38",
"    </a>",
"    ],",
"    <a class=\"drug drug_general\" href=\"UTD.htm?24/0/24584?source=see_link\">",
"     trazodone",
"    </a>",
"    , and",
"    <a class=\"drug drug_general\" href=\"UTD.htm?21/45/22233?source=see_link\">",
"     venlafaxine",
"    </a>",
"    [",
"    <a class=\"abstract\" href=\"UTD.htm?10/61/11226/abstract/39\">",
"     39",
"    </a>",
"    ] are generally not associated with congenital malformations. The teratogenic and postnatal effects of antidepressants are discussed separately. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?28/0/28682?source=see_link\">",
"     \"Depression in pregnant women: Management\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H1561492\">",
"    <span class=\"h1\">",
"     ANTIEPILEPTICS",
"    </span>",
"    &nbsp;&mdash;&nbsp;Teratogenic and neurobehavioral effects have been identified in children exposed to",
"    <a class=\"drug drug_general\" href=\"UTD.htm?25/11/25785?source=see_link\">",
"     valproate",
"    </a>",
"    , and less frequently,",
"    <a class=\"drug drug_general\" href=\"UTD.htm?25/10/25770?source=see_link\">",
"     carbamazepine",
"    </a>",
"    [",
"    <a class=\"abstract\" href=\"UTD.htm?10/61/11226/abstract/14\">",
"     14",
"    </a>",
"    ]. Although most studies suggest that the estimated rate of major congenital malformations with",
"    <a class=\"drug drug_general\" href=\"UTD.htm?6/28/6602?source=see_link\">",
"     lamotrigine",
"    </a>",
"    appears to be comparable to the rate in the general population, some studies suggest that lamotrigine may possibly cause orofacial clefts [",
"    <a class=\"abstract\" href=\"UTD.htm?10/61/11226/abstract/40\">",
"     40",
"    </a>",
"    ]. The known risks of prenatal exposure to antiepileptics are based primarily upon observations of epilepsy patients, and are discussed separately. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?22/6/22633?source=see_link&amp;anchor=H4#H4\">",
"     \"Risks associated with epilepsy and pregnancy\", section on 'Effect of antiepileptic drugs on the fetus'",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H1561506\">",
"    <span class=\"h1\">",
"     ANTIPSYCHOTICS",
"    </span>",
"    &nbsp;&mdash;&nbsp;Most studies have found that prenatal exposure to first- and second-generation antipsychotics did not appear to increase the risk of major physical malformations above rates observed in the general population [",
"    <a class=\"abstract\" href=\"UTD.htm?10/61/11226/abstract/4,41\">",
"     4,41",
"    </a>",
"    ]. Although one birth registry found that the risk of congenital malformations was significantly increased in newborns exposed to antipsychotics during pregnancy compared with unexposed infants, the risk was not significant when the analyses excluded concomitant exposure to anticonvulsants [",
"    <a class=\"abstract\" href=\"UTD.htm?10/61/11226/abstract/42\">",
"     42",
"    </a>",
"    ]. &nbsp;",
"   </p>",
"   <p>",
"    Use of antipsychotics during pregnancy may increase maternal weight. A population-based birth registry of 958,729 pregnancies found that a body mass index &ge; 26 (overweight or obesity) was significantly more probable in patients treated with antipsychotics than untreated women (odds ratio = 2) [",
"    <a class=\"abstract\" href=\"UTD.htm?10/61/11226/abstract/42\">",
"     42",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Fetal exposure to antipsychotics may vary due to differences in placental permeability to these drugs. A prospective observational study of 50 pregnant patients examined the placental passage of antipsychotics, defined as the ratio of umbilical cord serum drug concentration to maternal serum drug concentration [",
"    <a class=\"abstract\" href=\"UTD.htm?10/61/11226/abstract/22\">",
"     22",
"    </a>",
"    ]. (Umbilical cord and maternal plasma concentrations were drawn at delivery; drugs cross the placenta more readily late in pregnancy). The placental passage ratios were as follows:",
"   </p>",
"   <p>",
"    <ul class=\"bulletCompact-block\">",
"     <li>",
"      <a class=\"drug drug_general\" href=\"UTD.htm?36/36/37449?source=see_link\">",
"       Olanzapine",
"      </a>",
"      &ndash; 72 percent",
"     </li>",
"     <li>",
"      <a class=\"drug drug_general\" href=\"UTD.htm?31/50/32553?source=see_link\">",
"       Haloperidol",
"      </a>",
"      &ndash; 66",
"     </li>",
"     <li>",
"      <a class=\"drug drug_general\" href=\"UTD.htm?11/33/11802?source=see_link\">",
"       Risperidone",
"      </a>",
"      &ndash; 49",
"     </li>",
"     <li>",
"      <a class=\"drug drug_general\" href=\"UTD.htm?19/56/20361?source=see_link\">",
"       Quetiapine",
"      </a>",
"      &ndash; 24",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    The ratio for",
"    <a class=\"drug drug_general\" href=\"UTD.htm?19/56/20361?source=see_link\">",
"     quetiapine",
"    </a>",
"    was significantly lower than that for",
"    <a class=\"drug drug_general\" href=\"UTD.htm?36/36/37449?source=see_link\">",
"     olanzapine",
"    </a>",
"    and",
"    <a class=\"drug drug_general\" href=\"UTD.htm?31/50/32553?source=see_link\">",
"     haloperidol",
"    </a>",
"    .",
"   </p>",
"   <p>",
"    First-generation antipsychotics have been more widely used and studied during pregnancy than second-generation antipsychotics [",
"    <a class=\"abstract\" href=\"UTD.htm?10/61/11226/abstract/2,42\">",
"     2,42",
"    </a>",
"    ]. In addition, the risks of prenatal exposure to antipsychotics have been examined primarily in patients with hyperemesis gravidarum who received low doses of antipsychotics as antiemetics and were presumed to not have a psychiatric disorder, and secondarily in patients with psychotic disorders and mood disorders [",
"    <a class=\"abstract\" href=\"UTD.htm?10/61/11226/abstract/24,42\">",
"     24,42",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H89201049\">",
"    <span class=\"h2\">",
"     Postnatal effects",
"    </span>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H89201057\">",
"    <span class=\"h3\">",
"     Neonatal toxicity and withdrawal",
"    </span>",
"    &nbsp;&mdash;&nbsp;Chronic administration of antipsychotics during the third trimester may cause symptoms of neonatal toxicity and withdrawal, including [",
"    <a class=\"abstract\" href=\"UTD.htm?10/61/11226/abstract/1,6,24,41,43,44\">",
"     1,6,24,41,43,44",
"    </a>",
"    ]:",
"   </p>",
"   <p>",
"    <ul class=\"bulletCompact-block\">",
"     <li>",
"      Abnormal movements (dyskinesia)",
"     </li>",
"     <li>",
"      Abnormally increased or decreased muscle tone",
"     </li>",
"     <li>",
"      Motor restlessness",
"     </li>",
"     <li>",
"      Hyperreflexia",
"     </li>",
"     <li>",
"      Agitation",
"     </li>",
"     <li>",
"      Hyperactivity",
"     </li>",
"     <li>",
"      Tremor",
"     </li>",
"     <li>",
"      Sedation",
"     </li>",
"     <li>",
"      Irritability",
"     </li>",
"     <li>",
"      Crying",
"     </li>",
"     <li>",
"      Tachycardia",
"     </li>",
"     <li>",
"      Hypotension",
"     </li>",
"     <li>",
"      Difficulty breathing",
"     </li>",
"     <li>",
"      Difficulty feeding",
"     </li>",
"     <li>",
"      Gastrointestinal dysfunction (eg, functional bowel obstruction)",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    Many of the symptoms of toxicity and withdrawal were described in a United States Food and Drug Administration warning [",
"    <a class=\"abstract\" href=\"UTD.htm?10/61/11226/abstract/44\">",
"     44",
"    </a>",
"    ]. Although the incidence of these symptoms is not known, extrapyramidal symptoms (eg, abnormal movements, restlessness, and tremor) may be more likely to occur with first-generation antipsychotics and",
"    <a class=\"drug drug_general\" href=\"UTD.htm?11/33/11802?source=see_link\">",
"     risperidone",
"    </a>",
"    than with other second-generation antipsychotics [",
"    <a class=\"abstract\" href=\"UTD.htm?10/61/11226/abstract/4\">",
"     4",
"    </a>",
"    ]. Symptoms typically subside within hours to days, but may persist for weeks to months after birth [",
"    <a class=\"abstract\" href=\"UTD.htm?10/61/11226/abstract/4\">",
"     4",
"    </a>",
"    ]. Specific treatment is usually not necessary, but more severely affected newborns may require longer hospital stays [",
"    <a class=\"abstract\" href=\"UTD.htm?10/61/11226/abstract/44\">",
"     44",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H89201266\">",
"    <span class=\"h3\">",
"     Developmental effects",
"    </span>",
"    &nbsp;&mdash;&nbsp;Intrauterine exposure to antipsychotics may adversely affect neuromotor functioning during infancy. A prospective observational study that controlled for maternal psychiatric status and other variables found significantly poorer neuromotor performance (eg, posture, muscle tone, and reflexes) six months postpartum in babies with prenatal antipsychotic exposure (N = 22) compared to babies with no prenatal psychotropic exposure (N = 85) [",
"    <a class=\"abstract\" href=\"UTD.htm?10/61/11226/abstract/23\">",
"     23",
"    </a>",
"    ]. However, assessment at six months may not predict long-term outcome. In addition, information processing and learning were comparable for the two groups. &nbsp; &nbsp;",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H481720\">",
"    <span class=\"h2\">",
"     First-generation",
"    </span>",
"    &nbsp;&mdash;&nbsp;The reproductive safety risks of first-generation antipsychotics are generally regarded as low, based upon a literature that extends back to the 1960s [",
"    <a class=\"abstract\" href=\"UTD.htm?10/61/11226/abstract/2,5,22\">",
"     2,5,22",
"    </a>",
"    ]. &nbsp;",
"   </p>",
"   <p>",
"    Use of first-generation antipsychotics during pregnancy does not appear to increase perinatal mortality. A prospective observational study found that the frequency of stillbirths and neonatal deaths were each similar in patients treated with typical antipsychotics (N = 3056) and in untreated patients (N = 38,281) [",
"    <a class=\"abstract\" href=\"UTD.htm?10/61/11226/abstract/45\">",
"     45",
"    </a>",
"    ]. Perinatal mortality is discussed separately. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?20/38/21096?source=see_link\">",
"     \"Perinatal mortality\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    Most studies have not found an increased risk of birth defects following prenatal exposure to first-generation antipsychotics, including",
"    <a class=\"drug drug_general\" href=\"UTD.htm?29/38/30312?source=see_link\">",
"     chlorpromazine",
"    </a>",
"    ,",
"    <a class=\"drug drug_general\" href=\"UTD.htm?31/50/32553?source=see_link\">",
"     haloperidol",
"    </a>",
"    ,",
"    <a class=\"drug drug_general\" href=\"UTD.htm?18/49/19223?source=see_link\">",
"     perphenazine",
"    </a>",
"    ,",
"    <a class=\"drug drug_general\" href=\"UTD.htm?22/28/22984?source=see_link\">",
"     prochlorperazine",
"    </a>",
"    , and",
"    <a class=\"drug drug_general\" href=\"UTD.htm?19/2/19495?source=see_link\">",
"     trifluoperazine",
"    </a>",
"    [",
"    <a class=\"abstract\" href=\"UTD.htm?10/61/11226/abstract/1,4,5\">",
"     1,4,5",
"    </a>",
"    ]. Although a 1996 meta-analysis of three prospective observational studies and one retrospective chart review (2591 live birth infants exposed during pregnancy to first-generation antipsychotics and 71,746 unexposed infants) found a significantly increased risk of congenital malformations (odds ratio 1.21) [",
"    <a class=\"abstract\" href=\"UTD.htm?10/61/11226/abstract/24\">",
"     24",
"    </a>",
"    ], subsequent studies have not. As an example, a prospective observational study found that the rate of congenital malformations did not differ significantly between newborns exposed to haloperidol or penfluridol (N = 128) and unexposed newborns (N = 581) (3.1 versus 3.8 percent) [",
"    <a class=\"abstract\" href=\"UTD.htm?10/61/11226/abstract/43\">",
"     43",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    It is not clear if prenatal exposure to first-generation antipsychotics adversely affects birth weight. Two prospective observational studies (N = 846 and 83) each found that birth weights were significantly less (approximately 220 grams) in babies exposed to typical antipsychotics compared with unexposed babies [",
"    <a class=\"abstract\" href=\"UTD.htm?10/61/11226/abstract/43,46\">",
"     43,46",
"    </a>",
"    ]. However, a third prospective observational study found that birth weights were comparable for infants exposed to first-generation antipsychotics (N = 2860) and for unexposed infants (N = 35,353) [",
"    <a class=\"abstract\" href=\"UTD.htm?10/61/11226/abstract/45\">",
"     45",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Reviews have found that prenatal exposure to first-generation antipsychotics does not appear to adversely affect behavioral, cognitive, or emotional development [",
"    <a class=\"abstract\" href=\"UTD.htm?10/61/11226/abstract/2,47,48\">",
"     2,47,48",
"    </a>",
"    ]. As an example, a prospective observational study found that intelligence quotient scores measured at four years of age were comparable in children exposed during pregnancy to typical antipsychotics (N = 2141) and in unexposed children (N = 26,217) [",
"    <a class=\"abstract\" href=\"UTD.htm?10/61/11226/abstract/45\">",
"     45",
"    </a>",
"    ]. &nbsp;",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H1561513\">",
"    <span class=\"h2\">",
"     Second-generation",
"    </span>",
"    &nbsp;&mdash;&nbsp;Second-generation antipsychotics usually do not appear to be associated with fetal deaths or teratogenic effects, based upon reviews of the limited available data [",
"    <a class=\"abstract\" href=\"UTD.htm?10/61/11226/abstract/1,4\">",
"     1,4",
"    </a>",
"    ]. As an example, a prospective observational study compared pregnancy outcomes in 151 pregnant patients treated during the first trimester with atypical antipsychotics (primarily",
"    <a class=\"drug drug_general\" href=\"UTD.htm?36/36/37449?source=see_link\">",
"     olanzapine",
"    </a>",
"    ,",
"    <a class=\"drug drug_general\" href=\"UTD.htm?11/33/11802?source=see_link\">",
"     risperidone",
"    </a>",
"    , and",
"    <a class=\"drug drug_general\" href=\"UTD.htm?19/56/20361?source=see_link\">",
"     quetiapine",
"    </a>",
"    ) and a comparison group of 151 unexposed pregnant women. The rate of spontaneous abortions, stillbirths, and major congenital malformations was comparable for the two groups [",
"    <a class=\"abstract\" href=\"UTD.htm?10/61/11226/abstract/20\">",
"     20",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    The reported rates of fetal death and congenital malformations for specific second-generation drugs do not exceed rates in the general population:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      <a class=\"drug drug_general\" href=\"UTD.htm?42/11/43193?source=see_link\">",
"       Aripiprazole",
"      </a>",
"      &ndash; A review found three case reports of treatment with aripiprazole during pregnancy, including one in which the drug was used during conception and the first trimester [",
"      <a class=\"abstract\" href=\"UTD.htm?10/61/11226/abstract/49\">",
"       49",
"      </a>",
"      ]. Outcome was normal for all three cases. &nbsp;",
"     </li>",
"     <li>",
"      <a class=\"drug drug_general\" href=\"UTD.htm?34/21/35161?source=see_link\">",
"       Clozapine",
"      </a>",
"      &ndash; The manufacturer has received 523 reports about use of clozapine during pregnancy; congenital anomalies occurred in 4 percent and there was no pattern of defects [",
"      <a class=\"abstract\" href=\"UTD.htm?10/61/11226/abstract/4\">",
"       4",
"      </a>",
"      ]",
"     </li>",
"     <li>",
"      <a class=\"drug drug_general\" href=\"UTD.htm?36/36/37449?source=see_link\">",
"       Olanzapine",
"      </a>",
"      &ndash; The manufacturer has received 144 reports about prospective use of olanzapine during pregnancy; the frequency of congenital malformations was consistent with the rate in the general population [",
"      <a class=\"abstract\" href=\"UTD.htm?10/61/11226/abstract/4\">",
"       4",
"      </a>",
"      ]",
"     </li>",
"     <li>",
"      <a class=\"drug drug_general\" href=\"UTD.htm?19/56/20361?source=see_link\">",
"       Quetiapine",
"      </a>",
"      &ndash; The manufacturer has received 298 reports about prospective and retrospective use of quetiapine during pregnancy (most reports involved patients who took other medications); congenital anomalies occurred in 5 percent and there was no pattern of defects [",
"      <a class=\"abstract\" href=\"UTD.htm?10/61/11226/abstract/4\">",
"       4",
"      </a>",
"      ]",
"     </li>",
"     <li>",
"      <a class=\"drug drug_general\" href=\"UTD.htm?11/33/11802?source=see_link\">",
"       Risperidone",
"      </a>",
"      &ndash; The manufacturer has received 713 reports about use of risperidone during pregnancy. Among the 68 prospectively reported pregnancies with a known outcome, organ malformations occurred in 4 percent and spontaneous abortions in 17 percent [",
"      <a class=\"abstract\" href=\"UTD.htm?10/61/11226/abstract/50\">",
"       50",
"      </a>",
"      ]",
"     </li>",
"     <li>",
"      <a class=\"drug drug_general\" href=\"UTD.htm?4/39/4728?source=see_link\">",
"       Ziprasidone",
"      </a>",
"      &ndash; The manufacturer has received 57 reports about use of ziprasidone during pregnancy; normal outcomes occurred in 50 cases, spontaneous abortions in 5, malformation in 1, and stillbirth in 1 [",
"      <a class=\"abstract\" href=\"UTD.htm?10/61/11226/abstract/4\">",
"       4",
"      </a>",
"      ]",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    The association between exposure to second-generation antipsychotics during pregnancy and birth weight is not clear. One prospective observational study found that large for gestational age births occurred significantly more often in newborns exposed during pregnancy to second-generation antipsychotics (primarily",
"    <a class=\"drug drug_general\" href=\"UTD.htm?36/36/37449?source=see_link\">",
"     olanzapine",
"    </a>",
"    ,",
"    <a class=\"drug drug_general\" href=\"UTD.htm?11/33/11802?source=see_link\">",
"     risperidone",
"    </a>",
"    ,",
"    <a class=\"drug drug_general\" href=\"UTD.htm?19/56/20361?source=see_link\">",
"     quetiapine",
"    </a>",
"    , or",
"    <a class=\"drug drug_general\" href=\"UTD.htm?34/21/35161?source=see_link\">",
"     clozapine",
"    </a>",
"    ; N = 25), compared with control infants (N = 38) (20 versus 3 percent) [",
"    <a class=\"abstract\" href=\"UTD.htm?10/61/11226/abstract/46\">",
"     46",
"    </a>",
"    ]. Another prospective observational study found that exposure during pregnancy to olanzapine (N = 12) was associated with significantly higher infant birth weights, compared with exposure to other psychotropic drugs (N = 13) (3310 versus 2921 grams) [",
"    <a class=\"abstract\" href=\"UTD.htm?10/61/11226/abstract/51\">",
"     51",
"    </a>",
"    ]. By contrast, a prospective observational study found that low birth weight occurred in significantly more infants following prenatal exposure to second-generation antipsychotics (olanzapine, risperidone, or quetiapine; N = 151), compared with control infants (N = 151) (10 versus 2 percent) [",
"    <a class=\"abstract\" href=\"UTD.htm?10/61/11226/abstract/20\">",
"     20",
"    </a>",
"    ]. In addition, a prospective observational study of 13 infants exposed to olanzapine during pregnancy found that low birth weight occurred in 31 percent [",
"    <a class=\"abstract\" href=\"UTD.htm?10/61/11226/abstract/22\">",
"     22",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    There do not appear to be any high quality studies that have examined fetal exposure to second-generation antipsychotics and behavioral, cognitive, and emotional effects in these children [",
"    <a class=\"abstract\" href=\"UTD.htm?10/61/11226/abstract/4,48\">",
"     4,48",
"    </a>",
"    ]. &nbsp;",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H1561527\">",
"    <span class=\"h1\">",
"     BENZODIAZEPINES",
"    </span>",
"    &nbsp;&mdash;&nbsp;It is not clear if exposure to benzodiazepines or to hypnotic, benzodiazepine receptor agonists (eg,",
"    <a class=\"drug drug_general\" href=\"UTD.htm?14/61/15318?source=see_link\">",
"     zaleplon",
"    </a>",
"    ,",
"    <a class=\"drug drug_general\" href=\"UTD.htm?12/48/13064?source=see_link\">",
"     zolpidem",
"    </a>",
"    , or",
"    <a class=\"drug drug_general\" href=\"UTD.htm?17/24/17798?source=see_link\">",
"     zopiclone",
"    </a>",
"    ) during pregnancy increases the risk congenital malformations. To the extent that benzodiazepines are teratogenic, many authorities consider the absolute risk small [",
"    <a class=\"abstract\" href=\"UTD.htm?10/61/11226/abstract/6,19,24\">",
"     6,19,24",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Several studies suggest that benzodiazepines may not be associated with birth defects, including [",
"    <a class=\"abstract\" href=\"UTD.htm?10/61/11226/abstract/52,53\">",
"     52,53",
"    </a>",
"    ]:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      A birth registry study that found congenital malformations were comparable for infants exposed during pregnancy to hypnotic, benzodiazepine receptor agonists (N = 1341) and control infants (N = 1,125,734) (4.3 versus 4.7 percent) [",
"      <a class=\"abstract\" href=\"UTD.htm?10/61/11226/abstract/54\">",
"       54",
"      </a>",
"      ]",
"     </li>",
"     <li>",
"      A meta-analysis of seven cohort studies (1090 infants exposed during pregnancy to benzodiazepines and 71,776 controls) found that there was no relationship between fetal exposure to benzodiazepines and major malformations [",
"      <a class=\"abstract\" href=\"UTD.htm?10/61/11226/abstract/19\">",
"       19",
"      </a>",
"      ]",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    By contrast, other studies suggest that benzodiazepines or hypnotic, benzodiazepine receptor agonists may be associated with congenital malformations, including oral cleft [",
"    <a class=\"abstract\" href=\"UTD.htm?10/61/11226/abstract/24,55\">",
"     24,55",
"    </a>",
"    ]:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      A meta-analysis of six heterogeneous case-control studies (285 cases with fetal exposure to benzodiazepines and 14,686 controls) found that exposure was significantly associated with a significantly elevated risk of oral cleft (odds ratio 1.8) [",
"      <a class=\"abstract\" href=\"UTD.htm?10/61/11226/abstract/19\">",
"       19",
"      </a>",
"      ]",
"     </li>",
"     <li>",
"      A birth registry study found that congenital malformations were significantly increased in newborns exposed during pregnancy to benzodiazepines or hypnotic benzodiazepine receptor agonists (N = 1979), compared with all newborns (N = 873,879) (OR 1.2) [",
"      <a class=\"abstract\" href=\"UTD.htm?10/61/11226/abstract/56\">",
"       56",
"      </a>",
"      ]. In particular, the risk of pylorostenosis was nearly three times greater than expected and alimentary tract atresia nearly four times greater. &nbsp;",
"     </li>",
"     <li>",
"      A meta-analysis of four case-control studies (166 cases with fetal exposure to benzodiazepines and 5970 controls) found that major malformations were significantly associated with the use of benzodiazepines during pregnancy (odds ratio 3.0) [",
"      <a class=\"abstract\" href=\"UTD.htm?10/61/11226/abstract/19\">",
"       19",
"      </a>",
"      ]",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    Based upon case-control studies, fetal exposure to benzodiazepines may increase the risk of oral cleft from the general population base rate of 6 in 10,000 births to 11 in 10,000 births [",
"    <a class=\"abstract\" href=\"UTD.htm?10/61/11226/abstract/6\">",
"     6",
"    </a>",
"    ]. However, retrospective case-control studies may be subject to recall bias [",
"    <a class=\"abstract\" href=\"UTD.htm?10/61/11226/abstract/52\">",
"     52",
"    </a>",
"    ]. In addition, compared with pregnant patients who do not use benzodiazepines or hypnotic benzodiazepine receptor agonists, patients using these drugs may be older and more likely to smoke and use other drugs (eg, anticonvulsants) [",
"    <a class=\"abstract\" href=\"UTD.htm?10/61/11226/abstract/57\">",
"     57",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    An increased risk of preterm birth and low birth weight were reported by a birth registry for infants exposed in late pregnancy to benzodiazepines or hypnotic benzodiazepine receptor agonists [",
"    <a class=\"abstract\" href=\"UTD.htm?10/61/11226/abstract/56\">",
"     56",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Chronic administration of benzodiazepines proximal to delivery can cause neonatal toxicity and withdrawal, including [",
"    <a class=\"abstract\" href=\"UTD.htm?10/61/11226/abstract/2,6,52,56\">",
"     2,6,52,56",
"    </a>",
"    ]:",
"   </p>",
"   <p>",
"    <ul class=\"bulletCompact-block\">",
"     <li>",
"      Hypothermia",
"     </li>",
"     <li>",
"      Low Apgar scores",
"     </li>",
"     <li>",
"      Apnea",
"     </li>",
"     <li>",
"      Lethargy",
"     </li>",
"     <li>",
"      Hypotonia or hypertonia",
"     </li>",
"     <li>",
"      Restlessness",
"     </li>",
"     <li>",
"      Tremor",
"     </li>",
"     <li>",
"      Hyperreflexia",
"     </li>",
"     <li>",
"      Irritability",
"     </li>",
"     <li>",
"      Poor feeding",
"     </li>",
"     <li>",
"      Vomiting",
"     </li>",
"     <li>",
"      Diarrhea",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    This toxicity and withdrawal is widely reported [",
"    <a class=\"abstract\" href=\"UTD.htm?10/61/11226/abstract/5\">",
"     5",
"    </a>",
"    ], and may occur more often in preterm infants than term infants [",
"    <a class=\"abstract\" href=\"UTD.htm?10/61/11226/abstract/58\">",
"     58",
"    </a>",
"    ]. Symptoms may persist for up to three months [",
"    <a class=\"abstract\" href=\"UTD.htm?10/61/11226/abstract/5\">",
"     5",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    It is not clear if using benzodiazepines during pregnancy adversely affects neurobehavioral development, due to conflicting results among studies [",
"    <a class=\"abstract\" href=\"UTD.htm?10/61/11226/abstract/2,48\">",
"     2,48",
"    </a>",
"    ]. However, in the largest prospective study, motor and cognitive functioning were comparable at age three years for children exposed in utero to benzodiazepines (N = 1870) and unexposed children (N = 48,412) [",
"    <a class=\"abstract\" href=\"UTD.htm?10/61/11226/abstract/59\">",
"     59",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H1561534\">",
"    <span class=\"h1\">",
"     LITHIUM",
"    </span>",
"    &nbsp;&mdash;&nbsp;Use of",
"    <a class=\"drug drug_general\" href=\"UTD.htm?23/11/23736?source=see_link\">",
"     lithium",
"    </a>",
"    during pregnancy does not appear to increase perinatal mortality. A prospective observational study found that the frequency of miscarriages and stillbirths were each similar in patients treated with lithium (N = 138) and in controls (N = 148) [",
"    <a class=\"abstract\" href=\"UTD.htm?10/61/11226/abstract/60\">",
"     60",
"    </a>",
"    ]. Perinatal mortality is discussed separately. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?20/38/21096?source=see_link\">",
"     \"Perinatal mortality\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    <a class=\"drug drug_general\" href=\"UTD.htm?23/11/23736?source=see_link\">",
"     Lithium",
"    </a>",
"    appears to cause teratogenic effects that primarily involve the fetal heart [",
"    <a class=\"abstract\" href=\"UTD.htm?10/61/11226/abstract/2,6\">",
"     2,6",
"    </a>",
"    ]. The estimated incidence of major congenital anomalies among children of women treated with lithium during the first trimester is between 4 and 12 percent [",
"    <a class=\"abstract\" href=\"UTD.htm?10/61/11226/abstract/61\">",
"     61",
"    </a>",
"    ]. Cardiac malformations that have been observed include Ebstein&rsquo;s anomaly (abnormalities of the tricuspid valve and right ventricle), coarctation of the aorta, and mitral atresia [",
"    <a class=\"abstract\" href=\"UTD.htm?10/61/11226/abstract/6,61-63\">",
"     6,61-63",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Ebstein&rsquo;s anomaly may be the most common fetal cardiac defect caused by",
"    <a class=\"drug drug_general\" href=\"UTD.htm?23/11/23736?source=see_link\">",
"     lithium",
"    </a>",
"    . The estimated risk of the anomaly in the general population is 1 in 20,000 live births [",
"    <a class=\"abstract\" href=\"UTD.htm?10/61/11226/abstract/25-27\">",
"     25-27",
"    </a>",
"    ]; following first-trimester exposure to lithium, the risk appears to increase 20-fold to approximately 1 in 1000 [",
"    <a class=\"abstract\" href=\"UTD.htm?10/61/11226/abstract/64\">",
"     64",
"    </a>",
"    ], which many authorities consider low [",
"    <a class=\"abstract\" href=\"UTD.htm?10/61/11226/abstract/2,6,24,28,65\">",
"     2,6,24,28,65",
"    </a>",
"    ]. A meta-analysis of six case control studies (N = 264) found that the odds of exposure to lithium in cases of Ebstein&rsquo;s anomaly did not differ significantly from controls without the defect; however, the estimates were unstable because the number of events (exposure to lithium) was low [",
"    <a class=\"abstract\" href=\"UTD.htm?10/61/11226/abstract/66\">",
"     66",
"    </a>",
"    ]. Ebstein&rsquo;s anomaly is discussed separately. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?37/52/38729?source=see_link\">",
"     \"Ebstein's anomaly of the tricuspid valve\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    Birth weight may be increased in newborns exposed to",
"    <a class=\"drug drug_general\" href=\"UTD.htm?23/11/23736?source=see_link\">",
"     lithium",
"    </a>",
"    during pregnancy. A prospective observational study found that birth weights were significantly greater in babies exposed to lithium during pregnancy, compared with controls (3475 versus 3383 grams) [",
"    <a class=\"abstract\" href=\"UTD.htm?10/61/11226/abstract/60\">",
"     60",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Use of",
"    <a class=\"drug drug_general\" href=\"UTD.htm?23/11/23736?source=see_link\">",
"     lithium",
"    </a>",
"    during the second and third trimester can result in neonatal complications, including [",
"    <a class=\"abstract\" href=\"UTD.htm?10/61/11226/abstract/5,7,8,41,67-69\">",
"     5,7,8,41,67-69",
"    </a>",
"    ]:",
"   </p>",
"   <p>",
"    <ul class=\"bulletCompact-block\">",
"     <li>",
"      Premature labor",
"     </li>",
"     <li>",
"      Polyhydramnios",
"     </li>",
"     <li>",
"      Cardiomegaly",
"     </li>",
"     <li>",
"      Hepatomegaly",
"     </li>",
"     <li>",
"      Nephrogenic diabetes insipidus",
"     </li>",
"     <li>",
"      Goiter and hypothyroidism",
"     </li>",
"     <li>",
"      Gastrointestinal bleeding",
"     </li>",
"     <li>",
"      Shock",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    <a class=\"drug drug_general\" href=\"UTD.htm?23/11/23736?source=see_link\">",
"     Lithium",
"    </a>",
"    toxicity can also occur in newborns with late pregnancy exposure; symptoms include [",
"    <a class=\"abstract\" href=\"UTD.htm?10/61/11226/abstract/5,7,8,41,67-69\">",
"     5,7,8,41,67-69",
"    </a>",
"    ]:",
"   </p>",
"   <p>",
"    <ul class=\"bulletCompact-block\">",
"     <li>",
"      Low Apgar scores",
"     </li>",
"     <li>",
"      Shallow respirations, apnea, and cyanosis",
"     </li>",
"     <li>",
"      Bradycardia or tachycardia",
"     </li>",
"     <li>",
"      Cardiac arrhythmias and abnormal electrocardiogram (ECG)",
"     </li>",
"     <li>",
"      Seizures",
"     </li>",
"     <li>",
"      Lethargy or coma",
"     </li>",
"     <li>",
"      Muscle flaccidity and hypotonia",
"     </li>",
"     <li>",
"      Twitching",
"     </li>",
"     <li>",
"      Poor suck, grasp, and Moro reflexes",
"     </li>",
"     <li>",
"      Difficulty feeding",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    Neonatal",
"    <a class=\"drug drug_general\" href=\"UTD.htm?23/11/23736?source=see_link\">",
"     lithium",
"    </a>",
"    toxicity and complications are more common in newborns with higher serum lithium concentrations. In a study of 24 infants exposed in utero to lithium, significantly lower Apgar scores, higher rates of central nervous system and neuromuscular complications, and longer hospital stays were observed in infants born with umbilical cord serum lithium concentrations &gt;0.6",
"    <span class=\"nowrap\">",
"     mEq/L",
"    </span>",
"    (0.6",
"    <span class=\"nowrap\">",
"     mmol/L),",
"    </span>",
"    compared to infants with lower concentrations [",
"    <a class=\"abstract\" href=\"UTD.htm?10/61/11226/abstract/70\">",
"     70",
"    </a>",
"    ]. Lithium toxicity generally resolves in one to two weeks.",
"   </p>",
"   <p>",
"    Birth weight may be increased in babies exposed in utero to",
"    <a class=\"drug drug_general\" href=\"UTD.htm?23/11/23736?source=see_link\">",
"     lithium",
"    </a>",
"    . An observational study found that birth weight was significantly greater in lithium-exposed babies (N = 138) than unexposed babies (N = 148) (3475 versus 3383 grams) [",
"    <a class=\"abstract\" href=\"UTD.htm?10/61/11226/abstract/60\">",
"     60",
"    </a>",
"    ]. Maternal lithium dose was not correlated with birth weight.",
"   </p>",
"   <p>",
"    Available studies suggest that prenatal",
"    <a class=\"drug drug_general\" href=\"UTD.htm?23/11/23736?source=see_link\">",
"     lithium",
"    </a>",
"    exposure does not adversely affect developmental outcomes:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      A prospective study found that major developmental milestones (eg, smiling, lifting head, sitting, crawling, standing, talking, and walking) were achieved at comparable ages for",
"      <a class=\"drug drug_general\" href=\"UTD.htm?23/11/23736?source=see_link\">",
"       lithium",
"      </a>",
"      -exposed children (N = 22) and unexposed controls (N = 148) [",
"      <a class=\"abstract\" href=\"UTD.htm?10/61/11226/abstract/60\">",
"       60",
"      </a>",
"      ]",
"     </li>",
"     <li>",
"      A retrospective study found that behavioral measures of development were comparable for children exposed to",
"      <a class=\"drug drug_general\" href=\"UTD.htm?23/11/23736?source=see_link\">",
"       lithium",
"      </a>",
"      prenatally (N = 60) compared with their unexposed siblings (N = 57) [",
"      <a class=\"abstract\" href=\"UTD.htm?10/61/11226/abstract/71\">",
"       71",
"      </a>",
"      ]",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    <a class=\"drug drug_general\" href=\"UTD.htm?23/11/23736?source=see_link\">",
"     Lithium",
"    </a>",
"    appears to completely equilibrate across the placenta. An observational study of 27 infant-mother pairs found that the ratio of lithium serum concentrations in umbilical cord blood to maternal blood was 1.1, across a wide range of maternal concentrations [",
"    <a class=\"abstract\" href=\"UTD.htm?10/61/11226/abstract/70\">",
"     70",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H1561541\">",
"    <span class=\"h1\">",
"     ELECTROCONVULSIVE THERAPY",
"    </span>",
"    &nbsp;&mdash;&nbsp;Neither the number nor pattern of congenital malformations in children exposed in utero to electroconvulsive therapy (ECT) implicates it as a causal factor in organ dysgenesis [",
"    <a class=\"abstract\" href=\"UTD.htm?10/61/11226/abstract/6\">",
"     6",
"    </a>",
"    ]. A review of 300 case reports of ECT during pregnancy found five reports of congenital anomalies, including hypertelorism, talipes equinovarus (clubfoot), optic atrophy, anencephaly, and pulmonary cysts [",
"    <a class=\"abstract\" href=\"UTD.htm?10/61/11226/abstract/72\">",
"     72",
"    </a>",
"    ]. The review concluded that these malformations were not the result of ECT, and that there was no evidence of postnatal developmental effects. In addition, there is little or no evidence that fetal exposure to ECT adversely affects intrauterine growth, or causes neonatal toxicity or adverse developmental effects [",
"    <a class=\"abstract\" href=\"UTD.htm?10/61/11226/abstract/6\">",
"     6",
"    </a>",
"    ]. The most common adverse effects of ECT in the mother are premature contractions and labor, and in the fetus bradyarrhythmias [",
"    <a class=\"abstract\" href=\"UTD.htm?10/61/11226/abstract/73\">",
"     73",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    The risk of teratogenic effects and neonatal toxicity posed by ECT anesthetic drugs appears to be low [",
"    <a class=\"abstract\" href=\"UTD.htm?10/61/11226/abstract/67,72-74\">",
"     67,72-74",
"    </a>",
"    ]:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      <a class=\"drug drug_general\" href=\"UTD.htm?11/20/11591?source=see_link\">",
"       Glycopyrrolate",
"      </a>",
"      &ndash; The anticholinergic glycopyrrolate does not readily cross the placenta, and there do not appear to be any reports of teratogenesis with the injected solution",
"     </li>",
"     <li>",
"      <a class=\"drug drug_general\" href=\"UTD.htm?24/15/24823?source=see_link\">",
"       Methohexital",
"      </a>",
"      &ndash; Although the general anesthetic methohexital crosses the placenta, there do not appear to be any reports of teratogenesis with the drug",
"     </li>",
"     <li>",
"      <a class=\"drug drug_general\" href=\"UTD.htm?17/25/17816?source=see_link\">",
"       Propofol",
"      </a>",
"      &ndash; Although the general anesthetic propofol crosses the placenta, there do not appear to be any reports of teratogenesis with the drug",
"     </li>",
"     <li>",
"      <a class=\"drug drug_general\" href=\"UTD.htm?32/46/33510?source=see_link\">",
"       Succinylcholine",
"      </a>",
"      &ndash; The muscle relaxant succinylcholine generally does not appear to significantly affect the fetus; typically only a small amount at most crosses the placenta",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    In addition, it is unlikely that these drugs cause congenital malformations and toxicity because of the infrequent and brief exposure that occurs during a course of ECT.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"PATIENT_INFORMATION\">",
"    <span class=\"h1\">",
"     INFORMATION FOR PATIENTS",
"    </span>",
"    &nbsp;&mdash;&nbsp;UpToDate offers two types of patient education materials, &ldquo;The Basics&rdquo; and &ldquo;Beyond the Basics.&rdquo; The Basics patient education pieces are written in plain language, at the 5",
"    <sup>",
"     th",
"    </sup>",
"    to 6",
"    <sup>",
"     th",
"    </sup>",
"    grade reading level, and they answer the four or five key questions a patient might have about a given condition. These articles are best for patients who want a general overview and who prefer short, easy-to-read materials. Beyond the Basics patient education pieces are longer, more sophisticated, and more detailed. These articles are written at the 10",
"    <sup>",
"     th",
"    </sup>",
"    to 12",
"    <sup>",
"     th",
"    </sup>",
"    grade reading level and are best for patients who want in-depth information and are comfortable with some medical jargon.",
"   </p>",
"   <p>",
"    Here are the patient education articles that are relevant to this topic. We encourage you to print or e-mail these topics to your patients. (You can also locate patient education articles on a variety of subjects by searching on &ldquo;patient info&rdquo; and the keyword(s) of interest.)",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Basics topics (See",
"      <a class=\"medical medical_basics\" href=\"UTD.htm?4/5/4178?source=see_link\">",
"       \"Patient information: Bipolar disorder (The Basics)\"",
"      </a>",
"      and",
"      <a class=\"medical medical_basics\" href=\"UTD.htm?6/21/6483?source=see_link\">",
"       \"Patient information: Reducing the costs of medicines (The Basics)\"",
"      </a>",
"      .)",
"     </li>",
"     <li>",
"      Beyond the Basics topics (See",
"      <a class=\"medical medical_patient\" href=\"UTD.htm?38/55/39796?source=see_link\">",
"       \"Patient information: Bipolar disorder (manic depression) (Beyond the Basics)\"",
"      </a>",
"      and",
"      <a class=\"medical medical_patient\" href=\"UTD.htm?31/61/32726?source=see_link\">",
"       \"Patient information: Reducing the costs of medicines (Beyond the Basics)\"",
"      </a>",
"      .)",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    These educational materials can be used as part of psychoeducational psychotherapy. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?27/9/27802?source=see_link&amp;anchor=H21#H21\">",
"     \"Bipolar disorder in adults: Maintenance treatment\", section on 'Psychoeducation'",
"    </a>",
"    .) &nbsp;",
"   </p>",
"   <p>",
"    The National Institute of Mental Health also has educational material explaining the symptoms, course of illness, and treatment of bipolar disorder in a booklet entitled \"Bipolar Disorder,\" which is available online at the website",
"    <a class=\"external\" href=\"file://www.nimh.nih.gov/health/publications/bipolar-disorder/complete-index.shtml\">",
"     file://www.nimh.nih.gov/health/publications/bipolar-disorder/complete-index.shtml",
"    </a>",
"    or through a toll-free number, 866-615-6464. The web site also provides references, summaries of study results in language intended for the lay public, and information about clinical trials currently recruiting patients.",
"   </p>",
"   <p>",
"    More comprehensive information is provided in many books written for patients and family members, including The Bipolar Disorder Survival Guide: What You and Your Family Need to Know, written by David J. Miklowitz, PhD (published by The Guilford Press, 2002); An Unquiet Mind: A Memoir of Moods and Madness, written by Kay Jamison, PhD (published by Random House, 1995); and Treatment of Bipolar Illness: A Casebook for Clinicians and Patients, by RM Post, MD, and GS Leverich, LCSW (published by Norton Press, 2008).",
"   </p>",
"   <p>",
"    The Depression and Bipolar Support Alliance (",
"    <a class=\"external\" href=\"file://www.dbsalliance.org/\">",
"     file://www.dbsalliance.org",
"    </a>",
"    or 800-826-3632) is a national organization that educates members about bipolar disorder and how to cope with it. Other functions include increasing public awareness of the illness and advocating for more research and services. The organization is administered and maintained by patients and family members, and has local chapters.",
"   </p>",
"   <p>",
"    The National Alliance on Mental Illness (",
"    <a class=\"external\" href=\"file://www.nami.org/\">",
"     file://www.nami.org",
"    </a>",
"    or 800-950-6264) is a similarly structured organization devoted to education, support, and advocacy for patients with any mental illness. Bipolar disorder is one of their priorities.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H87632536\">",
"    <span class=\"h1\">",
"     SUMMARY AND RECOMMENDATIONS",
"    </span>",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Bipolar disorder is a mood disorder that is characterized by episodes of mania (",
"      <a class=\"graphic graphic_table graphicRef81976 \" href=\"UTD.htm?3/53/3932\">",
"       table 1",
"      </a>",
"      ), hypomania (",
"      <a class=\"graphic graphic_table graphicRef70757 \" href=\"UTD.htm?22/39/23164\">",
"       table 2",
"      </a>",
"      ), and major depression (",
"      <a class=\"graphic graphic_table graphicRef70852 \" href=\"UTD.htm?17/21/17756\">",
"       table 3",
"      </a>",
"      ), as well as mixed episodes (major depression concurrent with mania or hypomania). (See",
"      <a class=\"local\" href=\"#H1564410\">",
"       'Bipolar disorder'",
"      </a>",
"      above and",
"      <a class=\"medical medical_review\" href=\"UTD.htm?19/11/19639?source=see_link&amp;anchor=H4#H4\">",
"       \"Bipolar disorder in adults: Epidemiology and diagnosis\", section on 'Clinical manifestations and diagnostic criteria'",
"      </a>",
"      .)",
"     </li>",
"     <li>",
"      Teratogens are factors that can alter normal intrauterine development of fetal growth, anatomic structures, physical functioning, and postnatal development. This definition encompasses environmental exposures (eg, drugs), maternal medical disorders, infectious agents, and genetic conditions. (See",
"      <a class=\"local\" href=\"#H1564418\">",
"       'Teratogen'",
"      </a>",
"      above and",
"      <a class=\"medical medical_review\" href=\"UTD.htm?19/7/19574?source=see_link\">",
"       \"Principles of teratology\"",
"      </a>",
"      .)",
"     </li>",
"     <li>",
"      The estimated risk of major congenital malformations appears to vary among the medications that are most commonly used to treat bipolar disorder. The rank order from greatest to least teratogenic risk is: (See",
"      <a class=\"local\" href=\"#H1564426\">",
"       'General principles'",
"      </a>",
"      above.)",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    <ul class=\"hyphen-block\">",
"     <li>",
"      <a class=\"drug drug_general\" href=\"UTD.htm?25/11/25785?source=see_link\">",
"       Valproate",
"      </a>",
"     </li>",
"     <li>",
"      <a class=\"drug drug_general\" href=\"UTD.htm?25/10/25770?source=see_link\">",
"       Carbamazepine",
"      </a>",
"     </li>",
"     <li>",
"      <a class=\"drug drug_general\" href=\"UTD.htm?23/11/23736?source=see_link\">",
"       Lithium",
"      </a>",
"     </li>",
"     <li>",
"      <a class=\"drug drug_general\" href=\"UTD.htm?6/28/6602?source=see_link\">",
"       Lamotrigine",
"      </a>",
"     </li>",
"     <li>",
"      Antipsychotics",
"     </li>",
"     <li>",
"      Antidepressants",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Among the antiparkinsonian drugs that are used to treat extrapyramidal symptoms secondary to antipsychotics, reviews suggest that organ malformation appears to be less likely with",
"      <a class=\"drug drug_general\" href=\"UTD.htm?33/2/33824?source=see_link\">",
"       diphenhydramine",
"      </a>",
"      than",
"      <a class=\"drug drug_general\" href=\"UTD.htm?12/46/13031?source=see_link\">",
"       amantadine",
"      </a>",
"      ,",
"      <a class=\"drug drug_general\" href=\"UTD.htm?3/55/3958?source=see_link\">",
"       benztropine",
"      </a>",
"      , or",
"      <a class=\"drug drug_general\" href=\"UTD.htm?6/1/6165?source=see_link\">",
"       trihexyphenidyl",
"      </a>",
"      . (See",
"      <a class=\"local\" href=\"#H1564785\">",
"       'Antiparkinsonian drugs used for treating extrapyramidal symptoms'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      Most studies have not found that selective serotonin reuptake inhibitors (SSRIs) in the first trimester increased the risk of birth defects, with the possible exception of",
"      <a class=\"drug drug_general\" href=\"UTD.htm?14/50/15146?source=see_link\">",
"       paroxetine",
"      </a>",
"      . In addition, tricyclic antidepressants,",
"      <a class=\"drug drug_general\" href=\"UTD.htm?25/29/26073?source=see_link\">",
"       bupropion",
"      </a>",
"      ,",
"      <a class=\"drug drug_general\" href=\"UTD.htm?31/41/32408?source=see_link\">",
"       mirtazapine",
"      </a>",
"      ,",
"      <a class=\"drug drug_general\" href=\"UTD.htm?2/0/2057?source=see_link\">",
"       nefazodone",
"      </a>",
"      ,",
"      <a class=\"drug drug_general\" href=\"UTD.htm?24/0/24584?source=see_link\">",
"       trazodone",
"      </a>",
"      , and",
"      <a class=\"drug drug_general\" href=\"UTD.htm?21/45/22233?source=see_link\">",
"       venlafaxine",
"      </a>",
"      are generally not associated with congenital malformations. (See",
"      <a class=\"medical medical_review\" href=\"UTD.htm?28/0/28682?source=see_link\">",
"       \"Depression in pregnant women: Management\"",
"      </a>",
"      .)",
"     </li>",
"     <li>",
"      Teratogenic and neurobehavioral effects have been identified in children exposed to",
"      <a class=\"drug drug_general\" href=\"UTD.htm?25/11/25785?source=see_link\">",
"       valproate",
"      </a>",
"      , and less frequently,",
"      <a class=\"drug drug_general\" href=\"UTD.htm?25/10/25770?source=see_link\">",
"       carbamazepine",
"      </a>",
"      . Although most studies suggest that the estimated rate of major congenital malformations with",
"      <a class=\"drug drug_general\" href=\"UTD.htm?6/28/6602?source=see_link\">",
"       lamotrigine",
"      </a>",
"      appears to be comparable to the rate in the general population, some studies suggest that lamotrigine may possibly cause orofacial clefts. (See",
"      <a class=\"medical medical_review\" href=\"UTD.htm?22/6/22633?source=see_link&amp;anchor=H4#H4\">",
"       \"Risks associated with epilepsy and pregnancy\", section on 'Effect of antiepileptic drugs on the fetus'",
"      </a>",
"      .)",
"     </li>",
"     <li>",
"      Most studies have found that exposure during pregnancy to first and second-generation antipsychotics does not appear to increase the risk of major physical malformations above rates observed in the general population. However, chronic administration of antipsychotics during the third trimester may cause symptoms of neonatal toxicity and withdrawal. (See",
"      <a class=\"local\" href=\"#H1561506\">",
"       'Antipsychotics'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      It is not clear if exposure to benzodiazepines or to hypnotic, benzodiazepine receptor agonists during pregnancy increases the risk of congenital malformations. Chronic administration of benzodiazepines proximal to delivery can cause neonatal toxicity and withdrawal. (See",
"      <a class=\"local\" href=\"#H1561527\">",
"       'Benzodiazepines'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      <a class=\"drug drug_general\" href=\"UTD.htm?23/11/23736?source=see_link\">",
"       Lithium",
"      </a>",
"      appears to cause teratogenic effects that primarily involve the fetal heart. The estimated incidence of major congenital anomalies among children of women treated with lithium during the first trimester is between 4 and 12 percent. Ebstein&rsquo;s anomaly may be the most common fetal cardiac defect caused by lithium; the absolute risk in newborns exposed to lithium in utero is approximately 1 in 1000, compared with an estimated risk in the general population of 1 in 20,000 live births. In addition, use of lithium during the second and third trimester can result in neonatal complications and lithium toxicity. (See",
"      <a class=\"local\" href=\"#H1561534\">",
"       'Lithium'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      Neither the number nor pattern of congenital malformations in children exposed in utero to electroconvulsive therapy (ECT) implicates it as a causal factor in organ dysgenesis. The risk of neonatal toxicity and adverse developmental effects posed by ECT also appears to be low. (See",
"      <a class=\"local\" href=\"#H1561541\">",
"       'Electroconvulsive therapy'",
"      </a>",
"      above.)",
"     </li>",
"    </ul>",
"   </p>",
"  </div>",
"  <div id=\"topicAgreement\">",
"   Use of UpToDate is subject to the",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_in_page\" target=\"_blank\">",
"    Subscription and License Agreement",
"   </a>",
"   .",
"  </div>",
"  <div class=\"headingAnchor\" id=\"references\">",
"   <h1>",
"    REFERENCES",
"   </h1>",
"   <ol id=\"reference\">",
"    <li>",
"     Owen JA. Psychopharmacology. In: The American Psychiatric Publishing Textbook of Psychosomatic Medicine: Psychiatric Care of the Medically Ill, Second Edition, Levenson JL.  (Ed), American Psychiatric Publishing, Inc., Washington, DC 2011. p.957.",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?10/61/11226/abstract/2\">",
"      ACOG Committee on Practice Bulletins--Obstetrics. ACOG Practice Bulletin: Clinical management guidelines for obstetrician-gynecologists number 92, April 2008 (replaces practice bulletin number 87, November 2007). Use of psychiatric medications during pregnancy and lactation. Obstet Gynecol 2008; 111:1001.",
"     </a>",
"    </li>",
"    <li>",
"     American Psychiatric Association. Diagnostic and Statistical Manual of Mental Disorders, Fourth Edition, Text Revision, American Psychiatric Association, Washington, DC, 2000.",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?10/61/11226/abstract/4\">",
"      Einarson A, Boskovic R. Use and safety of antipsychotic drugs during pregnancy. J Psychiatr Pract 2009; 15:183.",
"     </a>",
"    </li>",
"    <li>",
"     Newport DJ, Fernandez SV, Juric S, Stowe ZN. Psychopharmacology during pregnancy and lactation. In: The American Psychiatric Publishing Textbook of Psychopharmacology, Fourth Edition, Schatzberg AF, Nemeroff CB.  (Eds), American Psychiatric Publishing, Inc., Washington, D.C. 2009. p.1373.",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?10/61/11226/abstract/6\">",
"      Yonkers KA, Wisner KL, Stowe Z, et al. Management of bipolar disorder during pregnancy and the postpartum period. Am J Psychiatry 2004; 161:608.",
"     </a>",
"    </li>",
"    <li>",
"     Frey BN, Macritchie KA, Soares CN, Steiner M. Bipolar disorder in women. In: Bipolar Disorder: Clinical and Neurobiological Foundations, Yatham LN, Maj M.  (Eds), Wiley-Blackwell, West Sussex 2010. p.463.",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?10/61/11226/abstract/8\">",
"      Menon SJ. Psychotropic medication during pregnancy and lactation. Arch Gynecol Obstet 2008; 277:1.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?10/61/11226/abstract/9\">",
"      Tomson T, Battino D. Teratogenic effects of antiepileptic medications. Neurol Clin 2009; 27:993.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?10/61/11226/abstract/10\">",
"      Cunnington M, Ferber S, Quartey G, International Lamotrigine Pregnancy Registry Scientific Advisory Committee. Effect of dose on the frequency of major birth defects following fetal exposure to lamotrigine monotherapy in an international observational study. Epilepsia 2007; 48:1207.",
"     </a>",
"    </li>",
"    <li>",
"     Stewart DE, Vigod SN, Stotland NL. Obstetrics and gynecology. In: The American Psychiatric Publishing Textbook of Psychosomatic Medicine: Psychiatric Care of the Medically Ill, Second Edition, Levenson JL.  (Ed), American Psychiatric Publishing, Inc, Washington, DC 2011. p.797.",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?10/61/11226/abstract/12\">",
"      Goodwin GM, Consensus Group of the British Association for Psychopharmacology. Evidence-based guidelines for treating bipolar disorder: revised second edition--recommendations from the British Association for Psychopharmacology. J Psychopharmacol 2009; 23:346.",
"     </a>",
"    </li>",
"    <li>",
"     Post RM, Altshuler LL. Mood disorders: Treatment of bipolar disorders. In: Kaplan &amp; Sadock's Comprehensive Textbook of Psychiatry, 9th edition, Sadock BJ, Sadock VA, Ruiz P.  (Eds), Lippincott Williams &amp; Wilkins, Philadelphia 2009. Vol I, p.1743.",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?10/61/11226/abstract/14\">",
"      Viguera AC, Koukopoulos A, Muzina DJ, Baldessarini RJ. Teratogenicity and anticonvulsants: lessons from neurology to psychiatry. J Clin Psychiatry 2007; 68 Suppl 9:29.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?10/61/11226/abstract/15\">",
"      Jain AE, Lacy T. Psychotropic drugs in pregnancy and lactation. J Psychiatr Pract 2005; 11:177.",
"     </a>",
"    </li>",
"    <li>",
"     CDC. Update on Overall Prevalence of Major Birth Defects --- Atlanta, Georgia, 1978--2005 file://www.cdc.gov/mmwr/preview/mmwrhtml/mm5701a2.htm (Accessed on May 24, 2011).",
"    </li>",
"    <li>",
"     New York State Department of Health (2010). Congenital Malformations Registry Summary Report, Statistical Summary of Children Born in 2006 and Diagnosed Through 2008. file://www.health.ny.gov/ (Accessed on December 26, 2011).",
"    </li>",
"    <li>",
"     Swedish National Board of Health and Welfare, Center for Epidemiology (2004). Registration of Congenital Malformations in the Swedish Health Registers, 1995-2001. file://www.socialstyrelsen.se/Lists/Artikelkatalog/Attachments/10350/2004-112-1_20041121.pdf (Accessed on December 26, 2011).",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?10/61/11226/abstract/19\">",
"      Dolovich LR, Addis A, Vaillancourt JM, et al. Benzodiazepine use in pregnancy and major malformations or oral cleft: meta-analysis of cohort and case-control studies. BMJ 1998; 317:839.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?10/61/11226/abstract/20\">",
"      McKenna K, Koren G, Tetelbaum M, et al. Pregnancy outcome of women using atypical antipsychotic drugs: a prospective comparative study. J Clin Psychiatry 2005; 66:444.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?10/61/11226/abstract/21\">",
"      Burt VK, Bernstein C, Rosenstein WS, Altshuler LL. Bipolar disorder and pregnancy: maintaining psychiatric stability in the real world of obstetric and psychiatric complications. Am J Psychiatry 2010; 167:892.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?10/61/11226/abstract/22\">",
"      Newport DJ, Calamaras MR, DeVane CL, et al. Atypical antipsychotic administration during late pregnancy: placental passage and obstetrical outcomes. Am J Psychiatry 2007; 164:1214.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?10/61/11226/abstract/23\">",
"      Johnson KC, LaPrairie JL, Brennan PA, et al. Prenatal antipsychotic exposure and neuromotor performance during infancy. Arch Gen Psychiatry 2012; 69:787.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?10/61/11226/abstract/24\">",
"      Altshuler LL, Cohen L, Szuba MP, et al. Pharmacologic management of psychiatric illness during pregnancy: dilemmas and guidelines. Am J Psychiatry 1996; 153:592.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?10/61/11226/abstract/25\">",
"      Lupo PJ, Langlois PH, Mitchell LE. Epidemiology of Ebstein anomaly: prevalence and patterns in Texas, 1999-2005. Am J Med Genet A 2011; 155A:1007.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?10/61/11226/abstract/26\">",
"      Correa-Villase&ntilde;or A, Ferencz C, Neill CA, et al. Ebstein's malformation of the tricuspid valve: genetic and environmental factors. The Baltimore-Washington Infant Study Group. Teratology 1994; 50:137.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?10/61/11226/abstract/27\">",
"      Pradat P, Francannet C, Harris JA, Robert E. The epidemiology of cardiovascular defects, part I: a study based on data from three large registries of congenital malformations. Pediatr Cardiol 2003; 24:195.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?10/61/11226/abstract/28\">",
"      Cohen LS, Wang B, Nonacs R, et al. Treatment of mood disorders during pregnancy and postpartum. Psychiatr Clin North Am 2010; 33:273.",
"     </a>",
"    </li>",
"    <li>",
"     Briggs GG, Freeman RK, Yaffe SJ. Diphenhydramine. In: Drugs in Pregnancy and Lactation, 9th edition, Lippincott Williams &amp; Wilkins, Philadelphia 2009. p.844.",
"    </li>",
"    <li>",
"     Burt VK, Stein K. Treatment of women. In: The American Psychiatric Publishing Textbook of Psychiatry, Fifth Edition, Hales RE, Yodofsky SC, Gabbard GO.  (Eds), American Psychiatric Publishing, Inc., Washington, DC 2008. p.1489.",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?10/61/11226/abstract/31\">",
"      Aselton P, Jick H, Milunsky A, et al. First-trimester drug use and congenital disorders. Obstet Gynecol 1985; 65:451.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?10/61/11226/abstract/32\">",
"      Sax&eacute;n I. Letter: Cleft palate and maternal diphenhydramine intake. Lancet 1974; 1:407.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?10/61/11226/abstract/33\">",
"      Alwan S, Friedman JM. Safety of selective serotonin reuptake inhibitors in pregnancy. CNS Drugs 2009; 23:493.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?10/61/11226/abstract/34\">",
"      Davis RL, Rubanowice D, McPhillips H, et al. Risks of congenital malformations and perinatal events among infants exposed to antidepressant medications during pregnancy. Pharmacoepidemiol Drug Saf 2007; 16:1086.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?10/61/11226/abstract/35\">",
"      Simon GE, Cunningham ML, Davis RL. Outcomes of prenatal antidepressant exposure. Am J Psychiatry 2002; 159:2055.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?10/61/11226/abstract/36\">",
"      Cole JA, Modell JG, Haight BR, et al. Bupropion in pregnancy and the prevalence of congenital malformations. Pharmacoepidemiol Drug Saf 2007; 16:474.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?10/61/11226/abstract/37\">",
"      Djulus J, Koren G, Einarson TR, et al. Exposure to mirtazapine during pregnancy: a prospective, comparative study of birth outcomes. J Clin Psychiatry 2006; 67:1280.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?10/61/11226/abstract/38\">",
"      Einarson A, Bonari L, Voyer-Lavigne S, et al. A multicentre prospective controlled study to determine the safety of trazodone and nefazodone use during pregnancy. Can J Psychiatry 2003; 48:106.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?10/61/11226/abstract/39\">",
"      Einarson A, Fatoye B, Sarkar M, et al. Pregnancy outcome following gestational exposure to venlafaxine: a multicenter prospective controlled study. Am J Psychiatry 2001; 158:1728.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?10/61/11226/abstract/40\">",
"      Holmes LB, Baldwin EJ, Smith CR, et al. Increased frequency of isolated cleft palate in infants exposed to lamotrigine during pregnancy. Neurology 2008; 70:2152.",
"     </a>",
"    </li>",
"    <li>",
"     National Institute for Health and Clinical Excellence. Bipolar disorder: The management of bipolar disorder in adults, children and adolescents, in primary and secondary care. National Clinical Practice Guideline Number 38 file://www.nice.org.uk/ (Accessed on December 30, 2011).",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?10/61/11226/abstract/42\">",
"      Reis M, K&auml;ll&eacute;n B. Maternal use of antipsychotics in early pregnancy and delivery outcome. J Clin Psychopharmacol 2008; 28:279.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?10/61/11226/abstract/43\">",
"      Diav-Citrin O, Shechtman S, Ornoy S, et al. Safety of haloperidol and penfluridol in pregnancy: a multicenter, prospective, controlled study. J Clin Psychiatry 2005; 66:317.",
"     </a>",
"    </li>",
"    <li>",
"     FDA Drug SafetyCommunication: Antipsychotic drug labels updated on use during pregnancy and risk of abnormal muscle movements and withdrawal symptoms in newborns. file://www.fda.gov/Drugs/DrugSafety/ucm243903.htm (Accessed on March 01, 2011).",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?10/61/11226/abstract/45\">",
"      Slone D, Siskind V, Heinonen OP, et al. Antenatal exposure to the phenothiazines in relation to congenital malformations, perinatal mortality rate, birth weight, and intelligence quotient score. Am J Obstet Gynecol 1977; 128:486.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?10/61/11226/abstract/46\">",
"      Newham JJ, Thomas SH, MacRitchie K, et al. Birth weight of infants after maternal exposure to typical and atypical antipsychotics: prospective comparison study. Br J Psychiatry 2008; 192:333.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?10/61/11226/abstract/47\">",
"      Yaeger D, Smith HG, Altshuler LL. Atypical antipsychotics in the treatment of schizophrenia during pregnancy and the postpartum. Am J Psychiatry 2006; 163:2064.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?10/61/11226/abstract/48\">",
"      Gentile S. Neurodevelopmental effects of prenatal exposure to psychotropic medications. Depress Anxiety 2010; 27:675.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?10/61/11226/abstract/49\">",
"      Gentile S. Antipsychotic therapy during early and late pregnancy. A systematic review. Schizophr Bull 2010; 36:518.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?10/61/11226/abstract/50\">",
"      Coppola D, Russo LJ, Kwarta RF Jr, et al. Evaluating the postmarketing experience of risperidone use during pregnancy: pregnancy and neonatal outcomes. Drug Saf 2007; 30:247.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?10/61/11226/abstract/51\">",
"      Babu GN, Desai G, Tippeswamy H, Chandra PS. Birth weight and use of olanzapine in pregnancy: a prospective comparative study. J Clin Psychopharmacol 2010; 30:331.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?10/61/11226/abstract/52\">",
"      Koren G, Pastuszak A, Ito S. Drugs in pregnancy. N Engl J Med 1998; 338:1128.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?10/61/11226/abstract/53\">",
"      Eros E, Czeizel AE, Rockenbauer M, et al. A population-based case-control teratologic study of nitrazepam, medazepam, tofisopam, alprazolum and clonazepam treatment during pregnancy. Eur J Obstet Gynecol Reprod Biol 2002; 101:147.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?10/61/11226/abstract/54\">",
"      Wikner BN, K&auml;ll&eacute;n B. Are hypnotic benzodiazepine receptor agonists teratogenic in humans? J Clin Psychopharmacol 2011; 31:356.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?10/61/11226/abstract/55\">",
"      Iqbal MM, Sobhan T, Ryals T. Effects of commonly used benzodiazepines on the fetus, the neonate, and the nursing infant. Psychiatr Serv 2002; 53:39.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?10/61/11226/abstract/56\">",
"      Wikner BN, Stiller CO, Bergman U, et al. Use of benzodiazepines and benzodiazepine receptor agonists during pregnancy: neonatal outcome and congenital malformations. Pharmacoepidemiol Drug Saf 2007; 16:1203.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?10/61/11226/abstract/57\">",
"      Wikner BN, Stiller CO, K&auml;ll&eacute;n B, Asker C. Use of benzodiazepines and benzodiazepine receptor agonists during pregnancy: maternal characteristics. Pharmacoepidemiol Drug Saf 2007; 16:988.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?10/61/11226/abstract/58\">",
"      Whitelaw AG, Cummings AJ, McFadyen IR. Effect of maternal lorazepam on the neonate. Br Med J (Clin Res Ed) 1981; 282:1106.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?10/61/11226/abstract/59\">",
"      Hartz SC, Heinonen OP, Shapiro S, et al. Antenatal exposure to meprobamate and chlordiazepoxide in relation to malformations, mental development, and childhood mortality. N Engl J Med 1975; 292:726.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?10/61/11226/abstract/60\">",
"      Jacobson SJ, Jones K, Johnson K, et al. Prospective multicentre study of pregnancy outcome after lithium exposure during first trimester. Lancet 1992; 339:530.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?10/61/11226/abstract/61\">",
"      Cohen LS, Friedman JM, Jefferson JW, et al. A reevaluation of risk of in utero exposure to lithium. JAMA 1994; 271:146.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?10/61/11226/abstract/62\">",
"      Weinstein MR, Goldfield M. Cardiovascular malformations with lithium use during pregnancy. Am J Psychiatry 1975; 132:529.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?10/61/11226/abstract/63\">",
"      Nguyen HT, Sharma V, McIntyre RS. Teratogenesis associated with antibipolar agents. Adv Ther 2009; 26:281.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?10/61/11226/abstract/64\">",
"      Cohen LS. Treatment of bipolar disorder during pregnancy. J Clin Psychiatry 2007; 68 Suppl 9:4.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?10/61/11226/abstract/65\">",
"      Gentile S. Drug treatment for mood disorders in pregnancy. Curr Opin Psychiatry 2011; 24:34.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?10/61/11226/abstract/66\">",
"      McKnight RF, Adida M, Budge K, et al. Lithium toxicity profile: a systematic review and meta-analysis. Lancet 2012; 379:721.",
"     </a>",
"    </li>",
"    <li>",
"     American Psychiatric Association. Use of electroconvulsive therapy in special populations. In: The Practice of Electroconvulsive Therapy: Recommendations for Treatment, Training, and Privileging, Second Edition, American Psychiatric Association, Washington, DC 2001. p.31.",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?10/61/11226/abstract/68\">",
"      Iqbal MM, Gundlapalli SP, Ryan WG, et al. Effects of antimanic mood-stabilizing drugs on fetuses, neonates, and nursing infants. South Med J 2001; 94:304.",
"     </a>",
"    </li>",
"    <li>",
"     Briggs GG, Freeman RK, Yaffe SJ. Lithium. In: Drugs in Pregnancy and Lactation, 9th edition, Lippincott Williams &amp; Wilkins, Philadelphia 2009. p.844.",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?10/61/11226/abstract/70\">",
"      Newport DJ, Viguera AC, Beach AJ, et al. Lithium placental passage and obstetrical outcome: implications for clinical management during late pregnancy. Am J Psychiatry 2005; 162:2162.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?10/61/11226/abstract/71\">",
"      Schou M. What happened later to the lithium babies? A follow-up study of children born without malformations. Acta Psychiatr Scand 1976; 54:193.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?10/61/11226/abstract/72\">",
"      Miller LJ. Use of electroconvulsive therapy during pregnancy. Hosp Community Psychiatry 1994; 45:444.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?10/61/11226/abstract/73\">",
"      Anderson EL, Reti IM. ECT in pregnancy: a review of the literature from 1941 to 2007. Psychosom Med 2009; 71:235.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?10/61/11226/abstract/74\">",
"      Rabheru K. The use of electroconvulsive therapy in special patient populations. Can J Psychiatry 2001; 46:710.",
"     </a>",
"    </li>",
"   </ol>",
"  </div>",
"  <div id=\"topicVersionRevision\">",
"   Topic 17159 Version 5.0",
"  </div>",
" </div>",
" <div id=\"footer\">",
"  <div id=\"supportFooter\">",
"   <span class=\"sfInfo\">",
"    &copy; 2013 UpToDate, Inc. All rights reserved.",
"   </span>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_footer\">",
"    Subscription and License Agreement",
"   </a>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Release: 21.6- C21.56",
"   </span>",
"   <br/>",
"   <span class=\"sfInfo\">",
"    Licensed to:",
"    <span class=\"emphasis\">",
"     AsanBook Dig. Med. Lib.",
"    </span>",
"   </span>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Support Tag: [1003-201.65.114.212-1237D62C13-S244013.14]",
"    <br/>",
"   </span>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f10_61_11226=[""].join("\n");
var outline_f10_61_11226=[" <div id=\"toggleOutline\">",
"  <a href=\"#\" title=\"Collapse Topic Outline\">",
"   <img alt=\"\" src=\"./../images/orange_arrow_left.myextg\"/>",
"  </a>",
" </div>",
" <div id=\"innerOutline\">",
"  <h1>",
"   TOPIC OUTLINE",
"  </h1>",
"  <div id=\"outline\">",
"   <ul>",
"    <li>",
"     <a class=\"sr_button\" href=\"#H87632536\" id=\"summRecButton\">",
"      <span>",
"       SUMMARY &amp; RECOMMENDATIONS",
"      </span>",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H1564395\">",
"      INTRODUCTION",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H1564402\">",
"      DEFINITIONS",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H1564410\">",
"      Bipolar disorder",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H1564418\">",
"      Teratogen",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H1564426\">",
"      GENERAL PRINCIPLES",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H1561478\">",
"      Resources",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H1564785\">",
"      ANTIPARKINSONIAN DRUGS USED FOR TREATING EXTRAPYRAMIDAL SYMPTOMS",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H1561485\">",
"      ANTIDEPRESSANTS",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H1561492\">",
"      ANTIEPILEPTICS",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H1561506\">",
"      ANTIPSYCHOTICS",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H89201049\">",
"      Postnatal effects",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H89201057\">",
"      - Neonatal toxicity and withdrawal",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H89201266\">",
"      - Developmental effects",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H481720\">",
"      First-generation",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H1561513\">",
"      Second-generation",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H1561527\">",
"      BENZODIAZEPINES",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H1561534\">",
"      LITHIUM",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H1561541\">",
"      ELECTROCONVULSIVE THERAPY",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#PATIENT_INFORMATION\">",
"      INFORMATION FOR PATIENTS",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H87632536\">",
"      SUMMARY AND RECOMMENDATIONS",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a href=\"#references\">",
"      REFERENCES",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   <div class=\"openRelatedGraphics\" id=\"PSYCH/17159\" rel=\"outline_link\">",
"    GRAPHICS",
"    <a class=\"graphics_icon\" href=\"#\" title=\"View All Related Graphics\">",
"     View All",
"    </a>",
"   </div>",
"  </h1>",
"  <div id=\"relatedGraphics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <div class=\"openRelatedGraphics\" id=\"PSYCH/17159|FIG\">",
"      <a href=\"#\" title=\"FIGURES\">",
"       FIGURES",
"      </a>",
"     </div>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_figure\" href=\"UTD.htm?32/30/33261\" title=\"figure 1\">",
"      Risk wk for fetal abnormalities",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_figure\" href=\"UTD.htm?22/46/23272\" title=\"figure 2\">",
"      The developing fetus",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <div class=\"openRelatedGraphics\" id=\"PSYCH/17159|TAB\">",
"      <a href=\"#\" title=\"TABLES\">",
"       TABLES",
"      </a>",
"     </div>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_table\" href=\"UTD.htm?3/53/3932\" title=\"table 1\">",
"      DSM-IV-TR diagnostic criteria for mania",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_table\" href=\"UTD.htm?22/39/23164\" title=\"table 2\">",
"      DSM-IV-TR diagnostic criteria for hypomania",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_table\" href=\"UTD.htm?17/21/17756\" title=\"table 3\">",
"      DSM-IV-TR diagnostic criteria for major depression",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   RELATED TOPICS",
"  </h1>",
"  <div id=\"relatedTopics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?19/11/19639?source=related_link\">",
"      Bipolar disorder in adults: Epidemiology and diagnosis",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?27/9/27802?source=related_link\">",
"      Bipolar disorder in adults: Maintenance treatment",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?37/22/38248?source=related_link\">",
"      Bipolar disorder in pregnant women: Treatment of major depression",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?4/16/4362?source=related_link\">",
"      Bipolar disorder in pregnant women: Treatment of mania, hypomania, and mixed episodes",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?39/24/40329?source=related_link\">",
"      Bipolar disorder in women: Contraception and preconception assessment and counseling",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?2/51/2874?source=related_link\">",
"      Bipolar disorder in women: Preconception and prenatal maintenance pharmacotherapy",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?28/0/28682?source=related_link\">",
"      Depression in pregnant women: Management",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?37/52/38729?source=related_link\">",
"      Ebstein's anomaly of the tricuspid valve",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_basics\" href=\"UTD.htm?4/5/4178?source=related_link\">",
"      Patient information: Bipolar disorder (The Basics)",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_patient\" href=\"UTD.htm?38/55/39796?source=related_link\">",
"      Patient information: Bipolar disorder (manic depression) (Beyond the Basics)",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_patient\" href=\"UTD.htm?31/61/32726?source=related_link\">",
"      Patient information: Reducing the costs of medicines (Beyond the Basics)",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_basics\" href=\"UTD.htm?6/21/6483?source=related_link\">",
"      Patient information: Reducing the costs of medicines (The Basics)",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?20/38/21096?source=related_link\">",
"      Perinatal mortality",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?19/7/19574?source=related_link\">",
"      Principles of teratology",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?22/6/22633?source=related_link\">",
"      Risks associated with epilepsy and pregnancy",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
" </div>"].join("\n");
var title_f10_61_11227="Severity of obstructive sleep apnea";
var content_f10_61_11227=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=SURG%2F55763&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=SURG%2F55763&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\">",
"   <div class=\"ttl\">",
"    Severity of obstructive sleep apnea",
"   </div>",
"   <div class=\"cntnt\">",
"    <table cellspacing=\"0\">",
"     <tbody>",
"      <tr>",
"       <td class=\"subtitle1\">",
"        Apnea hypopnea index (AHI)",
"       </td>",
"       <td class=\"subtitle1\">",
"        OSA severity",
"       </td>",
"       <td class=\"subtitle1\">",
"        OSA score",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        6-20",
"       </td>",
"       <td>",
"        Mild",
"       </td>",
"       <td>",
"        1",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        21-40",
"       </td>",
"       <td>",
"        Moderate",
"       </td>",
"       <td>",
"        2",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        &gt;41",
"       </td>",
"       <td>",
"        Severe",
"       </td>",
"       <td>",
"        3",
"       </td>",
"      </tr>",
"     </tbody>",
"    </table>",
"   </div>",
"   <div class=\"lgnd\">",
"    The apnea-hypopnea index (AHI) is the number of apneas and hypopneas per hour of sleep as measured in the sleep laboratory.",
"    <div class=\"footnotes\">",
"    </div>",
"    <div class=\"reference\">",
"     Data from: Gross JB, Bachenberg KL, Benumof JL, et al. Practice guidelines for the perioperative management of patients with obstructive sleep apnea: a report by the American Society of Anesthesiologists Task Force on Perioperative Management of patients with obstructive sleep apnea. Anesthesiology 2006; 104:1081.",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f10_61_11227=[""].join("\n");
var outline_f10_61_11227=null;
var title_f10_61_11228="PaO2 in cyanotic heart disease";
var content_f10_61_11228=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=PEDS%2F75461&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=PEDS%2F75461&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\">",
"   <div class=\"ttl\">",
"    Mean PaO",
"    <sub>",
"     2",
"    </sub>",
"    values in various types of cyanotic heart disease",
"   </div>",
"   <div class=\"cntnt\">",
"    <table cellspacing=\"0\">",
"     <tbody>",
"      <tr>",
"       <td class=\"subtitle1\" rowspan=\"2\">",
"        Conditions",
"       </td>",
"       <td class=\"subtitle1\" colspan=\"2\">",
"        Mean PaO",
"        <sub>",
"         2",
"        </sub>",
"        (mmHg)",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"subtitle2\">",
"        <p>",
"         Room air",
"        </p>",
"        <p>",
"         FiO",
"         <sub>",
"          2",
"         </sub>",
"         = 0.21",
"        </p>",
"       </td>",
"       <td class=\"subtitle2\">",
"        <p>",
"         100 percent oxygen",
"        </p>",
"        <p>",
"         FiO",
"         <sub>",
"          2",
"         </sub>",
"         = 1.0",
"        </p>",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Common mixing lesion*",
"       </td>",
"       <td>",
"        42",
"       </td>",
"       <td>",
"        64",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        HLHS",
"       </td>",
"       <td>",
"        47",
"       </td>",
"       <td>",
"        79",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        POTO",
"        <sup>",
"         &bull;",
"        </sup>",
"       </td>",
"       <td>",
"        39",
"       </td>",
"       <td>",
"        45",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        TGA",
"       </td>",
"       <td>",
"        30",
"       </td>",
"       <td>",
"        39",
"       </td>",
"      </tr>",
"     </tbody>",
"    </table>",
"   </div>",
"   <div class=\"lgnd\">",
"    Mean arterial partial pressure of oxygen for specific cyanotic heart defects during hyperoxia test with administration of room air or 100 percent oxygen.",
"    <div class=\"footnotes\">",
"     FiO",
"     <sub>",
"      2",
"     </sub>",
"     : fractional inspired oxygen concentration; HLHS: hypoplastic left heart syndrome; POTO: pulmonary outflow tract obstruction; TGA: transposition of the great arteries.",
"     <br>",
"      * Lesions include total anomalous pulmonary venous connection, tricuspid atresia with large ventricular septal defect, truncus arteriosus, double outlet right ventricle, and single ventricle without pulmonary stenosis.",
"      <br>",
"       <font class=\"bullet\">",
"        &bull;",
"       </font>",
"       Lesions include tetralogy of Fallot, tetralogy of Fallot associated with pulmonary atresia, tricuspid atresia associated with small ventricular septal defect, double outlet right ventricle associated with pulmonary stenosis, and single ventricle associated with pulmonary stenosis.",
"      </br>",
"     </br>",
"    </div>",
"    <div class=\"reference\">",
"     Data from: Jones RWA, Baumer JH, Joseph MC, Shinebourne EA. Arterial oxygen tension and response to oxygen breathing in differential diagnosis of congenital heart disease in infancy. Arch Dis Child 1976; 51-667.",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f10_61_11228=[""].join("\n");
var outline_f10_61_11228=null;
var title_f10_61_11229="Natural history hepatitis C";
var content_f10_61_11229=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=GAST%2F70891&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=GAST%2F70891&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\" style=\"width: 474px\">",
"   <div class=\"ttl\">",
"    Summary of the natural history of hepatitis C",
"   </div>",
"   <div class=\"cntnt\" style=\"width: 454px; height: 203px; background-image: url(data:image/gif;base64,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);\">",
"   </div>",
"   <div class=\"lgnd\">",
"    <div class=\"footnotes\">",
"    </div>",
"    <div class=\"reference\">",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f10_61_11229=[""].join("\n");
var outline_f10_61_11229=null;
var title_f10_61_11230="Efficacy Holter guided therapy";
var content_f10_61_11230=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=CARD%2F57256&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=2\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=CARD%2F57256&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=2\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\" style=\"width: 505px\">",
"   <div class=\"ttl\">",
"    Effective antiarrhythmic drug therapy improves outcome in survivors of SCD",
"   </div>",
"   <div class=\"cntnt\" style=\"width: 485px; height: 248px; background-image: url(data:image/gif;base64,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);\">",
"   </div>",
"   <div class=\"lgnd\">",
"    Total cardiac and sudden death mortality in survivors of sudden cardiac death (SCD) treated with antiarrhythmic drugs selected by Holter monitoring. Survival was higher among 98 responders in whom an antiarrhythmic drug that suppressed spontaneous ventricular arrhythmia was identified by Holter monitoring when compared&nbsp;with 25 nonresponders in whom ventricular arrhythmia persisted despite therapy with the best antiarrhythmic drug.",
"    <div class=\"footnotes\">",
"    </div>",
"    <div class=\"reference\">",
"     Data from: Graboys TB, Lown B, Podrid PJ, et al. Am J Cardiol 1982; 50:437.",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f10_61_11230=[""].join("\n");
var outline_f10_61_11230=null;
var title_f10_61_11231="TEE LA thrombus and spontaneous echo contrast";
var content_f10_61_11231=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic2\" style=\"width: 1040px;\">",
"  <div class=\"videoplayer\" h264=\"./images/CARD/51472/teelatt2_conv.mp4?title=TEE+LA+thrombus+and+spontaneous+echo+contrast\" style=\"width:328px;height:248px\">",
"  </div>",
"  <div class=\"figure\" style=\"width: 470px\">",
"   <div class=\"ttl\">",
"    Transesophageal echocardiogram (TEE) showing left atrial (LA) thrombus and spontaneous echo contrast",
"   </div>",
"   <div class=\"cntnt\" style=\"width: 259px; height: 226px; background-image: url(data:image/jpeg;base64,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);\">",
"   </div>",
"   <div class=\"lgnd\">",
"    The transesophageal echocardiogram shows a large thrombus in the left atrium. Spontaneous echo contrast can also be seen in the left atrium.",
"    <div class=\"footnotes\">",
"    </div>",
"    <div class=\"reference\">",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f10_61_11231=[""].join("\n");
var outline_f10_61_11231=null;
